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Background: Annual screening for adults with type 2 diabetes to detect the early onset of kidney disease
is widely recommended, but the recommendations are based on a limited methodological approach. In
addition, there are continuing uncertainties about underlying rates of progression of the condition and the
benefits of treatments with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Objectives: We aimed to estimate the clinical value and cost-effectiveness of different screening intervals
to diagnose early diabetic kidney disease.
Data sources: We used the following databases for the literature review (searched January 2005 to
August 2010): MEDLINE, EMBASE and the Cochrane Database of Systematic Reviews. Individual patient
data were obtained from the Oxford Regional Prospective Diabetes Study and the Collaborative
Atorvastatin Diabetes Study.
Methods: Data from systematically identified randomised trials reporting the impact on renal outcomes of
angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers for type 1 and type 2
diabetes patients with normoalbuminuria and microalbuminuria were pooled to derive estimates of effect.
Individual patient data for type 1 and type 2 diabetes patients were used to obtain parameters describing
progression and variability of measurement over time for the albumin-to-creatinine ratio (ACR) and
estimated glomerular filtration rate. Based on accepted diagnostic thresholds, we modelled whether these
tests accurately identified patients who were developing early diabetic kidney disease and required
intensification of treatment. Cost-effectiveness analyses were carried out using simulation outcome models
to estimate the incremental costs per quality-adjusted life-year (QALY) for different screening intervals.vii
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ABSTRACT
viiiResults: In total, 49 trials (n = 34,082 patients) were eligible for inclusion in the systematic review.
For type 1 diabetes, pooled estimates of urinary albumin excretion (UAE) for treated patients with
microalbuminuria were on average 67% [95% confidence interval (CI) 54% to 77%] lower at the end of
the trial than for untreated patients. There was no significant treatment effect for patients with
normoalbuminuria (p interaction = 0.006). For treated patients with type 2 diabetes and normoalbuminuria
or microalbuminuria, UAE was lower by, on average, 21% (95% CI 97% to 32%) or 27% (95% CI 15%
to 38%), respectively. The proportion (95% CI) of men and women with type 1 diabetes screened
annually for microalbuminuria over 6 years and inaccurately identified as having microalbuminuria would
be 48% (43% to 53%) and 55% (48% to 61%), respectively. The corresponding proportions for
type 2 diabetes are 36% (32% to 42%) and 48% (41% to 55%). Decreasing the screening interval to
3-yearly would reduce this for men with type 1 diabetes to 38% (33% to 44%), with an increase in those
not identified over 6 years from 1.5% (95% CI 1% to 2%) to 4% (95% CI 3% to 5%). For type 1
diabetes, incremental cost per QALY [standard deviation (SD)] of a 5-yearly compared with a 4-yearly
screening interval was £3612 (£6586), increasing to £9601 (£34,112) for annual compared with 2-yearly
screening. The probability that the intervention is cost saving is around 25%, and it has around an 80%
chance of being below a cost-effectiveness threshold of £30,000. For type 2 diabetes, incremental cost per
QALY (SD) of a yearly compared with a 2-yearly screening interval was £606 (£1782). The intervention is
almost certainly below a cost-effectiveness threshold of £5000.
Conclusions: These results support current UK guidance, which recommends annual screening with ACR
to identify early kidney disease in patients with diabetes, despite a high false-positive rate leading to, at
worst, unnecessary or, at best, early therapeutic intervention. For type 1 diabetes, screening costs for
annual compared with 2-yearly screening are well within the bounds of accepted cost-effectiveness.
Annual screening is even more cost-effective in type 2 diabetes than in type 1 diabetes. Identification of
alternative markers for developing diabetic nephropathy may improve targeting of treatment for those at
high risk.
Funding: The National Institute for Health Research Health Technology Assessment programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Despite strong evidence that the development of impaired renal function in patients with diabetes is
associated with poor disease outcomes, evidence supporting current practice to detect the onset of kidney
disease is limited. Annual screening for adults with diabetes to detect the onset of raised levels of urinary
albumin (microalbuminuria), and thus identify development of early kidney disease, is recommended in
clinical guidelines, with suggestions of more frequent screening for those at increased risk of developing
kidney disease. Although the existence of a beneficial treatment, in the form of angiotensin-converting
enzyme inhibitor/angiotensin 2 receptor blocker (ACEi/A2RB), is recognised, the extent to which there is
benefit for subgroups defined by type of diabetes and baseline presence or absence of microalbuminuria is
uncertain. Similarly, there is limited evidence to support recommendations of the frequency with which
both serum creatinine and urinary albumin, most commonly measured as a ‘spot’ albumin-to-creatinine
ratio (ACR), should be measured. Average rates of progression are slow but highly variable, and, in
addition, there is wide variation in the results obtained from a single individual over a short period of time.
There is also debate about the extent to which clinical management should differ between those with and
without early kidney disease.
Previous studies to determine an optimal screening interval for identifying kidney disease have used
average rates of urine albumin level progression to inform their estimates. However, when the rate of
disease progression is low compared with the variability of the measure used to monitor progression,
the majority of positive tests (in this case, diagnosis of diabetic kidney disease, also known as nephropathy)
are false positive (attributable to biological and assay variability rather than underlying disease). For these
false-positive individuals, the adverse effects of treatment may outweigh the potential benefits. From a
wider perspective, substantial resources may be diverted to providing treatment of minimal benefit. To
establish the optimal strategy for screening, we therefore drew together data about the effectiveness of
treatment and changes in albumin excretion level to carry out a cost-effectiveness modelling study.Objectives
Our objective was to determine the clinical value and cost-effectiveness of screening programmes for
kidney disease in people with type 1 and type 2 diabetes, including current practice of annual screening.
Specifically, we aimed to:
l determine whether the renal benefit of ACEi or A2RB treatment varies by presence or absence of early
kidney disease (baseline renal status) and type of diabetes
l quantify trends and variability in markers of early kidney disease, including estimated glomerular
filtration rate (eGFR) and ACR
l estimate the proportion of diagnoses of diabetic kidney disease that are likely to be a result of
measurement error and biovariability, rather than true change in underlying renal function; and hence
l estimate cost-effectiveness ratios for annual and other screening programmes for kidney disease in
type 1 and type 2 diabetes.Methods
We performed a systematic review of randomised controlled trials of ACEi and A2RB for the prevention or
treatment of diabetic kidney disease. We restricted analyses to trials that clearly identified participants’xxv
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SCIENTIFIC SUMMARY
xxvibaseline renal status and type of diabetes. We pooled data for the primary outcome, comparing the ratio
of urinary albumin levels at the end of each trial in those treated with ACEi or A2RB with comparator
groups not treated with ACEi or A2RB, using a random effects model to estimate heterogeneity of
outcomes (I2). We also carried out further limited reviews to inform our estimates of renal progression rates
in patients with microalbuminuria and their variation in specified subgroups of patients.
To estimate progression of albuminuria in patients with type 1 and type 2 diabetes, the variability of the
initial estimates of albumin levels, the variability of individual follow-up measurements and the variability of
rates of progression, we used data from two large cohorts: the Oxford Regional Prospective Diabetes Study
(ORPS) in type 1 diabetes and the Collaborative Atorvastatin Diabetes Study (CARDS) in type 2 diabetes.
These estimates were derived using a hierarchical linear model for log-ACR. A similar approach was used
to explore the data sets for eGFR measurements. The diagnostic strategies on which the clinical pathways
were modelled were those recommended by the National Institute for Health and Care Excellence.
A simulation model was used to express these results in the form of numbers of individuals identified from
screening, together with estimates of the proportion identified who would have ‘false-positive’ tests and,
therefore, might be unnecessarily treated.
For type 1 diabetes, we found no health-economic model that we could use to predict the impact of
screening for kidney disease and, therefore, needed to develop and validate a new model. Hence, we
combined our simulation model based on ORPS data with mortality, morbidity and cost data identified in
the literature review to produce a cost-effectiveness model. Risk of cardiovascular disease (CVD) estimates
were obtained from results of the Diabetes Control and Complications Trial; estimates of mortality post
CVD events were based on a study using linked administrative data on people with diabetes from Western
Australia; and information on the incidence of kidney disease and progression to CVD was obtained from
studies in Finland and Italy. When diabetes-specific data were unavailable, information from other
populations was used.
We examined the degree and source of parametric uncertainty and used the model to estimate lifetime
outcomes of using intensive and conventional blood glucose control to illustrate its potential application.
The type 1 model was validated by comparing simulated life expectancies with those calculated from a UK
life table, scaled to reflect a higher mortality risk among people with type 1 diabetes. For type 2 diabetes,
an existing health economic simulation model [the United Kingdom Prospective Diabetes Study (UKPDS)
outcomes model] was extended to incorporate our simulation model of ACR progression based on CARDS
data and the analysis of type 2 diabetes trials in our systematic review.
The current and alternative screening programmes with different screening intervals were evaluated
using these simulation models to determine whether current UK guidelines for annual screening are
cost-effective. Hospitalisation costs were obtained from previously published UKPDS data and adjusted
to current prices using the Hospital and Community Services pay and price index. The costs of kidney
disease and the costs of administering the screening test were obtained from the Chronic Kidney Disease
Costing Report. Treatment and clinical costs were also included using the Prescription Cost Analysis
England and Unit Costs of Health and Social Care reports. Utility values were obtained from a
meta-analysis of diabetes studies and, where some diabetic complications were not reported, further
published data from the UKPDS.Results
Our systematic review identified a total of 49 trials (34,082 patients). Urinary albumin excretion (UAE) for
patients with type 1 diabetes and microalbuminuria treated with ACEi or A2RB was 67% [95% confidence
intervals (CI) 54% to 77%; I2 = 83%] lower on average at the end of the trial than in those patients not
treated with ACEi or A2RB. There was no effect of treatment in patients with normoalbuminuria (absence
of microalbuminuria). For patients with type 2 diabetes, UAE was 21% (95% CI 7% to 32%; I2 = 85%)NIHR Journals Library www.journalslibrary.nihr.ac.uk
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those with normoalbuminuria and microalbuminuria, respectively.
Simulation modelling of the proportion of patients with true- and false-positive tests for development of
impaired renal function measured with eGFR was not possible in the ORPS (type 1 diabetes) cohort, where
the occurrence of a low glomerular filtration rate in the absence of microalbuminuria was so infrequent
that there were no data from which to derive parameters. In the CARDS (type 2 diabetes), simulation
modelling to identify progression to stage 3b kidney disease with an eGFR < 45ml/minute in patients with
normoalbuminuria suggested that, with annual eGFR measurement, 10 in 1000 patients would be
identified at 6 years post diagnosis of type 2 diabetes, 80% of whom might have been either inaccurately
or prematurely identified.
For type 1 diabetes, the mean increase in albumin excretion at 1 year for males with normoalbuminuria
was estimated at 3% (95% CI 2% to 5%) and for females 4% (95% CI 3% to 6%). The average ACR at
baseline (diagnosis of diabetes) was 0.77 mg/mmol (95% CI 0.71 to 0.83 mg/mmol) for males and
0.95 mg/mmol (95% CI 0.87 to 1.04mg/mmol) for females. In the simulation model, the proportion of the
male population diagnosed with microalbuminuria with annual testing increased from 7.7% at baseline to
20.4% at 3 years and 30.7% at 6 years. With 3-yearly testing, the proportions at 3 and 6 years,
respectively, were 14.7% and 22.7%. In men and women with type 1 diabetes, 48% (95% CI 43% to
53%) and 55% (95% CI 48% to 61%) of patients, respectively, tested annually for microalbuminuria over
6 years would be inaccurately identified with microalbuminuria, and in type 2 diabetes the proportions are
36% (95% CI 32% to 42%) and 48% (95% CI 41% to 55%), respectively. Reducing the screening
interval to 3-yearly would reduce this to a false-positive rate of 38% (95% CI 33% to 44%) for men with
type 1 diabetes, with an increase in those individuals not identified over the 6-year period from 1.5%
(95% CI 1% to 2%) to 4% (95% CI 3% to 5%).
Using the simulation models for type 1 diabetes, the incremental cost per quality-adjusted life-year (QALY)
(standard deviation) of a 5-yearly compared with a 4-yearly screening interval was £3612 (£6586),
increasing to £9601 (£34,112) for annual compared with 2-yearly screening. The probability the
intervention is cost-saving is around 25% and it has around an 80% chance of being below the
cost-effectiveness threshold of £30,000. For type 2 diabetes, the incremental cost per QALY of annual
screening compared with a 2-yearly interval was £606 (£1782), making the intervention highly
cost-effective. Screening at intervals less frequent than every 5 years has little impact on QALYs. The
intervention appears to have a 100% probability of being below a cost-effectiveness threshold of £5000.Discussion
The extent of reduction in renal albumin excretion with ACEi and A2RB treatment in patients with type 1
diabetes varies with presence or absence of microalbuminuria: treatment reduced albumin excretion rates
by two-thirds in patients with prior microalbuminuria, but there was no evidence of benefit for patients
without albumin in their urine. For type 2 diabetes, the relative benefit of treatment was approximately the
same regardless of the presence or absence of microalbuminuria.
The ACR remains highly variable as a measure and, despite confirmation with two subsequent tests, has a
high rate of false-positive diagnoses of microalbuminuria. In contrast, false-negative rates are low.
The eGFR has a limited role in monitoring renal progression in early diabetic kidney disease. In the current
analysis, it adds no additional information in predicting the progression to macroalbuminuria for patients
with type 1 and type 2 diabetes with chronic kidney disease stages ≥ 3 (eGFR > 60ml/minute).xxvii
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xxviiiAnnual screening with ACR appears to be cost-effective as an intervention to minimise the risk of adverse
renal outcomes for both patients with type 1 diabetes and patients with type 2 diabetes, despite a high
false-positive rate of screening leading to, at worst, unnecessary or, at best, early therapeutic intervention
with ACEi and A2RBs. The source of variability when screening for albuminuria is the physiological
variability of the disease marker in the individual. Improvements in test performance are unlikely and,
therefore, new disease markers for the detection of risk of diabetic kidney disease are needed.
There are a number of limitations to this work, including the need for further validation of the type 1 and
adapted type 2 health economic models, the exploratory nature of this work, which synthesises data from
a wide range of sources, the lack of cardiovascular outcome data for the impact of ACEi and A2RB, and
the limited range of options for screening considered. Our data for type 1 diabetes is drawn from a
younger cohort; a clinical trial is currently under way that will provide more information about treatment of
this group with A2RBs, even in the absence of elevated levels of albuminuria. In addition, options for
regular monitoring need to consider the practicality of moving away from annual screening intervals and
the importance of patients’ perceptions of screening intervals.Conclusions
The simulated outcomes from both type 1 and type 2 models provide an evidence base to support current
UK guidance for annual screening to identify the development of early kidney disease in both patients
with type 1 diabetes and patients with type 2 diabetes.Research priorities
Our type 1 health economic simulation model can be revised as further data become available from large
studies of patients with type 1 diabetes to allow our conclusions to be further tested.
The type 1 simulation model will provide a tool with which other health economic questions about type 1
diabetes can be addressed.
Our estimates of cost-effectiveness may be improved by establishing cohorts of individuals at increased
risk of developing microalbuminuria and diabetic kidney disease, with sampling at intervals more frequent
than annually.
Further research is needed, and is already under way among children with type 1 diabetes, to establish
whether individuals at risk of developing kidney disease might benefit from treatment before the
occurrence of microalbuminuria. For example, those with an ACR persistently in the upper range of normal
may represent a group at increased risk who may benefit from early treatment.
Alternative markers of kidney disease may be helpful to identify the risk of diabetic kidney disease. For
example, cystatin C is an alternative to eGFR measurement for those who maintain normoalbuminuria,
and might be included as a measure in cohort studies of individuals undergoing long-term monitoring of
renal function.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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cardiovascular risk equivalent. Subgroup analyses from trials currently in progress may provide information
that could change some of the assumptions around the benefits of screening included in our models.
Qualitative work may be required, along with subsequent surveys and, if appropriate, trials, to establish
whether patient knowledge of renal albumin status provides an additional motivational factor sufficient to
increase adherence to medication without causing an adverse impact on wellbeing.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.xxix
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Diabetes is one of the leading causes of death and disability. The number of people with diabetes isprojected to double worldwide over the next 30 years: 85% of patients are categorised as having
type 2 diabetes, with associated mortality predominantly from cardiovascular diseases (CVDs). Another
major complication of diabetes is diabetic kidney disease, which affects around 35% of the diabetic
population.1 At each successive stage of diabetic kidney disease there is an increased risk of cardiovascular
death.2 With younger onset of diabetes and a focus on preventing cardiovascular events among patients
with diabetes, the number of patients projected to progress to chronic kidney disease is likely to rise.
Optimising the clinical strategy for identification of deteriorating renal function is therefore of
major importance.
The measurement of albumin levels is widely accepted as a simple, safe and validated test for identifying
patients at an early stage of disease.3 However, there remains a number of unanswered questions about
the utility of this test, including whether it meets the criteria for a screening test and, if it does meet these
criteria, what the optimal interval for retesting is. A report from the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) programme identified the limited evidence supporting
universal screening for microalbuminuria,4 but, despite the concerns raised, yearly intervals for screening
continue to be incentivised within the United Kingdom Quality Outcomes Framework. Further work in this
area supported by the NIHR HTA includes a systematic review of early referral strategies for the
management of people with markers of kidney disease.5
The work described in this report, therefore, forms part of a commissioned stream of work by the NIHR
HTA programme to focus on a key recommendation of previous work: to identify an evidence base for the
frequency of screening tests for microalbuminuria. This work has involved utilising and developing new
approaches for determining the intervals at which a disease parameter should be monitored: systematic
review of the literature to establish effect size of treatment with renin–angiotensin–aldosterone system
inhibitors (RAASIs); deriving parameters from repeated measurements in cohort studies to identify
biological variability, measurement error and coefficients of variation in the rate of change of
microalbuminuria and glomerular filtration rate (GFR) over time; and health economic modelling to
establish the cost-effectiveness of different strategies for monitoring.
This introductory chapter, therefore, sets out what we know about the development and progression of
diabetic kidney disease to set the clinical background for this work, and provides the rationale for the
estimates for a range of the parameters used in health economic modelling.Diabetes mellitus, microalbuminuria and kidney diseaseRenal, or kidney, disease is a serious and common complication of diabetes. Kidney damage in diabetes
can arise from both microvascular (classic diabetic kidney disease) and arterial (renovascular) damage.6
Diabetic kidney disease, characterised by a sustained increase in urinary albumin excretion (UAE),7 is an
increasingly common cause of end-stage kidney disease. There are nearly 350 million people worldwide
with diabetes,8 and the numbers are projected to increase further. About one-third of those with type 2
diabetes9 and 35% with type 1 diabetes develop a progressive deterioration of renal function.10 In
addition, raised UAE is a marker of increased risk of CVD, with 40–50% of those with type 2 diabetes and
microalbuminuria eventually dying of CVD.
Diabetic kidney disease has a major impact on patients’ lives. It is expensive to treat and kidney disease
progression is a marker of subsequent morbidity and mortality.11 In the UK in 2004, the total annual
NHS costs for managing diabetic kidney disease were reported as £152M for type 1 diabetes and £614M
for type 2 diabetes.121
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INTRODUCTION AND RATIONALE
2Kidney disease is usually categorised into five stages determined by GFR, with the first stage identified by
albuminuria or other abnormal function (Table 1 and Figure 1), and the remaining four stages by
deterioration below thresholds of 90, 60, 30 and 15ml/minute/1.73 m2. In routine clinical practice, the
GFR is estimated from serum creatinine, age and sex using an equation derived from the Modification of
Diets in Renal Disease (MDRD) study.14
Epidemiology of microalbuminuria
Microalbuminuria is a marker of the early stages of kidney disease and reflects widespread vascular
damage. Thus, it is a marker of increased risk in both type 1 and type 2 diabetes.Definitions of microalbuminuria
Microalbuminuria is conventionally defined as levels of albumin ranging from 30 to 300mg in a 24-hour
urine collection (Table 2).15 Overt albuminuria, macroalbuminuria or proteinuria is defined as a UAE of
≥ 300mg/24 hours. There is increasing recognition, however, that there is not an arbitrary boundary
between levels of albumin excretion and that there is a continuum of progression in which the level of
albumin provides a marker of how far the disease has advanced.3 In recognition of this, a recent positionTABLE 1 Stages of chronic kidney disease based on urine albumin excretion (UAE) and estimated GFR (eGFR)
Stage eGFR UAE
1 Kidney damage with no impairment > 90ml/minute/1.73m2 Normal/micro/proteinuria
With other evidence of kidney disease
2 Mild impairment 60–90ml/minute/1.73m2 Normal/micro/proteinuria
With other evidence of kidney disease
3a Moderate impairment 45–59ml/minute/1.73m2 Normal/micro/proteinuria
3b Moderate impairment 30–44ml/minute/1.73m2 Normal/micro/proteinuria
4 Severe impairment 15–29ml/minute/1.73m2 Normal/micro/proteinuria
5 Renal failure < 15ml/minute/1.73m2; or Normal/micro/proteinuria
On dialysis
Kidney Disease Outcomes Quality Initiative.13
Normoalbuminaria Microalbuminaria
Threshold for diagnosis of
microalbuminaria
Rate of urinary albumin excretion
Time (years)
Glomerular filtration rate
ProteinuriaFIGURE 1 Development of diabetic kidney disease and micro- and macroalbuminuria.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 2 Definitions of normal UAE, microalbuminuria and proteinuria
Measure of albumin excretion Normal UAE Microalbuminuria Proteinuria
ACR
Female < 3.5 3.5–30.0 > 30
Male < 2.5 2.5–30.0 > 30
Timed overnight UAE rate (µg/minute) < 20 20–200 > 200
24-hour urine collection (mg/24 hours) < 30 30–300 > 300
ACR, albumin-to-creatinine ratio.
Kidney Disease Outcomes Quality Initiative.13
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respectively, by the terms ‘high albuminuria’ and ‘very high albuminuria’.16
In clinical practice, albuminuria is measured by the albumin-to-creatinine ratio (ACR) in a random or
first-pass morning sample of urine. Because women excrete less creatinine than men, clinicians in the UK
use different ACR thresholds for diagnosing microalbuminuria in men and women.17Are tests to detect the onset of microalbuminuria reliable?
Detecting whether levels of urinary albumin reach the threshold for diagnosis of microalbuminuria is not
straightforward. First, levels of albumin may be affected by concurrent illness including virus infections and
urinary tract infections. They may also be elevated after physical activity. Second, levels vary within an
individual. There is evidence, at least for type 1 diabetes, that the occurrence of intermittent tests above
the threshold for microalbuminuria predicts progression, and that those with levels of urinary albumin
close but below the threshold have an increased risk of progression.18 To address these issues, a standard
protocol for diagnosis of microalbuminuria requires additional tests following a positive test, with at least
one of the further tests required to also be above the diagnostic threshold (Figure 2). Standard protocols
recommended in guidelines vary slightly;15,19 however, they are broadly consistent in aiming to optimise
the delivery of targeted intensification of therapy to high-risk patients, for whom the treatments will
provide a greater absolute risk reduction than they would in those at lower risk.3Initial ‘spot’ urine sample
for microalbuminuria
If abnormal confirm on
‘first pass’ urine sample
Repeat testing for microalbuminuria
within the next 3–4 months
Tests confirm presence of microalbuminuria
if at least one of the two follow-up tests are positive
If both follow-up tests negative,
then repeat after 1 year
If normal repeat in 1 year
IGURE 2 Flow chart for confirmation of microalbuminuria. Tests need to be carried out in the absence of
roteinuria/urinary tract infection. Test abnormal if ACR > 2.5mg/mmol for men and > 3.5mg/mmol for women.
19F
p
Based on the guidance in National Institute for Health and Care Excellence CG66.
3
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INTRODUCTION AND RATIONALE
4The development and progression of diabetic kidney disease
Determinants for the development and progression of diabetic kidney disease are well established and
discussed in detail below. Although there are familial elements that contribute to the risk of developing
kidney disease, there are, as yet, no genetic traits that have been identified as contributing a substantial
risk. However, there are some differences in the risk factors for development and progression of diabetic
kidney disease between type 1 and 2 diabetes.Development and progression of diabetic kidney disease in type 1 diabetes
The epidemiology of diabetic kidney disease is most easily studied in patients with type 1 disease, as it is
usually possible to identify a defined time point of onset. Around 1.5% to 2.0% of patients develop
microalbuminuria annually, with one-third of patients having microalbuminuria after 15 years of diabetes,
and 50% at some point in their lives, although a recent study put the figure lower, at 35%.15,19 If
untreated, the rate of increase in UAE following development of microalbuminuria is approximately 20% a
year. Once identified as having microalbuminuria, less than half of the patients will progress to chronic
kidney disease, and the remainder will either regress or remain stable.1
A 25–50% elevation in GFR is seen soon after diagnosis in up to half of patients with type 1 diabetes
mellitus. The significance of these changes remains uncertain. These changes in the haemodynamic of the
circulation may represent early pathological changes, or may be a compensatory response to changes in
tubular reabsorption as a consequence of hyperinsulinaemia and other factors.20
At diagnosis, UAE is in the normal range for all patients with type 1 diabetes, unless there is ketosis. In the
early years, microalbuminuria is not found unless there is poor glycaemic control, in which case it may be a
reversible abnormality. Diabetic kidney disease results from characteristic structural and functional changes
to the glomerulus. These changes include mesangial expansion, glomerular basement membrane
thickening and glomerular sclerosis. Poor glycaemic control is the main reason for the development of
albuminuria and diabetic kidney disease.21 Once microalbuminuria develops, for many individuals there is
an overall increase in blood pressure.Development and progression of diabetic kidney disease in type 2 diabetes
There are now a wide range of studies that provide information about the development and progression
of diabetic kidney disease in patients with type 2 diabetes. As with type 1 diabetes, the initial development
of albuminuria is a consequence of poor glycaemic control, although elevated blood pressure and
dyslipidaemia may already be present at diagnosis. In the United Kingdom Prospective Diabetes Study
(UKPDS), approximately 7.3% of individuals were found to have microalbuminuria or worse already
present at diagnosis of diabetes.22 Modelled estimates from the study suggest that the median time that
patients remain free of microalbuminuria is 18.9 years. The figures for prevalence of kidney disease vary
between studies. For example, in the Wisconsin Epidemiological Study of Diabetic Retinopathy, 54.8% of
participants did not have kidney disease at 15 years,23 compared with 72.0% in the UKPDS cohort,22 with a
rate of progression from normoalbuminuria to microalbuminuria of 2.0% per year.Normoalbuminuric chronic kidney disease in type 2 diabetes
An important component of monitoring patients with type 2 diabetes is the role of serum creatinine tests
for identifying impaired renal function. A substantial proportion of individuals with type 2 diabetes, but
without microalbuminuria, have an estimated GFR (eGFR) of < 60ml/minute/1.73 m2. Studies using isotopic
GFR (iGFR) measurements in patients with type 2 diabetes suggest that up to 24% of those with stage 3
renal disease may not have albuminuria.24 Similar development of renal insufficiency in the absence of
albuminuria and retinopathy has been demonstrated in large-scale studies using eGFR.25 UK-based studies
in primary care suggested that, in patients who had diabetes and an eGFR < 60ml/minute/1.7 3m2, 63%
had normoalbuminuria.26 Although there is continuing uncertainty over the relationship between this
impaired renal function and diabetes, the most likely aetiology is hypertensive or intrarenal vascular
disease, with some degree of misclassification caused by a normal degree of declining renal function in
older people.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Risk factors affecting progression to microalbuminuria in type 1 diabetes
The strongest risk factor affecting progression from normal renal function to microalbuminuria is glycaemia
(Tables 3–5). Data from the Diabetes Control and Complications Trial (DCCT) confirms a 39% relative risk
reduction for development of microalbuminuria with intensive versus conventional treatment.45 Smoking is
also a strong predictor of the development of microalbuminuria with a hazard ratio of 1.28 quoted in one
study,46 and an odds ratio of 1.40 found in another.33 Following cessation of smoking, the rate of loss of
renal function is lower than among those who continue to smoke. Elevated blood pressure is also a strong
predictor of progression to microalbuminuria. Although protein intake is often cited as a risk factor for
progression to microalbuminuria, the evidence is tenuous.47
The Oxford Regional Prospective Study of Childhood Diabetes (ORPS) has identified the importance
of non-glycaemia-related factors in the development of microalbuminuria. In this young adult cohort of
type 1 patients, there was no glycated haemoglobin (HbA1c) threshold below which microalbuminuria
did not appear.48TABLE 3 Rates of progression of UAE in patients with diabetes
Study
(first author, year) Patients Findings
Type 1 diabetes: normoalbuminuria
Lin 200827 725 normoalbuminuric patients from the
DCCT followed for a median of 6.5 years
In the fully adjusted mixed-effects regression
models, the AER increase was 1.44 µg/minute/
year in the primary prevention group
Bilous 200928 710 normoalbuminuric patients without
retinopathy followed for 6 years
Least squares mean of annual change in
UAER = 0.54 µg/minute (95% CI 0.52 to
0.57 µg/minute)
Type 1 diabetes: microalbuminuria
Lin 200827 642 microalbuminuric patients from the DCCT
followed for a median of 6.5 years
In the fully adjusted mixed-effects regression
models, the AER increase was 8.71 µg/minute/
year in the secondary prevention group
Rossing 200529 181 patients followed up for a median of
7.9 years
Mean annual rate of progression (± SEM) of
urinary albumin was 6.2 ± 1.7%). Annual
progression rate (± SEM) without
antihypertensives was 11.1 ± 2.6
Type 2 diabetes: normoalbuminuria
Bilous 200928 954 normoalbuminuric patients without
retinopathy or hypertension, followed for
6 years
Least squares mean of annual change in
UAER = 0.69 µg/minute (95% CI 0.65 to 0.74)
Type 2 diabetes: microalbuminuria
Ravid 199330 45 microalbuminuric patients followed for
5 years
AER increased from a mean ± SD of
123 ± 58mg/24 hours to a mean ± SD of
310 ± 167mg/24 hours after 5 years
Ahmad 199731 51 microalbuminuric patients followed for
5 years
AER increased from a mean ± SD of
76.3 ± 44.6mg/24 hours to a mean ± SD of
122.4 ± 129.6 mg/24 hours after 5 years
Christensen 198532 10 patients followed for 4.9 years Annual increase in urinary albumin 19 ± 22
(mean ± SD)
AER, albumin excretion rate; CI, confidence interval; DCCT, Diabetes Control and Complications Trial; SD, standard
deviation; SEM, standard error of the mean; UAER, UAE rate.
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TABLE 4 Large observational studies (n >500) that identified risk factors predicting the progression of UAE
Study
(first author, year)
Type of
diabetes
Baseline urinary
albumin Measurement of progression n
aVergouwe 201033 1 Normoalbuminuria Microalbuminuria defined as an AER of
20–200 g/minute, where the result is obtained as
an average from two 24-hour urine collections
1115
Kilpatrick 200834 1 Normoalbuminuria An increase in AER of ≥ 40mg/24 hours
(28 µg/minute) on any annual evaluation
1441
aChaturvedi 200135 1 Normoalbuminuria AER between 20 and 200 µg/minute 1134
Waden 200936 1 Mixed Shift to higher urinary albumin level,
microalbuminuria defined as UAER ≥ 30 and
< 300mg/24 hours and macroalbuminuria
defined as UAER ≥ 300mg/24 hours in two of
three consecutive timed measurements
2107
RCPEDRG 200037 1 Mixed Geometric mean of two consecutive urinary
albumin concentrations above 200mg/l, or a
single value above 1000mg/l on a first void,
morning, spot sample
1164
Rossing 200238 1 Mixed Shift to higher urinary albumin level,
microalbuminuria defined as UAER 31–299mg/
24 hours and macroalbuminuria defined as UAER
≥ 300mg/24 hours in two of three consecutive
timed measurements
537
Retnakaran 200639 2 Normoalbuminuria Microalbuminuria defined as urinary albumin
concentration of 50–299mg/l
4031
Amini 200740 2 Normoalbuminuria Microalbuminuria defined as 24-hour urinary
albumin concentration of 30–300mg
505
Agrawal 201141 2 Mixed Normoalbuminuria defined as 0–29mg/g,
microalbuminuria 30–300mg/g and
microalbuminuria > 300mg/g. Progression to
next level after at least two measurements
1791
Bruno 200342 2 Mixed 1253
Xu 200843 Not
specified
Normoalbuminuria Random morning urine sample,
normoalbuminuria defined as ACR < 30mg/g
1330
AER, albumin excretion rate; RCPEDRG, Royal College of Physicians of Edinburgh Diabetes Register Group; UAER, UAE rate.
Shading denotes normoalbuminuria at baseline.
a Study used data from EUROpean DIABetes (EURODIAB) prospective complications study.
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6Risk factors affecting progression to microalbuminuria in type 2 diabetes
As with type 1 diabetes, glycaemia is one of the most important markers of progression to
microalbuminuria in patients with type 2 diabetes. However, the effects of other adverse risk markers are
more difficult to establish, as there are typically a number of coexistent risk factors in any one individual,
with uncertainty about the period of exposure.
Evidence for the overall impact of glycaemia on progression to microalbuminuria is now available from a
number of studies. In an epidemiological analysis of the UKPDS, the hazard ratio for a 1% increase in
HbA1c was estimated as 1.08.22 There is also strong epidemiological evidence that elevated systolic blood
pressure is related to progression to microalbuminuria.
Ethnicity is a factor in determining progression to end-stage kidney disease. For example, the incidence
rate of requiring renal replacement therapy for diabetic kidney disease for those of Asian ethnic origin was
486.6 [95% confidence interval (CI) 185.1 to 788.1] cases per million person-years per year, comparedNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 5 Independent risk factors and hazard ratios for progression of albumin levels in patients with diabetes
(in order of frequency of reporting)
Risk factor
Study
(first author, year)
Type of
diabetes
Baseline urinary
albumin
HR/OR/
RR/SERR Effect size (95% CI)
HbA1c per 1%
change in A1c
Kilpatrick 200834 1 Normoalbuminuria HR 1.13 (1.05 to 1.22)a
Chaturvedi 200135 1 Normoalbuminuria OR 1.29 (1.14 to 1.47)
Rossing 200238 1 Normo- and
microalbuminuria
RR 1.13 (1.04 to 1.23)
Waden 200936 1 Normo- and
microalbuminuria
HR 1.34 (1.20 to 1.51)d
Retnakaran 200639 2 Normoalbuminuria HR 1.08 (1.03 to 1.12)
Agrawal 201141 2 Normo- and
microalbuminuria
Not significant
Bruno42 2 Normo- and
microalbuminuria
OR 1.26 (0.78 to 2.03)g
Xu 200843 NS Normoalbuminuria Not significant
Fasting plasma
glucose
(per 10mg/dl)
Xu 200843 NS Normoalbuminuria OR 1.01 (1.00 to 1.02)
Male sex Waden 200936 1 Normo- and
microalbuminuria
HR 1.74 (1.30 to 2.33)
Retnakaran 200639 2 Normoalbuminuria HR 1.18 (1.01 to 1.39)
Xu 200843 NS Normoalbuminuria Not significant
Cholesterol Chaturvedi 200135 1 Normoalbuminuria Not significant
Waden 200936 1 Normo- and
microalbuminuria
HR 1.19 (1.04 to 1.36)
LDL cholesterol Chaturvedi 200135 1 Normoalbuminuria Significantc
Xu 200843 NS Normoalbuminuria Not significant
HDL cholesterol Chaturvedi 200135 1 Normoalbuminuria Significantc
Bruno 200342 2 Normo- and
microalbuminuria
OR 0.54 (0.33 to 0.89)g
Xu 200843 NS Normoalbuminuria Not significant
Triglycerides per
10-fold increase
Chaturvedi 200135 1 Normoalbuminuria SERRb 1.31 (1.05 to 1.65)
Retnakaran 200639 2 Normoalbuminuria HR 1.09 (1.04 to 1.14)
Xu 200843 NS Normoalbuminuria Not significant
UAE
Per microgram
per minute
Chaturvedi 200135 1 Normoalbuminuria OR 1.04 (1.01 to 1.08)
Per 10-fold
increase
Rossing 200238 1 Normo- and
microalbuminuria
RR Log-UA: 2.63
(1.65 to 4.19)
Per 20mg/l Retnakaran 200639 2 Normoalbuminuria HR 1.004 (1.002
to 1.007)
continued
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TABLE 5 Independent risk factors and hazard ratios for progression of albumin levels in patients with diabetes
(in order of frequency of reporting) (continued )
Risk factor
Study
(first author, year)
Type of
diabetes
Baseline urinary
albumin
HR/OR/
RR/SERR Effect size (95% CI)
Log-ACR Agrawal 201141 2 Normo- and
microalbuminuria
OR 1.27 (1.11 to 1.45)
Microalbuminuria Bruno 200342 2 Normo- and
microalbuminuria
OR 1.42 (0.98 to 2.06)
ACR≥ 10 vs.
< 5mg/g
Xu 200843 NS Normoalbuminuria OR 2.71 (1.89 to 3.90)
Systolic blood
pressure
Chaturvedi 200135 1 Normoalbuminuria Not significant
Waden 200936 1 Normo- and
microalbuminuria
HR 1.01 (1.00 to 1.02)
Retnakaran 200639 2 Normoalbuminuria HR 1.01 (1.01 to 1.02)
Bruno 200342 2 Normo- and
microalbuminuria
OR 1.21 (0.67 to 2.18)g
Xu 200843 NS Normoalbuminuria OR 1.02 (1.01 to 1.04)
Diastolic blood
pressure
Chaturvedi 200135 1 Normoalbuminuria Not significant
Agrawal 201141 2 Normo- and
microalbuminuria
Not significantf
Current smoker Chaturvedi 200135 1 Normoalbuminuria Not significante
Rossing 200238 1 Normo- and
microalbuminuria
RR 1.61 (1.11 to 2.33)
Ever smoked Waden 200936 1 Normo- and
microalbuminuria
HR 1.22 (0.92 to 1.63)
Retnakaran 200639 2 Normoalbuminuria HR 1.20 (1.01 to 1.42)
Agrawal 201141 2 Normo- and
microalbuminuria
Not significant
Xu 200843 NS Normoalbuminuria OR 1.49 (1.12 to 1.99)
Retinopathy Chaturvedi 200135 1 Normoalbuminuria RR 1.80 (1.10 to 2.80)
Rossing 200238 1 Normo- and
microalbuminuria
RR 1.90 (1.26 to 2.88)
Retnakaran 200639 2 Normoalbuminuria HR 1.25 (1.05 to 1.49)
Agrawal 201141 2 Normo- and
microalbuminuria
Not significant
Body mass index Chaturvedi 200135 1 Normoalbuminuria Significante
Agrawal 201141 2 Normo- and
microalbuminuria
Not significantf
Xu 200843 NS Normoalbuminuria Not significant
Waist-to-hip ratio Chaturvedi 200135 1 Normoalbuminuria SERRb 1.27 (1.02 to 1.50)
Waist (cm) Retnakaran 200639 2 Normoalbuminuria HR 1.010 (1.004
to 1.016)
HbA1C variability Waden 200936 1 Normo- and
microalbuminuria
HR 1.92 (1.49 to 2.47)
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8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 5 Independent risk factors and hazard ratios for progression of albumin levels in patients with diabetes
(in order of frequency of reporting) (continued )
Risk factor
Study
(first author, year)
Type of
diabetes
Baseline urinary
albumin
HR/OR/
RR/SERR Effect size (95% CI)
Duration of
diabetes
Chaturvedi 200135 1 Normoalbuminuria Not significant
Waden 200936 1 Normo- and
microalbuminuria
HR 1.01 (0.99 to 1.02)
Agrawal 201141 2 Normo- and
microalbuminuria
Not significant
Bruno 200342 2 Normo- and
microalbuminuria
OR 1.39 (0.85 to 2.28)g
Xu 200843 NS Normoalbuminuria Not significant
Age Chaturvedi 200135 1 Normoalbuminuria Not significant
At diagnosis Retnakaran 200639 2 Normoalbuminuria HR 1.01 (0.97 to 1.06)
Agrawal 201141 2 Normo- and
microalbuminuria
Not significant
Per 5 years Xu 200843 NS Normoalbuminuria Not significant
Ethnicity Retnakaran 200639 2 Normoalbuminuria HR 1.21 (0.89 to 1.65)
(Afro-Caribbean);
2.02 (1.59 to 2.60)
(Indian Asian)
Agrawal 201141 2 Normo- and
microalbuminuria
Not significant
Chandie Shaw 200644
(South Asian migrants)
2 OR 3.9 (1.1 to 14)
White cell count Retnakaran 200639 2 Normoalbuminuria HR 1.06 (1.02 to 1.10)
Previous CVD Retnakaran 200639 2 Normoalbuminuria HR 1.46 (1.23 to 1.73)
Plasma creatinine Xu 200843 NS Normoalbuminuria OR 2.92 (1.27 to 6.69)
History of
photocoagulation
Agrawal 201141 2 Normo- and
microalbuminuria
Not significantf
History of cataract
surgery
Agrawal 201141 2 Normo- and
microalbuminuria
Not significantf
Hypertension Bruno 200342 2 Normo- and
microalbuminuria
OR 0.67 (0.35 to 1.28)
Use of antihypertensive
medication
ACE inhibitors Xu 200843 NS Normoalbuminuria OR 0.60 (0.38 to 0.95)
Other
antihypertensives
Xu 200843 NS Normoalbuminuria OR 1.15 (0.83 to 1.59)
Type of diabetes therapy
Insulin Xu 200843 NS Normoalbuminuria OR 2.35 (1.60 to 3.45)
Oral medication Xu 200843 NS Normoalbuminuria OR 2.02 (1.49 to 2.74)
continued
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TABLE 5 Independent risk factors and hazard ratios for progression of albumin levels in patients with diabetes
(in order of frequency of reporting) (continued )
Risk factor
Study
(first author, year)
Type of
diabetes
Baseline urinary
albumin
HR/OR/
RR/SERR Effect size (95% CI)
Fibrinogen Bruno 300342 2 Normo- and
microalbuminuria
OR 1.54 (0.92 to 2.58)g
ApoB Bruno 200342 2 Normo- and
microalbuminuria
OR 1.34 (0.81 to 2.24)g
ApoB, apolipoprotein B; CI, confidence interval; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein;
HR; hazard ratio; LDL, low-density lipoprotein; NS, not specified; OR, odds ratio; RR, relative risk; SERR, standardised
estimates of relative risk.
Chaturvedi et al.35 also tested von Willebrand factor, fibrinogen, insulin per kilogram body weight, peripheral neuropathy,
autonomic neuropathy, injection of insulin and CVD and found them not to be significant; RRs were not reported.
Agrawal et al.41 also tested insulin treatment at baseline, lipid profile, pancreatic reserve measured by C-peptide,
fibrinogen, plasminogen activator inhibitor-1, previous cardiovascular events, history of vitrectomy, history of macular
oedema and eGFR and found them not to be significant; RRs were not reported.
a Units not stated, assumed per 1% increase.
b Standardised estimate of RR reported in the paper.
c Significant in some analyses; RRs not reported.
d Baseline HbA1c predictive of incident microalbuminuria.
e A later analysis of the same data set (Vergouwe33) did find smoking and body mass index to be significant factors;
reasons for difference not clear.
f Found to be significant in analysis of intensified treatment effect.
g Highest vs. lowest quartile.
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10with 35.6 (95% CI 17 to 54.2) in white Caucasians.49 Another survey found that people of Asian or
Afro-Caribbean origin were almost six times as likely as white Caucasians to be receiving treatment for
end-stage renal failure associated with diabetes.50 In the UKPDS analysis of predictors of progression of
microalbuminuria, the hazard ratio for Indian-Asian ethnicity was 2.0 in a multivariate model.22
Other factors (with associated hazard ratios) found to predict progress to kidney disease noted in the
UKPDS include previous retinopathy (1.25), previous CVD (1.46), male sex (1.18) and elevated
triglycerides (1.09).Search strategy and search results: risk factors for diabetic kidney diseasel The PubMed database was searched to identify prospective cohort studies of ≥ 500 patients with
diabetes that reported hazard ratios or odds ratios for risk factors for progression of UAE.
l Multiple searches were conducted using medical subject heading terms and text words that included
diabetes or diabetes mellitus, combined with relevant text key words such as diabetic nephropathy,
urinary albumin, microalbuminuria, renal disease, renal outcomes and risk factors or progression.
l In total, 89 potential records were identified, 11 of which were eligible for inclusion, and, of these,
6 specifically reported risk factors for progression from normoalbuminuria to microalbuminuria.Impact of impaired renal function on long-term outcomes
Mortality in type 1 diabetes
Persistent microalbuminuria is a marker for a high risk of mortality. The importance of microalbuminuria is
emphasised by data from long-term cohort studies which suggest that type 1 diabetes patients without
kidney disease achieve long-term survival comparable to the general population.51NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Microalbuminuria is well established as a strong predictor of increased mortality in patients with type 2
diabetes compared with those with normoalbuminuria (see Tables 3–5). Since the excess risk was identified
over 25 years ago,7,52 further studies have also characterised the risk of cardiovascular events and
cancer.53,54 Microalbuminuria confers an increased risk of death and cardiovascular morbidity or mortality
with odds ratios of 2.4 and 2.0, respectively.7 However, those patients who have no proteinuria
20–25 years after the onset of type 2 diabetes have a risk of developing overt kidney disease of only about
1% per year. In the UKPDS,22 cardiovascular deaths were 2.0% and 0.7%, respectively, for those with
microalbuminuria and those with normoalbuminuria at 15 years after onset of type 2 diabetes.
In addition to the excess risk imposed by microalbuminuria, studies have confirmed that albuminuria and
reduced eGFR are independently related to CVD event rates, cancer and non-CVD-related death in
low-risk patients with type 2 diabetes.7,52,55 Compared with those with normal renal status, these
markers are predictive of a twofold increase in CVD risk in patients with an eGFR 30–59ml/minute/1.73 m2
or macroalbuminuria.
Quantifying progression to chronic kidney disease is complicated by competing risks, particularly for
patients with type 2 diabetes. CVD is the major cause of morbidity and mortality for patients with
type 2 diabetes. Generally, if eGFR is < 30ml/minute/1.73 m2, then there is a greater chance of death than
progression to renal dialysis. Conversely, if eGFR is > 30 ml/minute/1.73 m2, then death from other causes
is more likely than the patient reaching end-stage kidney disease.
The implications of an eGFR < 60ml/minute/1.73 m2 for an individual aged < 75 years may differ from
those for an individual > 75 years. Recent work has suggested that rates of morbidity and mortality among
the older age group do not differ among those with an eGFR 45–60ml/minute/1.73 m2 and those with
an eGFR > 60ml/minute/1.73 m2. Rates of morbidity and mortality rise only once eGFR falls below
45ml/minute/1.73m2.56 These findings support an approach to screening for chronic kidney disease in
patients with diabetes that uses age to determine the cut-off for more intensive management, and aims to
identify rapid decline in renal function rather than identify individuals > 75 years at increased risk without
either microalbuminuria or an eGFR < 45ml/minute/1.73 m2.Interventions to prevent the development of microalbuminuria
The rationale for screening for microalbuminuria depends on the existence of an effective treatment for
those identified as at increased risk, and the extent to which there is a difference in benefit between
treating those identified and all patients. A series of large, interventional clinical trials has confirmed that
intensive control of glycaemia and blood pressure among individuals with early diabetes reduces the
occurrence of microalbuminuria. The DCCT trial demonstrated substantial reductions in the development
of microalbuminuria with intensive glycaemic management.45 Similarly, both the UKPDS57 and ADVANCE
(Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation)58 trials have
confirmed that the treatment of patients with type 2 diabetes leads to a risk reduction with, for example, a
relative reduction of 20% in onset of new microalbuminuria.58 However, the extent to which treatment
should differ between those with and without microalbuminuria is unclear.
Blood pressure, in particular, is a target for treatments that may have renal benefit. Conventional
thresholds at which to initiate treatment to lower blood pressure are 130/80 and 125/75mmHg for people
with diabetes and those with diabetes and kidney disease, respectively.59 Trials that evaluated lowering
blood pressure below these thresholds, including UKPDS60 and ADVANCE,61 confirm that participants
allocated to regimens targeting lower blood pressures had reduced risks of developing microalbuminuria.
However, in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study, which targeted
patients with more advanced diabetes and prior cardiovascular events, similar benefits were not seen when
targeting a systolic blood pressure of 120mmHg rather than 130mmHg.6211
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Farmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
INTRODUCTION AND RATIONALE
12There is strong evidence that overactivity of the renin–angiotensin–aldosterone system (RAAS) is implicated
in the deterioration of renal function in patients with diabetic kidney disease. Angiotensin-converting
enzyme (ACE) and angiotensin 2 receptor blockers (A2RBs) slow deterioration of GFR and lower the rate of
albumin excretion. The extent to which benefits occur at early stages of the disease is unknown. There is
some evidence that suppression immediately reduces UAE rates, leading to a lower rate of progression of
kidney disease,63 but, to date, a systematic review of the literature has not addressed this question.
We could not identify any studies that separately examine the impact of other specific interventions that
are known predictors of the development of microalbuminuria, for example smoking cessation.Risk reduction in microalbuminuria
Strategies for risk reduction in diabetes patients with microalbuminuria may be envisaged as falling into two
broad and potentially overlapping categories. First, there may be therapies that are effective in reducing
morbidity and mortality for any individual with diabetes; however, the overall absolute risk reduction may
be greatest when individuals are already high risk because of their microalbuminuria. Second, there may be
therapies for which the treatment effect differs in those with and without microalbuminuria.
Reducing blood pressure among those with microalbuminuria may result in a greater reduction in risk than
a reduction in those without microalbuminuria. This raises issues of cost–benefit, requiring judgements
about the benefit of absolute risk reduction and the adverse impacts of additional medication.
Control of lipids and treatment goals are managed in the same way in the presence or absence of
microalbuminuria.64 Other strategies, such as low-protein diets, have been found to be effective only in
moderate to severe kidney failure, not at early stages of kidney disease.
There is good evidence for targeting the overactivity of the RAAS with ACE inhibitors (ACEi) and A2RBs to
reduce progression to kidney disease and reduce risks of cardiovascular events. However, the widespread
use of ACEi in patients with type 2 diabetes (up to 50% of patients with diagnosed diabetes are treated
for hypertension) indicates that, at least for some groups of patients, there may be limited opportunity for
treatment optimisation.64Characteristics of tests for early and established kidney
disease in diabetesIn routine clinical practice, two biochemical markers are widely used to screen for and monitor chronic
kidney disease: urinary albumin (either 24-hour urine collection or a spot ACR) and eGFR, usually
estimated from serum creatinine measurement.
The within-person variation of albumin excretion is large in people with diabetes, with the lowest
within-person coefficient of variation (CV) found for the concentration of albumin in the first morning void
(36%) and for the ACR (31%) (see Chapter 3 for a discussion of the implications of this biological
variability). Assuming a CV of 5% for the measurement of urinary creatinine, a goal of 15% for the
analytical CV for albumin is considered acceptable for estimating the ACR.16
Test strip methods for microalbuminuria have been assessed and do not perform uniformly across all
concentrations. In addition, there is a possibility of urinary dilution or other urinary proteins leading to false
results. However, the routine use of low-cost, low-accuracy methods to determine whether a clinic visit
might be necessary is an approach that might be explored.65
The GFR is the volume of fluid filtered from the renal glomerular capillaries into the Bowman’s capsule per
unit time. GFR predicts CVD, end-stage kidney disease and death. For routine clinical management, eGFR
is calculated from serum creatinine, although these calculations are not valid for children. Serum creatinine
and eGFR are continuous variables subject to biovariability and measurement error. The equations used toNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14calculate eGFR from serum creatinine can result in the misclassification of some people as having early
stage 3 chronic kidney disease.
The concentration of creatinine in peripheral blood is inversely associated with kidney function, usually
measured using GFR. The rate of production of creatinine is proportional to muscle bulk, which varies
among individuals, and thus age, ethnicity and body mass can also be used to estimate GFR (hence, eGFR)
after measurement of serum creatinine. The two most commonly used equations to estimate GFR are the
Cockcroft–Gault and MDRD formulae. The Cockcroft–Gault formula was developed in healthy individuals
and is based on serum creatinine, weight and age. The MDRD equation was developed in American
patients with renal insufficiency and is based on serum creatinine and age. The MDRD equation is
recommended for reporting by UK laboratories. The formula is not well validated in the very old or ethnic
minority groups other than African-Americans. In addition, its use is not valid for children or people with
extremes of body size, muscle mass or nutritional status. As the relationship between serum creatinine and
renal function is non-linear, the equations to estimate eGFR at more normal degrees of renal function are
inaccurate. Laboratories reporting eGFR are encouraged not to report absolute values when eGFR is
> 60 ml/minute/1.73 m2 (about half normal).Models of care for identifying and treating kidney disease
in diabetesStrategies for surveillance of diabetic kidney disease are laid out in recent practice guidelines and
recommendations.15,19 When screening for and monitoring kidney disease, all patients with diabetes are
asked to provide a first-pass morning urine specimen once a year. In the absence of proteinuria or urinary
tract infection, this is sent for estimation of ACR. If a first-pass specimen is unavailable, then a spot sample
should be used and, if abnormal, screening should be repeated with a first-pass specimen (although the
U.S. Kidney Disease Outcomes Quality Initiative 200266 recommend routine use of a spot urine sample).
A blood sample should be taken annually to measure the level of serum creatinine and estimate the GFR
using the MDRD equation.14 If an abnormal ACR is obtained, then at each of the next two clinic visits
(within a maximum of 3–4 months) a further urine sample should be sent. Microalbuminuria is confirmed if
either one of those repeat ACR tests is abnormal (> 2.5 mg/mmol for men or > 3.5 mg/mmol for women).19
If early diabetic kidney disease is detected with persistent microalbuminuria, then the use of ACEi (weighing
up risks with pregnant women) is recommended, with the alternative of using A2RBs if the ACEi is poorly
tolerated. Blood pressure should be maintained below 130/80 mmHg (compared with the threshold of
140/80 mmHg for other diabetes patients). The British Renal Society recommends a referral threshold of
eGFR of 30ml/minute for patients with diabetes, or an average reduction in eGFR of > 4ml/year.
In addition to the guidance offered by the National Institute for Health and Care Excellence (NICE), general
practitioners (GPs) in the UK are offered incentives through the Quality Outcomes Framework to achieve
targets for blood pressure measurement, albumin screening and treatment with ACEi. Despite these
financial incentives for testing, the proportion of patients being tested for microalbuminuria in the last
15 months (2009/10) varies in England from 80% to 92% (www.nchod.nhs.uk).Costs of screening for kidney disease in diabetesThe rationale for any screening programme requires that a net benefit can be achieved at a reasonable
cost as a result of savings from improved outcomes. Recent guidance has noted the absence of health
economic papers addressing the issue of screening for diabetic kidney disease.19 There is, however, a basic
model of the cost-effectiveness of urine albumin screening included in a report published in 2005 which
compares the options of universal treatment with ACEi, annual screening and annual screening of only
those not treated with ACEi.4 The third option was marginally favoured over universal treatment without13
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INTRODUCTION AND RATIONALE
14testing; however, the authors noted the extreme sensitivity of these findings to a range of assumptions
and, in addition, did not address the potential of varying the interval of screening.
Modelling treatment strategies based on microalbuminuria status requires prediction and health economic
models to estimate outcomes based on the presence or absence of microalbuminuria. Such models require
a more detailed specification than the risk calculators used for predicting risk of cardiovascular disease or
mortality.67 To date, such models have not been available, for either type 1 or type 2 diabetes. However,
some models are now available that predict the occurrence of microalbuminuria,33 drawing on data from
large cohort studies and incorporating estimating equations based on renal function. However, the models
available for type 1 diabetes do not incorporate estimates of outcomes by renal function, and the UKPDS
outcomes model68 does not currently incorporate estimating equations derived from long-term follow-up
data (see Chapter 5).
An additional difficulty of current approaches to estimating benefit from identifying people with early kidney
disease is the individual variability of progression and the relatively poor precision of the tests. Longitudinal
studies suggest that, although protein excretion tends, in general, to increase over time, the rate and
direction of change varies between individuals.69,70 Current approaches do not account for individual
variability and thus fail to fully adjust for the possibility that more frequent testing may result in an increase
in the number of false-positive tests. This may result in overestimates of the benefit of evaluated
screening programmes.Aims and objectivesThe aim of the work reported in this monograph, and set out in our original research protocol
(see Appendix 1), is to develop a clinical and economic model of renal function decline, and then to
estimate the clinical effectiveness and cost-effectiveness of different screening models for early kidney
disease in types 1 and 2 diabetes.Research questionsThere is now sufficient evidence, laid out in this introductory chapter, that treatments are available that
reduce the risk of progressing from diabetic kidney disease to chronic kidney disease, in addition to
modifying the associated risks of CVD. However, the differential benefit of these treatments in those
identified with early kidney disease and those who do not have detectable kidney disease remains unclear.
Our objective is, therefore, to determine the clinical value and cost-effectiveness of screening programmes
for early kidney disease in people with type 1 and type 2 diabetes, including current practice of annual
screening. Specifically, our aim is to:
l determine whether the renal benefit of ACEi or A2RB treatment varies by the presence or absence of
early kidney disease (renal disease status) and type of diabetes (see Chapter 2);
l quantify trends and variability in markers of kidney disease including eGFR and ACR (see Chapters 3
and 4);
l estimate the proportion of diagnoses of diabetic kidney disease that are likely to be a result of
measurement error and biovariability, rather than true change in underlying renal function
(see Chapters 3 and 4); and hence
l estimate cost-effectiveness ratios of screening programmes at various time intervals for kidney disease
in patients with type 1 and type 2 diabetes (see Chapters 5 and 6).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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renin–angiotensin aldosterone inhibition using
angiotensin-converting enzyme inhibitors and
angiotensin-2 receptor blockersBackgroundAs discussed in the first chapter of this report, a successful screening programme requires evidence that
treatment can improve outcomes for those detected with a problem, and provides no benefit, is not
potentially harmful or is not unrealistically costly when applied to those not detected with a problem.
This chapter, therefore, outlines the evidence needed to make judgements about the utility of
a screening programme for detecting early kidney disease and, if beneficial, the optimal frequency
for screening.
The RAASIs are of established benefit for preventing the progression of established diabetic kidney disease
and the class of drugs includes ACEi and A2RBs.71,72 This chapter looks at the evidence for the clinical
effectiveness of ACEi and A2RB treatment. ACEi are currently recommended as a first-line treatment for
reducing the development and progression of kidney disease, and preventing mortality and CVD in
patients with type 1 and type 2 diabetes. A2RBs are recommended for patients who have an ACEi
intolerance. With the detection of albuminuria in patients with diabetes, apart from reviewing the extent
to which already-recommended treatments have been implemented, the use of ACEi or A2RBs to
consistently lower blood pressure from below 140/80 to below 130/80 mmHg is the main therapeutic
strategy. Microalbuminuria is defined as an elevated UAE (≥ 30mg/24 hours).71,72 This chapter,
therefore, sets out the evidence for the clinical effectiveness of these medications in improving renal
outcomes separately for those with and without microalbuminuria, and for those with type 1 and
type 2 diabetes.Methods
Search strategy
Trials published up to January 2005 were identified from the reference lists of two Cochrane systematic
reviews on this topic.63,64 Additional articles published between January 2005 and August 2010 were
identified as follows: MEDLINE (January 2005 to August 2010), EMBASE (January 2005 to August 2010)
and the Cochrane Controlled Trials Register (issue 1, 2005, to issue 8, 2010) were searched using the
search strategy described in a previous Cochrane systematic review for diabetes and randomised controlled
trials,63 as well as terms to identify diabetes, urinary albumin, ACEi or A2RBs (see Appendix 2). Reference
lists of identified trials and relevant reviews were also searched.Trial selection criteria
Included trials met the following criteria: (1) randomised controlled design; (2) outcomes for patients with
type 1 and type 2 diabetes were reported separately; (3) the intervention used was either an ACEi or an
A2RB; the comparator group was a placebo, no treatment or antihypertensive group (other than ACEi or
A2RB); (4) trial duration was ≥ 6 months; and (5) at least one outcome was separately reported for
patients with normoalbuminuria or micro-/macroalbuminuria and urinary albumin levels were reported,
either as a timed albumin excretion rate, or as a spot test ACR. The outcomes evaluated were (1) UAE at
the end of the trial; (2) progression to microalbuminuria (30–300mg/24 hours); (3) progression to15
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RENIN–ANGIOTENSIN ALDOSTERONE INHIBITIONmacroalbuminuria (> 300mg/24 hours); (4) regression to normoalbuminuria (< 30mg/24 hours); (5) change
in GFR in ml/minute/1.73 m2; and (6) death.Data extraction
Relevant publications were identified in duplicate and the data independently extracted. Disagreements were
resolved by consensus with a third author. Structured forms were used for data reviewing extraction (see
Appendix 3). Unpublished trial data were sought from authors of trials published since 2000. In trials that
compared two doses of the same ACEi or A2RB with a comparator (placebo, no treatment or other
antihypertensive), only the data from the higher dose were included in the meta-analysis to avoid
double counting.73
When multiarm trials had both placebo arms and active comparator arms (a non-ACEi/A2RB
antihypertensive), we preferentially selected the antihypertensive arm as the comparator for the
ACEi/A2RB arm. In a secondary analysis designed to inform our cost-effectiveness models (see Chapters 5
and 6), we also preferentially selected the active antihypertensive comparator arms from these trials
for use in a metaregression of effect size on blood pressure difference. Trials that looked at both an
ACEi and an A2RB in comparison with a placebo, no treatment or other antihypertensive treatment
were included in the meta-analysis by splitting the data from the comparator group between the
required comparisons.Statistical methods
Statistical analysis was carried out using Stata version 11.1 (StataCorp, College Station, TX, USA). Data on
progression to micro-/macroalbuminuria and regression to normoalbuminuria were analysed as
dichotomous data using a Mantel–Haenszel fixed-effects model and specifying the risk ratio as the effect
measure. The analysis of continuous urinary albumin data was based on an inverse variance method that
also used a fixed-effects model.73 For comparison, we report results and CIs from random-effects
analyses based on the DerSimonian and Laird method.74 A ‘ratio of means effect measure’ was used to
allow us to combine the 35 trials that measured UAE using albumin excretion rate (mg/24 hours) with the
five trials that reported ACR (mg/mmol or mg/g) into a single analysis.75–77 We took the ratio of means to
be the ratio of the final value in the intervention group to the final value in the comparator group,
so that a ratio of means < 1 favours intervention. A comparison with standard analysis methods using
mean difference and standardised mean difference verified that ratio of means was a suitable
analysis method.
The following sensitivity analyses were carried out to verify that our results were not sensitive to these
approximations, or to trials in which the comparator group was not an antihypertensive group;
double-blinding was not clearly stated; it was not clearly stated that at least two measurements of urinary
albumin were made to categorise patients with normo-, micro- and macroalbuminuria (applied both at
baseline and end point); the number of participants was < 200. Statistical heterogeneity between studies
was assessed with the I2 statistic. For the GFR data, we used an inverse variance, fixed-effect model and
ratio of means. For a few studies, it was necessary to impute or approximate data. We undertook
random-effects metaregression to evaluate the explanatory value of baseline urinary albumin
(microalbuminuria vs. normoalbuminuria) and medication type (ACEi vs. A2RB) on effect size separately for
type 1 and type 2 diabetes. Because a high degree of statistical heterogeneity was observed between
studies in the analysis of continuous data, a post-hoc multivariate metaregression analysis was carried out
to test whether the heterogeneity was explained by the following factors: study length; trial size; average
participant age; country of trial; comparator type (no treatment, placebo or active comparator); medication
type (ACEi or A2RB); treatment dose (categorised as high dose vs. low dose based on usual dose in the
British National Formulary and excluding one study of a drug not licensed in the UK; temocapril, Acecol,
Sankyo); difference in baseline UAE between the treatment and comparator groups, whether or not
approximations were made; or year of trial publication. In addition, the effect of comparator type (placebo
or no treatment vs. another antihypertensive) on effect size was investigated using subgroup analyses
and metaregression.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Univariate and multivariate metaregression were carried out using the metareg routine in Stata version
11.1, applying the method of DerSimonian and Laird.74 Heterogeneity was estimated from the
Mantel–Haenszel model,73 and reported using the I2 statistic.
Because subgroup analyses of trials comparing ACEi/A2RB with other antihypertensives suggested an
effect of ACEi/A2RB on renal outcomes beyond that attributable to blood pressure reduction, we also
conducted a metaregression of effect size on between-arm blood pressure difference and used this to
inform the cost-effectiveness modelling in Chapters 5 and 6.Results
Description of studies
The reference lists of two Cochrane systematic reviews identified 65 trials, 38 of which were assessed for
full eligibility (a selection of the excluded studies are listed in Appendix 4). Of these, three trials could not
be included in the meta-analysis because they measured urinary protein instead of urinary albumin.78–80
A fourth trial was excluded because consistent data could not be extracted,81 leaving 34 trials which fully
met our inclusion criteria. In addition, 7849 articles were identified from the search of MEDLINE, EMBASE
and The Cochrane Library from January 2005 to August 2010. Of these articles, 1450 were duplicates
(Figure 3), leaving 6399 articles for review. After screening the titles and abstracts, 671 articles were
examined in more detail for eligibility. A further 659 articles were excluded, leaving 12 papers (15 trials)
that met our inclusion criteria.
A total of 49 trials (representing 34,082 patients) were therefore included in the meta-analysis, three of
which had multiple arms,82–84 which were included as separate comparisons, resulting in a total of
52 comparisons (see Figure 3). Six trials were included in the analysis of patients with type 1 diabetes and
normoalbuminuria (seven comparisons). A total of 15 trials were included in the analysis of patients with
type 1 diabetes and micro- or macroalbuminuria. As one trial was included for both the normoalbuminuria
and the microalbuminuria groups,85 this gives a total of 20 trials of type 1 diabetes patients. In the analysis
of patients with type 2 diabetes and normoalbuminuria, 10 trials were included; 22 trials were included
in the analysis of patients with type 2 diabetes and micro- or macroalbuminuria (24 comparisons). As
four trials were included in both the normoalbuminuria and microalbuminuria groups, this gives a total of
28 included trials for type 2 diabetes.61,86–88 One trial could not be included in the analysis because only
one patient was left in the comparator group at the end of the trial.89
Of the 21 trials of RAASI carried out in people with type 1 diabetes, only 3 used A2RBs (Table 6),82,88 all of
which were carried out on patients with normoalbuminuria. The remaining trials of type 1 diabetes
patients used ACEi. As regards type 2 diabetes, three trials of normoalbuminuric patients used A2RBs, and
nine trials of microalbuminuric patients used A2RBs; the remaining trials all used ACEi (see Table 6).
All trials of type 1 diabetes included normotensive or controlled hypertensive patients, and the majority of
trials allowed patients to take antihypertensive medications (other than RAASI) (see Table 6). In contrast to
this, nearly all trials in type 2 diabetes and normoalbuminuria included hypertensive patients, whereas 6 of
the 21 trials in type 2 diabetes patients with microalbuminuria specifically selected hypertensive patients
(see Table 6). Only one trial in type 1 diabetes,85 and two trials in type 2 diabetes,86,88 directly compared
patients with normo- and microalbuminuria.Trials of type 1 diabetes
The ratio of mean UAE in treatment versus comparator groups at the end of the trial for type 1 diabetes is
shown in Figure 4. In patients normoalbuminuric at baseline, the ratio of means was 0.96 (95% CI 0.94 to
0.99) in the fixed-effects model (inverse variance) and 0.94 (95% CI 0.79 to 1.12) in the random-effects
model (DerSimonian and Laird). This equated to a 4% and 6% lower UAE in the treatment group versus17
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FIGURE 4 Ratio of mean UAE in treatment and comparator arms of trials. Ratio of mean UAE at the end of trials of
RAASI treatment versus comparator (boxes) and pooled estimates across trials (diamonds) calculated by the
fixed-effects inverse variance (I-V) method and by the DerSimonian and Laird random-effects (D+L) method, in
patients with (a) type 1 and (b) type 2 diabetes, stratified by baseline urine albumin status. Horizontal bars and
diamond widths denote 95% CIs and box sizes indicate relative weight in the I-V analysis. ATLANTIS, ace-inhibitor
trial to lower albuminuria in normotensive insulin-dependent subjects; BENEDICT, Bergamo nephrologic diabetes
complications trial; CCB, calcium channel blocker; DIRECT, DIabetic REtinopathy Candesartan Trials; EUCLID, a study
comparing cardiovascular effects of ticagrelor and clopidogrel in patients with peripheral artery disease; NT, no
treatment; RENAAL, reduction in end points in noninsulin-dependent diabetes mellitus with the angiotensin II
antagonist losartan; ROADMAP, randomized olmesartan and diabetes microalbuminuria prevention; SMART, shiga
microalbuminuria reduction trial. (continued)
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RENIN–ANGIOTENSIN ALDOSTERONE INHIBITIONthe comparator groups, respectively. In microalbuminuric patients, the ratio of means was 0.40 (95% CI
0.36 to 0.44) using a fixed-effects model (60% lower) and 0.33 (95% CI 0.23 to 0.46) using a
random-effects model (67% lower).
A subgroup analysis by comparator type was conducted to explore the difference between RAASI and an
antihypertensive comparator, and RAASI and placebo versus no treatment. These subgroup analyses were
not possible in patients with normoalbuminuria, as all trials used placebo as the comparator. In trials of
microalbuminuric patients, subgroup analyses gave a ratio of means of 0.44 (95% CI 0.39 to 0.48) in
12 placebo or no treatment trials, and a ratio of means of 0.20 (95% CI 0.14 to 0.27) in two active
comparator trials. This and other sensitivity analyses are listed in Table 7.
Trials of type 2 diabetes
The ratio of mean UAE in treatment versus comparator groups at the end of the trial for type 2 diabetes is
shown in Figure 4. In patients normoalbuminuric at baseline, the ratio of means was 0.88 (95% CI 0.84 to
0.92) using a fixed-effects model (inverse variance) and 0.79 (95% CI 0.68 to 0.93) using a random-effects
model (DerSimonian and Laird). This equated to a 12% and 21% lower UAE in the treatment group than in
the comparator group, respectively. In microalbuminuric patients, the ratio of means was 0.77 (95% CI 0.74
to 0.80) using a fixed-effects model and 0.73 (95% CI 0.62 to 0.85) using a random-effects model (23% and
27% lower, respectively).
For patients with normoalbuminuria, a subgroup analysis by comparator type gave a ratio of means of 0.89
(95% CI 0.85 to 0.93) in five placebo or no treatment trials, and a ratio of means of 0.65 (95% CI 0.51 to
0.83) in two active comparator trials. The subgroup analysis of trials of microalbuminuric patients gave a ratio of
means of 0.70 (95% CI 0.66 to 0.75) in 13 placebo or no treatment trials, and a ratio of means of 0.82 (95%
CI 0.78 to 0.86) in 7 active comparator trials. A sensitivity analysis, restricted to trials of at least 200 patients,
showed that effects remained statistically significant in trials of normoalbuminuric patients, but were smaller in
magnitude (summary ratio of means 0.92, 95% CI 0.88 to 0.96). These sensitivity analyses are listed in Table 7.Other outcomes
Type 1 diabetes
Results for progression and regression of albuminuria are presented in Figure 5. RAASI treatment of
normoalbuminuric patients led to no significant difference in the number of patients who progressed to
microalbuminuria, with a relative risk of 0.96 (95% CI 0.76 to 1.23, p = 0.25, I2 = 24%). All trials using
ACEi favoured the treatment group, although the effect was not significant. In contrast, all trials using
A2RBs favoured the comparator group, although, again, not significantly. ACEi treatment of patients with
microalbuminuria resulted in fewer progressing to macroalbuminuria (UAE > 300mg/24 hours), with a
relative risk of 0.39 (95% CI 0.23 to 0.64, p = 0.0005, I2 = 0%). Treatment with ACEi also resulted in more
patients regressing from microalbuminuria to normoalbuminuria, with a relative risk of 5.81 (95% CI 2.05
to 16.43, p = 0.001, I2 = 0%). In those studies in which it was assessed, there was no significant effect of
treatment on mortality (see Figure 5) or GFR (data not shown).
Type 2 diabetes
Results for progression and regression of albuminuria are presented in Figure 6. Patients with both
normo- and microalbuminuria benefited from treatment with RAASI in terms of progression or regression
of urinary albumin, but the effect was larger for patients with microalbuminuria. Fewer patients with
normoalbuminuria treated with RAASI progressed to microalbuminuria, with a relative risk of 0.84 (95% CI
0.79 to 0.89, p = 0.002, I2 = 19%). RAASI treatment resulted in fewer patients progressing from micro- to
macroalbuminuria, with a relative risk of 0.52 (95% CI 0.43 to 0.63, p = 0.00001, I2 = 48%). More patients
regressed from micro- to normoalbuminuria in the treated group than in comparator groups, with a
relative risk of 1.20 (95% CI 1.12 to 1.29, p = 0.03, I2 = 75%). In those studies in which it was assessed,
there was no significant effect of treatment on mortality (Figure 7) or GFR.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 5 Relative risk of progression and regression of albuminuria in treatment and comparator arms of trials in
type 1 diabetes. Relative risk of progression and regression of albuminuria during trials of RAASI treatment vs.
comparator (boxes) and pooled estimates across trials (diamonds) calculated by the fixed-effects inverse variance (I-V)
method and by the DerSimonian and Laird random-effects (D+L) method, in patients with type 1 diabetes, stratified
by baseline urine albumin status. Horizontal bars and diamond widths denote 95% CIs and box sizes indicate relative
weight in the I-V analysis. (a) Progression from normo- to microalbuminuria; (b) progression from micro- to
macroalbuminuria; and (c) regression from micro- to normoalbuminuria. ATLANTIS, ace-inhibitor trial to lower
albuminuria in normotensive insulin-dependent subjects; DIRECT, DIabetic REtinopathy Candesartan Trials; EUCLID, a
study comparing cardiovascular effects of ticagrelor and clopidogrel in patients with peripheral artery disease.
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FIGURE 6 Relative risk of progression and regression of albuminuria in treatment and comparator arms of trials in type 2
diabetes. Relative risk of progression and regression of albuminuria during trials of RAASI treatment versus comparator
(boxes) and pooled estimates across trials (diamonds) calculated by the fixed-effects inverse variance (I-V)method and by
theDerSimonian and Laird random-effects (D+L)method, in patients type 2 diabetes, stratifiedbybaselineurine albumin
status. Horizontal bars and diamond widths denote 95% CIs and box sizes indicate relative weight in the I-V analysis.
(a) Progression from normo- to microalbuminuria; (b) progression from micro- to macroalbuminuria; and (c) regression
from micro- to normoalbuminuria. BENEDICT, Bergamo nephrologic diabetes complications trial; DIRECT, DIabetic
REtinopathy Candesartan Trials; ROADMAP, randomized olmesartan and diabetes microalbuminuria prevention;
SMART, shiga microalbuminuria reduction trial.
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IGURE 7 Relative risk of all-cause mortality in treatment and comparator arms of trials. Relative risk of all-cause
ortality during trials of RAASI treatment versus comparator (boxes) and pooled estimates across trials (diamonds)
alculated by the fixed-effects inverse variance (I-V) method in patients with (a, b) type 1 and (c, d) type 2 diabetes,
tratified by baseline urine albumin status. Horizontal bars and diamond widths denote 95% CIs and box sizes
dicate relative weight in the I-V analysis. (a) Normoalbuminuria; (b) microalbuminuria; (c) normoalbuminuria; and
) microalbuminuria. ATLANTIS, ace-inhibitor trial to lower albuminuria in normotensive insulin-dependent subjects;
ENEDICT, Bergamo nephrologic diabetes complications trial; DIRECT, DIabetic REtinopathy Candesartan Trials;
ENAAL, reduction in end points in noninsulin-dependent diabetes mellitus with the angiotensin II antagonist
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In a univariate metaregression of type 1 diabetes studies, it was found that treatment effect in trials of
microalbuminuric patients was significantly greater than in trials of normoalbuminuric patients (p = 0.006).
In studies of type 2 diabetes, differences in treatment effect between microalbuminuria and
normoalbuminuria were not significant (p = 0.65). Metaregression of the type of medication (ACEi or
A2RB) could not be performed for type 1 diabetes, as too few trials used A2RB; however, medication type
was not found to significantly affect urinary albumin levels in patients with type 2 diabetes (p = 0.43).
Comparator type (antihypertensive medication vs. no antihypertensive medication) did not significantly
alter treatment effect either for type 1 diabetes (p = 0.34) or for type 2 diabetes (p = 0.86). In multivariate
metaregression, the effect of the following factors on heterogeneity were explored: baseline urinary
albumin, medication type, trial country, age, differences in baseline urinary albumin levels, trial size, data
extraction method and dose of RAASI. None of these factors individually reduced the I2 statistic by > 20%,
with trial country having the biggest impact on the heterogeneity in both type 1 and type 2 diabetes trials.DiscussionThis is the first systematic review of RAASI designed to look for possible differences in benefits between
type 1 and type 2 diabetes. Previous studies of microalbuminuric patients found that RAASI reduced
progression of proteinuria.82,126 We have confirmed this and, further, shown that there is benefit in both
type 1 and type 2 diabetes. However, the benefit of RAASI in primary microalbuminuria prevention found
in a previous review in patients with normoalbuminuria63 was only confirmed in our review for patients
with type 2 diabetes. These separate analyses by type of diabetes have been made possible by a number
of new trials, the largest being ADVANCE,61 which were not included in the previous systematic reviews.
In addition, we found no evidence of a difference in response between A2RB and ACEi in patients with
type 2 diabetes, but this result should be treated with caution, as it is largely based on comparisons across
trials of either treatment against placebo, rather than head-to-head trials of ACEi versus A2RB. We were
unable to make a similar comparison for type 1 diabetes because of insufficient A2RB trial numbers.
We used a systematic search strategy to ensure that all relevant published trials were included in the
review. Confining the search to those trials that separately reported outcomes for type 1 and type 2
patients allowed us to explore potential differences between the conditions. In the analysis of continuous
outcomes, heterogeneity between the trials is large, even within subgroups defined by type of diabetes
and baseline urinary albumin levels. The metaregression suggested that no single factor could explain the
heterogeneity between the trials and that it was attributable to multiple factors, for example geographic
setting, treatment type, treatment dose, trial size, type of comparator or baseline imbalance between
randomisation groups. However, the greater impact of baseline urinary albumin on treatment effect size in
type 1 diabetes than in type 2 diabetes was confirmed by the analysis of dichotomous outcomes, which
showed relatively little heterogeneity.
The appropriate use of fixed or random effects in meta-analysis continues to be discussed. In fixed-effects
analyses, CIs do not reflect heterogeneity between studies.127 Thus, in Figure 4, the narrow CIs for
fixed-effects analyses reflect the large quantity of data available rather than the degree of heterogeneity
between the trials. Random-effects analyses incorporate heterogeneity when calculating CIs, but arguably
give too much weight to small studies. For example, in the random-effects analysis in Figure 4, the largest
study is > 100 times the size of the smallest, but has < 10 times the weight in the analysis. In presenting
results from both analyses, we demonstrate that our broad clinical conclusions are not sensitive to the
choice of method. Regardless of the method of analysis, RAASI protects against the onset and progression
of microalbuminuria in type 2 diabetes, but in type 1 diabetes is beneficial only to patients with
established microalbuminuria.
No significant effect of treatment on GFR or mortality was found. Few trials reported these outcomes, and,
of those that did, the largest trials had a duration of 5 years. In the absence of longer-term outcome data,33
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RENIN–ANGIOTENSIN ALDOSTERONE INHIBITIONany conclusions drawn about the benefits of RAASI from our results are dependent on the acceptance of
UAE as a surrogate measure.128–130 The evidence to date for and against the use of urinary albumin as a
surrogate for long-term outcomes has recently been summarised elsewhere.131
There are some remaining concerns that the benefits of RAASI may be mediated solely by their
antihypertensive effect. Our data (see Table 7) include a subgroup analysis that separates the
placebo-controlled trials from the active comparator trials. The renal benefits of ACEi and A2RB are evident
when the comparator is active (another antihypertensive), suggesting that there is an effect over and
above that from blood pressure lowering. Another study, published in 2005,128 found that the effect of
RAASI was dependent on blood pressure lowering. In two of three analyses that stratified trials by
comparator type, the effect was larger in the trials that compared RAASI to active antihypertensive
treatment. The difference between our findings and those of the 2005 paper may be a result of the
additional trials included. However, a recent paper has carried out a network meta-analysis that confirms
our findings.132 The authors also conclude that, when two agents bring about the same drop in blood
pressure, the ACEi/A2RB will have an additional effect. However, they also caution that, for a definitive
analysis of this issue, an individual patient data meta-analysis or a randomised trial is required.
The randomisation method was not reported in the majority of the included trials, which is a limitation of
our review in that it could be a potential source of bias in the meta-analysis. In a sensitivity analysis
restricted to the largest trials (n≥ 200), type 2 diabetes patients who were normoalbuminuric at baseline
showed a lower treatment effect size than those in the main analysis (see Table 7); however, the effect
was not large compared with the uncertainty in the CIs. In other analyses, there was little or no evidence
of publication bias.
This review does not provide evidence to support routine use of RAASI for type 1 normoalbuminuric
diabetes patients. Our conclusions are based on an analysis that includes two trials intended to prevent
microalbuminuria in this group, with neither providing evidence of slowing progression to
microalbuminuria.28,82 The mechanisms for the difference in response to ACEi in type 1 and 2 diabetes are
unclear, although there may be differences in response to interstitial expansion.79,82 Although changes in
albumin excretion are associated with differences in CVD, it is possible that the lack of impact of ACEi
demonstrated on progression to albuminuria in type 1 diabetes does not extend to a lack of effect on
development of CVD. The high rate of comorbidity among people with diabetes may mean that, in
practice, many people without microalbuminuria have other indications for RAASI use. A recent study
among diabetic individuals > 55 years of age suggested that virtually all of this group have additional
indications for treatment with RAASI,133 including hypertension and other cardiovascular risk factors.
However, in otherwise healthy younger people with type 1 diabetes, there is no indication for treatment
with RAASI. A recent trial of losartan and lisinopril versus placebo suggested that treatment of this
group of patients may even be potentially harmful,82 although this may be a drug-specific effect or a
chance finding.
Current practice is to monitor urinary albumin in all adults with diabetes in order to initiate RAASI
treatment when kidney disease is detected. In type 1 diabetes, our results support this strategy of targeting
RAASI at those with kidney disease. However, in type 2 diabetes, we find that RAASI has similar
albumin-lowering effects in those with and without kidney disease. Our findings suggest that RAASI
treatment of type 2 diabetes patients with normoalbuminuria may be beneficial in terms of progression to
microalbuminuria. As a high proportion of those with type 2 diabetes is already treated with ACEi for
raised blood pressure, the impact of screening may be lessened. This even raises the possibility of using
ACEi to treat larger numbers of normoalbuminuric type 2 diabetes patients as a means of preventing
progression to microalbuminuria.
The findings of this systematic review inform the health economic analysis reported in Chapter 6, in
addition to the information provided about the impact of ACEi and A2RBs in type 1 and type 2 diabetes.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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disease for type 1 diabetesBackgroundPrevious work to estimate optimal screening intervals at which to test for the occurrence of kidney disease
in patients with diabetes has focused on rates of progression of albuminuria and GFR.4 However, this
approach does not fully account for variability, including the within-test biological and assay variability that
cause false-positive identifications of microalbuminuria. Current estimates of test accuracy are modelled
from reports of cross-sectional study data that give the proportions of individuals identified with
combinations of albumin and eGFR screening.19
To take into account variability in rates of progression and test accuracy when determining the optimal test
intervals for kidney disease screening, we used an approach that was initially developed in cholesterol and
blood pressure monitoring134,135 but that has since been extended to other areas of monitoring, including
diabetes.136,137 Using these methods, annual monitoring of cholesterol and blood pressure has been shown
to lead to more false-positive tests than true-positive tests: that is, a positive test for high cholesterol
(or high blood pressure) is more likely to arise from measurement error than from ‘true change’.134 For
many clinical monitoring tests, the variability within each measurement is greater than the likely change
over 1 year, and regular cycles of testing create repeated opportunities for the occurrence of false-positive
tests. In type 1 diabetes, the implication of a false-positive urine albumin test is unnecessary, and possibly
harmful, pharmacological treatment in individuals with normal urine albumin levels.
We applied these methods to data from ORPS to examine the optimal interval for microalbuminuria
screening in patients with type 1 diabetes. We evaluated annual urine albumin testing using data drawn
from this longitudinal study in which regular testing of renal function was carried out. In addition to
providing information about the properties of repeated testing, presented as the ‘signal-to-noise’ ratio,
it also provided evidence regarding the impact of different schedules of testing on the extent of
false-positive diagnoses. These data were used to inform the development of health economic models for
progression of type 1 diabetes, presented in Chapter 5 of this report.Methods
Data sources
We evaluated progression of ACR, eGFR and associated parameters in a cohort of newly diagnosed type 1
diabetes patients drawn from ORPS. A comprehensive description of the population and the research
design is provided in a previous study report.48 Briefly, between 1986 and 1996 young people, living in
Oxfordshire, UK, and diagnosed with type 1 diabetes before the age of 16, were invited to participate
in a longitudinal study. Children with diabetes secondary to another condition were excluded. Annual
assessment of clinical and biochemical measures included three consecutive early morning urine
specimens. Urine samples were assayed for albumin and creatinine in a central laboratory and the urinary
ACR was calculated for each urine sample. Albumin was measured by an enzyme-linked immunosorbent
assay, and creatinine using the modified Jaffe method. Serum creatinine samples were used to calculate
eGFR using the Schwartz formula in patients < 18 years of age,138 and the MDRD formula for those
≥ 18 years.14 Annual assessments continued for up to 20 years. Written consent was obtained from
parents and children were asked to give assent before commencement of the study. Ethical approval was
obtained from the local ethics committees.35
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The parameters describing the progression of urine ACR, its variability and its test performance were
derived from the repeated measurement in the ORPS data set. We used WinBUGS 1.4 (MRC Biostatistics
Unit, Cambridge, UK)139 to fit the linear random-effects model described below, and report model
parameters with 95% credible intervals as approximations to 95% CIs. We considered the parameters
describing the progression of ACR under three main headings: (1) the between-subject variation in
baseline ACR (often referred to as the intercept), for which the tendency for patients’ ACR to
systematically differ from other patients’ was modelled as a mean and standard deviation of log-ACR;
(2) the average change in ACR over time, which was modelled as the change in log-ACR per year;
and (3) the difference between the observed ACR and the underlying ACR for a single individual,
conceptualised as the within-person variability in any individual ACR measurement arising from the analytic
variability in the assay and short-term biological variability. The first two of these components use
random-effects models with normal distributions to describe the underlying log-ACR for each patient over
time, whereas the third component uses a t-distribution to summarise the within-measurement variability.
An inverse t-distribution with three degrees of freedom was used to describe the within-measurement
variability of log-ACR. The t-distribution was used because the variation in individual measurements was
too great to be described by a normal distribution; in particular, some measurements were much further
from the mean than the standard deviation. The model included effects of age and sex on underlying
ACR. A previous report from ORPS suggested that the age effect could be partly attributable to puberty,
but, after adjustment for age, we found no significant effect on ACR (p = 0.4) and, therefore, did not
include it in the final model.
We also fitted models for trends and variation in eGFR using the same methods. Residual plots indicated
an approximate normal distribution for eGFR and, therefore, no log transformation was required. We
allowed mean eGFR and mean rate of change to vary between men and women, but held other
parameters the same for both men and women.
Results are reported as mean and standard deviation for log-ACR scale and eGFR and geometric mean of
ACR with CIs. The average signal-to-noise ratio is also reported, with the signal being the average change
over time, and the noise being the standard deviation of the t-distribution for component within-person
variability in any individual ACR measurement.
As previously described,140 these estimates of between- and within-person trends and variability in log-ACR
allow us to estimate the proportions of diagnoses of microalbuminuria attributable to the onset of kidney
disease (true-positive results), and the proportion attributable to within-measurement variability (false-
positive results). Likewise, we are able to estimate the number of people correctly or incorrectly classified
with normoalbuminuria (true negative and false negative, respectively). These estimates can be derived
only by modelling methods such as simulation. The high variability in any measurement of urine ACR
makes it impossible to classify any individual patient in a real data set as a ‘true’ or ‘false’ positive for
microalbuminuria. However, simulation allows us to classify individual patients in the simulated data set
and, hence, estimate the proportion of patients who would be thus classified in a real cohort. The
statistical validity and clinical utility of this approach have been established previously.134,140
A simulated population of 75,000 individuals generated with the same distribution of age, sex, ACR and
duration of diabetes was created. In each patient, the simulated ‘true ACR’ value at each year is calculated
from his or her initial ACR value and annual rate of change. The true ACR value is assumed to be
unobservable to patient or clinician. The measured ACR value in any given urine sample is simulated from
the true value at that time and the model estimate of the within-measurement variability of ACR. We
assumed that the screening process would follow the NICE guidance: (i) microalbuminuria defined by ACR
> 2.5 mg/mmol for men or 3.5 mg/mmol for women; (ii) testing follows a sequence of tests following on
from an initial positive test; (iii) screening starts at 12 years of age.19 Therefore, an individual of age
≥ 12 years in the simulated population was assumed to be diagnosed with microalbuminuria if his or her
first measured ACR was above the threshold, and at least one of two further ACR tests were also aboveNIHR Journals Library www.journalslibrary.nihr.ac.uk
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ACR was above the threshold or ‘false positive’ if the true ACR was below the threshold. Similarly, when a
patient was not diagnosed with microalbuminuria – either because the first measured ACR was below the
threshold or because the first measured ACR was above the threshold but not confirmed by subsequent
measured ACR in the same year – we classified this as ‘true negative’ if the true ACR was below the
threshold and ‘false negative’ if the true ACR was above the threshold. We assumed that patients not
diagnosed with microalbuminuria continue to be monitored in subsequent years and hence may
subsequently be diagnosed with microalbuminuria.
We carried out simulation modelling for annual, biennial (every 2 years) and triennial (every 3 years)
screening. We also compared long-term predictions from the model with previously published reports on
the prevalence of albuminuria at different ages from large studies of type 1 diabetes. There were
insufficient data to study eGFR monitoring in type 1 diabetes because there were no cases of eGFR
< 60ml/minute during ORPS follow-up.ResultsThe characteristics of the participants in the ORPS included in this analysis are shown in Table 8. From a
total of 543 adolescents, data from 535 were eligible for inclusion in the analysis. They were followed up
for a median of 10.6 years (interquartile range 6.9 to 13.4 years).TABLE 8 Baseline characteristics of the ORPS cohort
Variable Number of patients (n = 542) Value [median (Q1, Q3)]
Gender
Male 296 54.6%
Female 246 45.4%
Age at diagnosis (years) 535 9.6 (5.6, 14.8)
Duration of diabetes (years) 535 1.05 (0.87, 5.47)
HbA1c (mmol/mol) 520 83 (68, 125)
Body mass index (kg/m2) 535 18 (17, 24)
Systolic blood pressure (mmHg) 537 100 (92, 120)
Diastolic blood pressure (mmHg) 537 65 (58, 82)
eGFR (ml/minute) 320 159 (134, 225)
ACR 542 0.95 (0.61, 4.14)
Microalbuminuriaa
Yes 30 5.5%
No 512 94.5%
a Microalbuminuria is defined as 2/3 of measurements over the threshold, the threshold being 2.5 mg/mol for males and
3.5mg/mol for females. The measurement is not necessarily baseline – it is the first available measurement.
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38Albumin-to-creatinine ratio
Table 9 reports the parameters used in defining the model that estimates trends and variation in log-ACR.
The mean log-ACR of 0.031 (95% CI –0.053 to 0.110) in males and 0.20 (95% CI 0.10 to 0.29) in
females is equivalent to geometric mean ACR of 1.03 (95% CI 0.95 to 1.12) and 1.22 (95% CI 1.11 to
1.34), respectively. The average changes in log-ACR per year of 0.035 (95% CI 0.02 to 0.049) in males
and 0.047 (95% CI 0.031 to 0.063) in females correspond to average increases in ACR of 4% and 5% per
year, respectively. However, the standard deviation around this average, 0.11 on the log-ACR scale,
corresponds to wide variation in this rate of change: the estimated 25th and 75th centiles of the change in
ACR are a 4% per year decrease in males (3% in females) and 12% per year increase in males (13% in
females), respectively. The estimated standard deviation of within-measurement variability in log-ACR is
0.79 (95% CI 0.73 to 0.86), which corresponds to a within-measurement coefficient of variation in ACR of
> 100%. The average signal-to-noise ratio is 0.044 in males and 0.059 in females for annual screening,
0.088 in males and 0.120 in females for biennial screening, and 0.13 in males and 0.18 in females for
triennial screening.
The results of modelling the rate of identification of microalbuminuria for males and females separately are
shown in Tables 10 and 11. Each section of the tables shows the cumulative rate of positive test results,
the percentage of those tests that are ‘false positive’ and the percentage of those repeatedly testing
negative that are ‘false negative’. Each of these outcomes is shown under assumptions of annual, biennial
and triennial screening. Initially assuming annual screening, Table 10 (males) shows the modelled
cumulative rate of identified microalbuminuria for the first year after diagnosis of diabetes, and the
cumulative diagnoses of microalbuminuria over subsequent years. Over the first 6 years after diagnosis of
diabetes, annual, biennial and triennial screening would identify 327, 270, and 244 cases of
microalbuminuria per 1000 males with type 1 diabetes, respectively. Over 18 years, annual, biennial
and triennial screening would identify 575, 529 and 503 cases of microalbuminuria per 1000 males with
type 1 diabetes.
Table 10 (columns 5–7) shows the percentage of those inaccurately identified with microalbuminuria, that
is the number of false positives as a percentage of the total number of positive tests. For an initial test, an
estimated 53% of microalbuminuria diagnoses would be true positive, and 47% would be false positive,
with the inaccuracy attributable to the variability in ACR measurements. We estimate that, by year 6, with
a regimen of annual, biennial and triennial screening, 48%, 41% and 38% of individuals identified withTABLE 9 Parameter estimates (95% CIs) in a random-effects model of trend and variation in log-ACR based on the
ORPS cohort
Parameter Interpretation Parameter estimate
αm Mean log-ACR at 7.4 years’ duration of diabetes in males 0.031 (−0.053 to 0.110)
αw Mean log-ACR at 7.4 years’ duration of diabetes in females 0.20 (0.10 to 0.29)
λ Effect of age at diagnosis on mean log-ACR −0.0059 (−0.018 to 0.0069)
σa Standard deviation of log-ACR 0.68 (0.63 to 0.73)
βm Mean annual change in log-ACR in males 0.035 (0.020 to 0.049)
βw Mean annual change in log-ACR in females 0.047 (0.031 to 0.063)
σb Standard deviation of annual change in log-ACR 0.110 (0.099 to 0.120)
ρ Correlation between actual value of log-ACR and rate of change 0.57 (0.49 to 0.64)
σw Standard deviation of within-measurement variability of log-ACRa 0.79 (0.73 to 0.86)
a Residual error is distributed equivalent to a t-distribution with 3.6 degrees of freedom, which gives a standard deviation
of residual log-ACR of 0.79.
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DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14microalbuminuria would be false positive, and, by year 18, 27%, 22% and 20%, respectively. The
estimated false-negative rates, again with a regimen of annual, biennial and triennial screening, are,
respectively, 0.7%, 2.1% and 3.4% by year 18.
Table 11 shows the corresponding estimates for females with type 1 diabetes. Over 18 years, a regimen of
annual, biennial and triennial screening would identify 484, 436 and 411 cases of microalbuminuria per
1000 females with type 1 diabetes, 33%, 27% and 24% of which would be false-positive diagnoses. Of
those repeatedly testing negative for microalbuminuria, 0.5%, 1.7% and 2.7% would be false negatives.
In summary, in males and females with type 1 diabetes, 48% (95% CI 43% to 53%) and 55% (95% CI
48% to 61%) of patients, respectively, tested annually for microalbuminuria over 6 years would be
false positive, that is inaccurately identified with microalbuminuria.
The estimated true- and false-positive test rates reported in Tables 10 and 11 are based on the parameter
estimates shown in Table 9. Figure 8 compares estimates from the fitted model with actual data by
overlaying the predicted mean log-ACR, adjusted for duration of diabetes and gender, with the actual
data derived from the ORPS. Figure 9 also shows the performance of the simulation model in predicting
the development of microalbuminuria, macroalbuminuria and regression to microalbuminuria in
comparison with the original data on which the model is based.50.00
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regression from microalbuminuria to normoalbuminuria (dots), with 95% CIs (vertical lines), in the ORPS compared
with model estimates (dashed lines). (a) Normoalbuminuria; (b) microalbuminuria; (c) macroalbuminuria; and
(d) regression to normoalbuminuria.
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42Because ORPS was primarily a study of young people with type 1 diabetes (maximum age 35 by end of
follow-up), we compared model predictions to the prevalences of microalbuminuria and macroalbuminuria
after diagnosis reported by other large studies of people up to 40 years (Figure 10).1,51,141–147 The studies
used different criteria (e.g. number of confirmatory tests) for diagnosing microalbuminuria.
To illustrate the sensitivity of our conclusions to the fitted parameter values, Figure 11 shows how the
estimated false-positive rate would vary in hypothetical populations with higher rates of progression of
albuminuria. This illustrates the change in the number of false-positive tests when the average rate of
change in ACR per year is increased above that observed in our cohort.
Glomerular filtration rate
During 463 person-years of follow-up on 386 patients (aged 5–27 years) with a total of 752 eGFR
measurements, there were no cases of eGFR < 60ml/minute. Table 12 reports the parameters for change
in eGFR in the cohort. The estimated average decrease in eGFR was 2.1 (95% CI 0.39 to 3.7) ml/minute
per year in males and 3.0 (95% CI 1.8 to 4.3) ml/minute per year in females. The estimated
between-person standard deviation of the decrease was 3.3 (95% CI 1.8 to 4.7) ml/minute per year, so
74% of male patients and 82% of female patients will have a decreasing eGFR. The within-measurementNIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 12 Parameter estimates (ml/minute) in a random-effects model of trend and variation in eGFR in people
with type 1 diabetes
Parameter Interpretation Parameter estimate (95% CIs)
αm Mean eGFR at 6 years’ duration of diabetes in males 165 (159 to 170)
αw Mean eGFR at 6 years’ duration of diabetes in females 160 (155 to 165)
λ Effect of age at diagnosis of diabetes on mean eGFR (per year of age) −2.0 (−2.9 to −1.1)
σa Between-person standard deviation of eGFR 28 (25 to 31)
βm Mean annual increase in eGFR in men −2.1 (−3.7 to −0.39)
βw Mean annual increase in eGFR in women −3.0 (−4.3 to −1.8)
σb Standard deviation of annual increase in eGFR 3.3 (1.8 to 4.7)
ρ Correlation between mean eGFR and annual rate of change 0.14 (−0.22 to 0.44)
σw Standard deviation of within-measurement variability of eGFR 22 (20 to 23)
MODELLING PROGRESSION OF KIDNEY DISEASE FOR TYPE 1 DIABETES
44variability of eGFR has an estimated standard deviation of 22 (95% CI 20 to 23) ml/minute, giving average
signal-to-noise ratios for annual, biennial and triennial screening, respectively, of 0.095, 0.19 and 0.29 in
males and 0.14, 0.27 and 0.41 in females.
Discussion
The high short-term variability of ACR measurements results in a high number of false-positive diagnoses
of microalbuminuria. This is consistent with previous studies of the long-term monitoring of other chronic
conditions such as hypertension and hypercholesterolaemia.134,135 However, in the case of ACR monitoring,
the within-measurement variability is so high that even the practice of confirming a high result with further
tests does not prevent a high rate of false-positive diagnoses. By comparison, the rate of false-negative
diagnoses is small (Tables 10 and 11).
Limitations of the analysis include the use of a relatively young cohort collected in the UK around 20 years
ago. Nevertheless, our model appears to make predictions for rates of microalbuminuria much later in the
course of type 1 diabetes that match other studies (see Figure 10), despite the difficulties in modelling a
measurement (ACR) that is far from normally, or even log-normally, distributed (see Figures 8 and 9). Our
model predicts a levelling off of the prevalence of diabetic kidney disease, which corresponds with the
clinical observation that not all patients will inevitably develop kidney disease, and with the reported
course of comparator studies charted in Figure 4b.
Guidelines from the American Diabetes Association (ADA) and NICE15,148 agree in recommending annual
screening for microalbuminuria, but differ on when it should begin: from 10 years of age and 5 years’
duration (ADA) and from 12 years of age (NICE). However, whereas the ADA guidelines recommend ACEi
for young people with persistent elevated ACR, no such recommendation exists in the NICE guidelines for
young people with type 1 diabetes and the recommendation is made only for adults. The potential benefit
of this treatment for adolescents at high risk is being explored in an ongoing randomised trial,149 which
includes adolescents with persistently elevated albumin levels within the normal range. This trial may
indicate whether those detected with intermittent microalbuminuria are at increased risk of a wider range
of adverse outcomes, regardless of whether they subsequently develop microalbuminuria. If ACEi does
prove beneficial in a young population, then alternative strategies for screening would be needed to better
target those who might benefit.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Our estimates of trend and variation for eGFR are limited by the known difficulties with eGFR formulae in
young age groups. Further, it was not appropriate to model the rate of false-positive tests for low eGFR
because of a lack of data: there were no cases of low eGFR in the cohort. This may partly reflect the
relatively young cohort and, in addition, the difficulties in estimating GFR in this age group. However, data
from the DCCT/EDIC (Epidemiology of Diabetes Interventions and Complications) cohort suggest that, even
much later in the course of type 1 diabetes, decline in eGFR is almost exclusively a feature of patients
with elevated urine albumin.150 The same study also found that, at the time of first diagnosis of
microalbuminuria, only 7% of people with type 1 diabetes are already being treated with ACEi or A2RB
treatment.1 Therefore, in type 1 diabetes, urine albumin testing is more likely to have an important role
than eGFR in identifying people requiring ACEi or A2RB treatment.
In Chapter 2 we found evidence that ACEi or A2RB is highly beneficial in patients with type 1 diabetes and
microalbuminuria, but not in patients with type 1 diabetes and normoalbuminuria. The clinical implication
of our results for annual ACR screening is that approximately one in every three patients for whom ACEi or
A2RB is recommended because of a diagnosis of microalbuminuria is in fact normoalbuminuric, and has
much less to gain from the treatment. Less frequent screening (biennial or triennial) results in fewer
false-positive tests and, therefore, better targeting of treatment – but rates of treatment overall are slightly
lower (see Tables 10 and 11). In Chapters 5 and 6, we extend the work of this chapter to estimate the
relative cost-effectiveness of annual, biennial and triennial monitoring of renal function with ACR in
patients with type 1 diabetes.45
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DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Chapter 4 Modelling progression of kidney
disease in type 2 diabetesBackgroundIn this chapter, we have applied the methods described in Chapter 3 to data from the Collaborative
Atorvastatin Diabetes Study (CARDS) to examine the impact of screening interval on detection of kidney
disease in a UK population with type 2 diabetes. As in Chapter 3, we use statistical estimation to quantify
between-patient variation in both renal function and rate of change of renal function, as well as the
natural variability of biological measures that leads to error in diagnosis. We use simulation models to
estimate whether screening annually, or at 2- or 3-yearly intervals, is likely to produce more false- than
true-positive diagnoses of microalbuminuria: that is, more likely to detect ‘measurement error’ than ‘true
change’ in albuminuria status.Methods
Data
The randomised trial CARDS was a trial of atorvastatin versus placebo in people with type 2 diabetes. The
protocol and the characteristics of the study cohort have been described in full elsewhere.151–153 Briefly,
132 clinical centres in the UK and Ireland recruited 2832 people with type 2 diabetes aged 40–75 years
with low-density lipoprotein cholesterol ≤ 4.14 mmol/l, fasting triglycerides ≤ 6.78 mmol/l and at least one
of the following conditions: hypertension, retinopathy, micro- or macroalbuminuria and current smoking
status. Exclusion criteria included previous coronary heart disease or stroke, previous surgery for peripheral
vascular disease, plasma creatinine ≥ 150 µmol/l, and HbA1c ≥ 12%. Patients were recruited between 1997
and 2001. Safety parameters, including urine albumin and urine creatinine, were measured 1, 2, 3 and 6
months after randomisation, and at 6-monthly intervals thereafter. Albumin and creatinine were measured
using a Hitachi 747 autoanalyser (Boehringer Mannheim Corp, Indianapolis, IN) on urine samples that
were confirmed free of infection by dipstick testing. At the recommendation of the data monitoring board,
the study was stopped in June 2003 following an interim analysis of the primary cardiovascular end point,
which showed a highly significant (p < 0.001) benefit of atorvastatin.Statistical analysis
As described in Chapter 3, we fitted longitudinal models for trends and variation in log-ACR. Log-ACR at
diagnosis of diabetes was modelled as a patient-level, normally distributed random effect. Change over
time in log-ACR was modelled as a patient-level, normally distributed random effect, correlated with actual
value of ACR. Within-measurement variability in log-ACR was modelled using a t-distribution with three
degrees of freedom, uncorrelated with actual level of ACR. The model parameters were estimated using
WinBUGS (MRC Biostatistics Unit, Cambridge, UK).139 We also fitted models for trends and variation in
eGFR using the same methods as described above, except for the modelling of the within-measurement
variability, for which we used a normal distribution. Residual plots indicated an approximate normal
distribution for eGFR and, therefore, a log transformation was not required. We allowed mean eGFR and
mean rate of change to vary between men and women, but held other parameters the same for men and
women. Models were stratified by baseline urine albumin status. We report means and standard deviations
of log- and eGFR, geometric means of ACR and the average signal-to-noise ratio as defined in Chapter 3.
Although we did not have data with which to validate individual tests for microalbuminuria in the CARDS
database, the model estimates of within-person variability allowed us to estimate the proportion of positive
tests that were false positive – that is, attributable to measurement variability rather than to true change in47
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48underlying renal function. With the same methodology as described in Chapter 3, we used simulation
modelling to calculate the proportion of those identified with true- and false-positive tests in a population
similar to that of CARDS, under the assumption of annual screening according to NICE guidelines. Our
primary analysis models an annual screening programme as described above, and compares this to 2-yearly
screening (biennial) and 3-yearly screening (triennial), while maintaining the NICE protocol for use of
confirmatory samples when the first sample measures above threshold. In sensitivity analyses, we assess
the degree of change in model parameters that would be required to reach different clinical conclusions.
We also used simulation to estimate rates and accuracy of diagnoses of stage 3b kidney disease, defined
by eGFR < 45ml/minute in normoalbuminuric patients.ResultsThe characteristics of the participants in the CARDS included in this analysis are shown in Table 13.
Data from 2562 participants were eligible for inclusion in this analysis.
Albumin-to-creatinine ratio
Table 14 reports the parameters used in defining the model that estimates trends and variation in log-ACR.
The mean log-ACR of 0.41 (95% CI 0.28 to 0.53) in men and 0.29 (95% CI 0.11 to 0.48) in women are
equivalent to geometric mean ACR at diagnosis of diabetes of 1.51 (95% CI 1.32 to 1.70) mg/mol and
1.34 (95% CI 1.12 to 1.62) mg/mol, respectively. The average change in log-ACR per year of 0.018
corresponds to a 2% per year increase in ACR in both sexes (Figure 12). The standard deviation around
this average, 0.022 on the log-ACR scale, corresponds to variation in the rate of change: the estimated
25th and 75th centiles of the annual increase in ACR are a 0.3% and 3.3% increase per year, respectively.TABLE 13 Characteristics at baseline of included participantsa
Variable Number of participants Value [median (Q1, Q3)]
Gender
Male 1780 69.5%
Female 782 30.5%
Age at diagnosis (years) 2562 53 (46, 60)
Duration of diabetes (in years) 2562 7 (3, 11)
HbA1c (mmol/mol) 2562 61 (51, 72)
Body mass index (kg/m2) 2562 31 (28, 34)
Systolic blood pressure (mmHg) 2562 143 (134, 153)
Diastolic blood pressure (mmHg) 2562 83 (78, 88)
eGFR (ml/minute) 2562 64 (58, 71)
ACR 2562 1.10 (0.58, 2.78)
Microalbuminuriab
Yes 550 21.5%
No 2012 78.5%
a Participants included in the analysis to derive the parameters for change in ACR and eGFR from CARDS (n = 2562).
b Microalbuminuria was identified on the basis of two raised sequential pretreatment readings (Colhoun et al. 2004153).
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FIGURE 12 Estimated cumulative proportion of patients with microalbuminuria and macroalbuminuria drawn from a
cohort based on CARDS using parameters obtained from CARDS (modelled ACR) compared with data obtained
directly from the CARDS cohort. The circles and lines are mean (95% CI) of ACR by duration (0–1, 1–2, 2–3, etc.)
stratified by gender (men top, women bottom). The numbers are based on the same 535 who made up the model.
TABLE 14 Parameter estimates (95% CIs) in a random-effects model of trend and variation in log-ACR based on the
CARDS cohort
Parameter Interpretation Parameter estimate
αm Mean log-ACR at 10 years’ duration of diabetes in men 0.41 (0.28 to 0.53)
αw Mean log-ACR at 10 years’ duration of diabetes in women 0.29 (0.11 to 0.48)
λ Effect of age at diagnosis on mean log-ACR 0.00092 (−0.01 to 0.012)
σa Standard deviation of log-ACR 1.1 (1.0 to 1.2)
βm Mean annual change in log-ACR in men 0.018 (−0.00094 to 0.035)
βw Mean annual change in log-ACR in women 0.018 (−0.0075 to 0.038)
σb Standard deviation of annual change in log-ACR 0.022 (0.0052 to 0.042)
ρ Correlation between actual value of log-ACR and rate of change 0.66 (0.09 to 0.96)
σw Standard deviation of within-measurement variability of log-ACRa 0.85 (0.74 to 1.00)
a Residual error is distributed equivalent to a t-distribution with 3.2 degrees of freedom, which gives a standard deviation
of residual log-ACR of 0.85.
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50The estimated standard deviation of within-measurement variability in log-ACR is 0.85 (95% CI 0.74 to
1.00), which corresponds to a within-measurement coefficient of variation in ACR > 100%. The average
signal-to-noise ratios, defined as average change divided by within-measurement standard deviation, are
therefore 0.021, 0.042 and 0.063 for annual, biennial and triennial screening, respectively.
Tables 15 and 16 report the estimated rates of identification of microalbuminuria modelled from these
estimates. Results for men and women are shown separately (see Tables 15 and 16). The tables show the
cumulative rate of positive test results, the percentage of those that are false positive and the percentage
of those repeatedly testing negative that are false negative. Each of these outcomes is shown under
assumptions of annual, biennial and triennial screening.
Over the first 6 years after diagnosis of diabetes, annual, biennial and triennial screening would, respectively,
identify 451, 394 and 365 cases of microalbuminuria per 1000 men with type 2 diabetes. Over 18 years,
annual, biennial and triennial screening would identify 582, 534 and 505 cases, respectively.
In an initial screening test, an estimated 78% of those identified with microalbuminuria would be
true positive, and 22% would be false positive. By year 6, with assumptions of annual, biennial and
triennial screening, respectively, 36%, 30% and 27% of diagnoses of microalbuminuria in men would be
false positive, and, by year 18, 35%, 29% and 26%. By year 18, estimated false-negative rates for men
were 0.1%, 0.8% and 1.7% for annual, biennial and triennial screening, respectively.
Table 16 shows the corresponding estimates for women with type 2 diabetes. Over 18 years, we estimate
that annual, biennial and triennial screening, respectively, would identify 431, 382 and 354 cases of
microalbuminuria per 1000 women with type 2 diabetes, 50%, 44% and 40% of which would be
false positive. Of those testing negative for microalbuminuria, 0.1%, 0.3% and 0.7% would
be false negative.
In summary, in men and women with type 2 diabetes, 36% (95% CI 32% to 42%) and 48% (95% CI
41% to 55%), respectively, of patients tested annually for microalbuminuria over 6 years would be
inaccurately identified as having microalbuminuria. If screening intervals were extended to 3-yearly, the
corresponding figures would be 27% (95% CI 23% to 31%) and 37% (95% CI 30% to 44%).
Figure 13 shows the degree to which the model reproduces the CARDS data by comparing model
predictions to observed data. Figure 14 examines the extent to which the resulting model can be
generalised by comparing model-predicted rates of microalbuminuria identification to observed prevalence
of microalbuminuria in other cohort studies, with the limitation that different studies have used different
criteria (e.g. number of confirmatory tests) for diagnosing microalbuminuria.
To illustrate the sensitivity of our conclusions to the exact parameter values, Figure 15 shows how the
estimated false-positive rate would vary under different assumptions about the average rate of progression
of log-ACR. This illustrates the change in the number of false-positive tests when the average rate of
change in ACR per year used within the model is increased above that observed in our cohort.
Estimated glomerular filtration rate
Data on 2012 CARDS participants with normoalbuminuria at baseline and 550 CARDS participants with
microalbuminuria at baseline were used in obtaining model estimates. Table 17 reports the parameters
used in defining the model that estimates trends and variation in eGFR in people with type 2 diabetes and
normoalbuminuria. The estimated mean eGFR at 10 years since diagnosis of diabetes is 69 (95% CI 69 to
70) ml/minute in men and 62 (95% CI 61 to 64) ml/minute in women, and the between-person standard
deviation is 8.7 (95% CI 8.1 to 9.3) ml/minute. The estimated average change in eGFR per year is 0.26NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 13 Estimated prevalence of normo-, micro- and macroalbuminuria, and estimated incidence of apparent
regression from microalbuminuria to normoalbuminuria (dots), with 95% CIs (vertical lines), in the CARDS
compared with model estimates using parameters obtained from CARDS (modelled ACR) (dashed lines).
(a) Normoalbuminuria; (b) microalbuminuria; (c) macroalbuminuria; and (d) regression to normoalbuminuria.
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FIGURE 14 Proportion of patients who test positive for microalbuminuria or macroalbuminuria by duration of
diabetes estimated from parameters obtained from the CARDS (simulation model) compared with other cohort
studies in type 2 diabetes. Bars and whiskers denote 95% CIs.
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54F
p
w
sTABLE 17 Parameter estimates (ml/minute) in a random effects model of trend and variation in eGFR in people
with type 2 diabetes
Parameter Interpretation
With type 2 diabetes and
normoalbuminuria (95% CI)
With type 2 diabetes and
microalbuminuria (95% CI)
αm Mean eGFR at 10 years’ duration
of diabetes in men
69 (69 to 70) 67 (66 to 68)
αw Mean eGFR at 10 years’ duration
of diabetes in women
62 (61 to 64) 60 (58 to 62)
λ Effect of age at diagnosis on
mean eGFR (per year)
−0.58 (−0.66 to −0.50) −0.61 (−0.72 to −0.50)
σa Between-person standard
deviation
8.7 (8.1 to 9.3) 9.6 (8.9 to 10.0)
βm Mean annual increase in eGFR
in men
0.26 (0.13 to 0.40) −0.13 (−0.27 to 0.014)
βw Mean annual increase in eGFR
in women
0.24 (0.061 to 0.42) −0.048 (−0.35 to 0.23)
σb Standard deviation of annual
increase in eGFR
0.50 (0.28 to 0.69) 0.72 (0.45 to 0.95)
ρ Correlation between mean eGFR
and annual rate of change
0.46 (0.25 to 0.82) 0.42 (0.23 to 0.62)
σw Standard deviation of within-
measurement variability of eGFR
4.9 (4.8 to 5.1) 5.0 (4.8 to 5.2)
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DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14(95% CI 0.13 to 0.40) ml/minute in men, and 0.24 (95% CI 0.061 to 0.42) ml/minute in women. The
estimated between-person standard deviation of the reduction per year is 0.50 (95% CI 0.28 to 0.69)
ml/minute. The estimated standard deviation of within-measurement variation in eGFR is 4.9 (95% CI 4.8
to 5.1) ml/minute. The signal-to-noise ratio is therefore 0.053 for annual monitoring, 0.11 for biennial
monitoring and 0.16 for triennial monitoring. Table 17 also shows the corresponding parameter estimates
for participants with normoalbuminuria and microalbuminuria at baseline. Figure 16 illustrates the
observed mean eGFR by duration of diabetes compared with the modelled estimates of progression and
shows how the modelled rate of change matches the original cohort data.
Table 18 shows the modelled estimates of the proportion of normoalbuminuric men classified as having
stage 3b kidney disease (eGFR < 45ml/minute) over time for annual, biennial or triennial eGFR screening.
In annual screening, for example, there would be 20 men identified with stage 3b kidney disease (95% CI
16 to 26) per 1000 after 18 years, and 67% (95% CI 53% to 83%) of these would be false positive.
Similar estimates were obtained for women (data not shown).30
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FIGURE 16 Observed mean (dot) and 25th and 75th centiles (vertical lines) of eGFR in men (top) and women (bottom)
with type 2 diabetes and normoalbuminuria, and model estimate of trends (dashed line).
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As for type 1 diabetes (Chapter 3), we found that the short-term variability of ACR measurement is so great
that the variability itself accounts for a high proportion of microalbuminuria diagnoses, even though these
diagnoses are based on repeated testing of an individual. Replacing current practice with biennial or
triennial screening would reduce the total number of false-positive diagnoses. Under all schemes the
false-negative rate – people with underlying microalbuminuria incorrectly classified as normoalbuminuria – is
small compared with the false-positive rate. We also found that, in the majority of patients, eGFR does not
decline until after the onset of microalbuminuria, which implies that urine albumin testing has a more
important role to play than serum creatinine in the monitoring of renal function in type 2 diabetes.
Our model is subject to limitations such as the degree to which the CARDS cohort is typical of the general
UK type 2 diabetic population. For example, the extent to which ACEi and A2RB treatment rates within a
randomised trial of HME-CoA reductase inhibitors (statins) are representative of the general diabetic
population is not known. However, Figure 14 suggests that microalbuminuria rates predicted by our model
are not atypical of type 2 diabetes. The microalbuminuria results in Figure 14 also show good model fit
over a wide timescale despite the relatively short follow-up time in CARDS. Although our exact numerical
results are subject to limitations, the general principle that high within-measurement variability brings
about repeated opportunity for false-positive results is not in doubt (Box 1), and Figure 15 illustrates that
our broad conclusions can be quite robust even to large changes in a key model parameter.
The clinical implication of the high number of false-positive diagnoses of microalbuminuria is
overtreatment, with ACEi and A2RB, of patients whose diagnosis of microalbuminuria is in fact a result of
measurement error rather than underlying renal dysfunction. The systematic review in Chapter 2 found
that, in type 2 diabetes, even patients with normal renal function can benefit from ACEi and A2RB. This
contrasts with the situation in type 1 diabetes, in which there is little evidence of benefit from treatment in
normoalbuminuric people. It follows that the cost-effectiveness of monitoring people with type 2 diabetes
for onset of microalbuminuria is difficult to predict. This, and the relative value of different monitoring
intervals, is therefore the subject of a full cost-effectiveness modelling exercise in Chapter 6.BOX 1 Classification error in screening programmes with repeated testing
This classification error of a screening programme with repeated testing (equivalent to a monitoring
programme) is methodologically different from a diagnostic problem. At any given time point, classification
error may occur in either direction, as in a diagnostic problem – either falsely making a positive diagnosis as
microalbuminuria or falsely excluding the diagnosis of microalbuminuria. However, those classified as not
having microalbuminuria are subsequently invited for further monitoring, with the potential for
reclassification, whereas those identified as having microalbuminuria will never be reclassified as having
normoalbuminuria under current practice. This creates an asymmetrical situation in which the risk of a
false-positive ‘label’ accumulates with every recall for monitoring, with the result that more frequent
monitoring increases the false-positive rate.57
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type 2 diabetes
This chapter outlines two health economic patient-level simulation models that we have used tointegrate the information provided in the previous two chapters. These models were used to conduct
the economic evaluation of the various options for monitoring renal function that are reported in the
next chapter.
Patient-level simulation models are valuable tools in studying diabetes. The development of clinical
outcomes for an individual patient, for example progression to renal failure, can take years and sometimes
decades to become apparent. It is therefore both costly and potentially unethical to undertake clinical trials
of sufficient duration to obtain long-term outcomes on all patients.
Individual-level simulation models were chosen to conduct the analyses required for this study because
they can model both the progression of diabetes-related complications and quantify outcomes in terms of
mean quality-adjusted life expectancy.68 This approach to simulation modelling is more commonly used,
instead of the more traditional Markov outcomes models, in diabetes156 because it accounts for
heterogeneity in the characteristics of individuals and the interdependence of different diabetes-related
complications. We have, wherever possible, conformed to the ADA guidelines for diabetes health
economic modelling.157
The analysis of screening programmes for diabetes reported in the next chapter is informed by a simulation
method developed specifically for this project, and an adaption of an existing simulation model – the
UKPDS outcomes model – for use in type 2 diabetes. The methods used to develop these models and their
underlying assumptions are reported in this chapter.A simulation model for type 1 diabetesPatient-level simulation modelling is required to examine the cost-effectiveness of various monitoring
strategies because there are no long-term randomised controlled trials of different screening strategies for
type 1 diabetes. Patient-level simulation modelling, which projects outcomes and costs over long periods
of time, can be used to determine the outcomes of the different strategies and thereby inform
cost-effectiveness analysis of various screening strategies.
There are currently no published patient-level simulation models developed specifically to examine the
impact of screening for diminished renal function in type 1 diabetes. Appendix 5 includes a summary of
current diabetes health economic models. Patient-level simulation models are common in type 2 diabetes;
there are Markov models of the progression of type 1 diabetes,158–160 and more general simulation models
have been used for economic evaluation.161 Most of the existing simulation models for use in type 1
diabetes have been developed using information from other patient populations to capture transitions
between important health states. For example, the risk of CVD has been estimated from the Framingham
study,162 or using equations developed with data obtained from type 2 diabetes patients in the UKPDS.163
The validity of using Framingham- and UKPDS-derived risk equations to predict risk of CVD in a cohort of
type 1 diabetes patients was recently tested and it concluded that these equations ‘poorly predict events in
type 1 diabetes’.164
We have, therefore, developed a patient-level simulation model for type 1 diabetes that has been
specifically designed to evaluate options for monitoring renal function. The model draws on results from
several recent studies published after the previous type 1 diabetes models were developed. The new model
uses data from a wide variety of sources, with the majority of parameters derived from data of studies59
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SIMULATION MODELS FOR TYPE 1 AND TYPE 2 DIABETES
60involving type 1 diabetes patients. When, for specific parameters, there were few or no type-1-specific
data available, we supplemented the model by including studies of type 2 diabetes patients.Model structure
The type 1 diabetes simulation model is built around a series of ‘key health states’ and ‘interlinking
dependencies’. Figure 17 shows the different states of the model and how a type 1 diabetes patient can
progress through its different states over their lifetime. The aim of this model is to estimate the first
occurrence of a cardiovascular event (including stroke or a myocardial infarction) for type 1 diabetes
patients, either with or without end-stage kidney disease and death, in order to estimate lifetime
outcomes and quality-adjusted life expectancy associated with different screening programmes. The arrows
indicate dependencies linking key health states. For example, the occurrence of kidney disease elevates the
risk of myocardial infarction and death.
Data sources
The data sources used in the model construction are summarised in Table 19 and the functional form and
coefficients used in each numbered equation are described in Table 20. Two equations for CVD-related
death are used to capture both the acute and long-term impact on mortality of this disease. The key
studies used to construct this model report time to first event and, therefore, the model focuses on these
states (i.e. there are no equations to estimate second or subsequent events).45,167
Progression to kidney disease
The progression of ACR from normoalbuminuria to microalbuminuria, and the diagnostic error in testing
for microalbuminuria, was modelled using the simulation model for type 1 diabetes reported in Chapter 3.
Patients with positive tests were assumed to be treated with ACEi to slow the progression of kidney
disease, with further blood pressure lowering if not controlled. The treatment effect of ACEi was modelled
as an absolute risk reduction in the progression of kidney disease as described in the systematic review
reported in Chapter 2.Update patient risk factors
using risk factor equations:
Age
History of micro/macro
Enter cohort of type 1 diabetes patients
Commence model cycle
Run the screening simulation model
Progression to micro/macro
Administer ACE-i
Run event equations
Cardiovascular incidence
Intensive treatment
Conventional treatment
CVD mortality
Myocardial infarction
Stroke
ESRD
ESRD incidence
ESRD + CVD incidence
ESRD all-cause mortality
 
Equation 1
Equation 2
 
Equation 3
Equation 4
Equation 5
Equations 8 and 9
Equation 10
Equation 11
Calculate
QALYs
Update history of events
History of CVD/ESRD
Death
Yes No
Equations 6 and 7
FIGURE 17 Diagram depicting the structure and relationship among equations, disease progression, screening and
treatment steps used in the type 1 diabetes simulation model.
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TABLE 19 Summary of data sources used with patient populations and uses put into the model
Publication Data source Section of the model Number of patients
Oke et al. 2010165 ORPS Progression to kidney disease 483 type 1 patients
Nathan et al. 200545 DCCT Incidence of CVD event 1441 type 1 patients
Hayes et al. 2011166 Western Australia Mortality post CVD event, and
history of CVD event
12,792 (603)
type 1 patients
Finne et al. 2005167 Finnish Diabetes Register Incidence of ESRD 20,005
Zoccali et al. 2002168 Italian ESRD patients’ progression to CVD,
mortality or all-cause death
228 ESRD patients
(30 type 1)
UKPDS 6868 UKPDS Hazard ratios for age and sex All type 2 patients
Kelly et al. 2011169 Swedish Diabetes Registry Hazard ratios for micro- and
macroalbuminuric diabetes
patients progressing to ESRD
Lung et al. 2011170 Meta-analysis Utility values Type 1 and type 2
ESRD, end-stage renal disease.
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Cardiovascular disease incidence and related mortality
A key outcome of the model is the occurrence of the first cardiovascular event (stroke or myocardial
infarction). We used information from the DCCT to estimate the incidence of CVD by degree of renal
function. The DCCT was a clinical study conducted from 1983 to 1993 to compare the effects of standard
blood glucose control versus intensive control on the complications of diabetes.45 The DCCT randomised
1441 type 1 diabetes patients, who were aged 13–39 years and had no history of CVD or hypertension at
entry into conventional or intensive blood glucose treatment. Intensive control consisted of maintaining
HbA1c levels as close as possible to a normal level of ≤ 6%.45 Patients were followed up for a mean of
6.5 years with annual, central laboratory measurements of fasting lipid levels, serum creatinine values,
HbA1c (quarterly measurements) and other risk factors of CVD. In total, 90% of the patients from the
DCCT were followed up in a cohort study known as the EDIC to assess the incidence and predictors of
CVD events (including heart attack, stroke, interventional procedures) and diabetic complications related to
the eye, kidney and nerves.45 We obtained survival estimates from the DCCT for patients who had a first
occurrence of non-fatal myocardial infarction, stroke or death from CVD with microalbuminuria,
macroalbuminuria and kidney disease as time-dependent covariates, using data in published reports.45
Estimates of mortality following the occurrence of CVD events were based on a recent study involving
linked administrative data on people with diabetes over the age of 35 from Western Australia, which were
collected between 1990 and 1999 to estimate equations forecasting mortality.166 The observational cohort
consisted of 12,792 patients (630 of whom had type 1 diabetes) with one of the following complications
of diabetes: myocardial infarction, stroke, heart failure, amputation or renal failure. The study reported a
logistic regression to estimate mortality within the first month post event and a Gompertz proportional
hazards model to estimate mortality due to CVD after 1 month. Type 1 diabetes was identified through
diagnostic codes indicating insulin-dependent diabetes on one or more hospital admissions and where
there was no evidence of these patients ever having used oral antidiabetic medications.End-stage kidney disease
To estimate the incidence of end-stage kidney disease in our model, we used data from a cohort study
that comprised 20,005 type 1 diabetes patients in Finland (data from 1965 to 1999).167 All patients were
diagnosed when < 30 years of age and were identified from the Finnish Diabetes Register; the maximum
follow-up length was 37 years (median 16.7 years). Cumulative incidence estimates among male and
female patients with type 1 diabetes according to age at diagnosis of diabetes were reported.61
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study that reported survival curves for the duration of the study (53 months).168 The study was based on a
cohort of 228 haemodialysis patients (15% of whom were diabetes patients) who had been undergoing
regular dialysis treatment for at least 6 months (median duration 43 months).Mortality from other causes
The final transition in the model is death from non-CVD causes. Owing to the lack of information from a
type 1 diabetes population, we derived information about these probabilities from age- and sex-specific
mortality rates from all other causes from cause-specific US life tables for the general population.171
Non-CVD mortality rates for 5-year age intervals were estimated as the difference between all-cause
mortality and the reported CVD cause-specific mortality.Quality of life
Utility values associated with the major health states were derived from a meta-analysis of
preference-based quality-of-life [quality-adjusted life-year (QALY)] measures for people with diabetes.170
This study was a systematic review of studies that reported QALY measures elicited from people with
diabetes, including those with a history of complications. Meta-analysis was used to obtain a mean utility
value for diabetes patients overall, and for patients with no complications, stroke, myocardial infarction,
ulcer, amputation and end-stage kidney disease Appendix 6.Translation of reported results
When published equations to estimate transition rates were not available (e.g. equations describing the
transition to CVD and kidney disease), we obtained data about the underlying hazard by estimating
survival times from published graphs. This involved using a program called Dagra 2.05 (Blue Leaf Software,
Hamilton, New Zealand) to trace out the reported survival curves and export them as time-to-event data.172
Using this approach we were able to replicate the cumulative hazard of a CVD event for both the
conventional and the intensive treatment groups in the DCCT.45 This involved fitting a parametric
proportional hazards model. Tests were consistent with intensive therapy having a proportional effect on
the hazard, reducing the risk of a CVD event when compared with the conventional treatment group.
A Weibull proportional hazards regression model (equations 1 and 2) was used to build the simulation
model for type 1 diabetes, as this had previously been shown to fit the data well for people with type 2
diabetes. Coefficients used in the Weibull model included the following: the hazard ratios of
microalbuminuria and albuminuria based on reported estimates involving a Cox model.45 As parameters for
the impact of age and sex are not reported in the literature, we used the parameters estimated from the
UKPDS 68.68 Patients were assumed to have a 70% probability of having a myocardial infarction and a
30% probability of having a stroke when patients had a cardiovascular event, based on two large
diabetes trials.68,173
For myocardial infarction and stroke, we used Hayes and colleagues’ logistic regression (equations 3–5) to
estimate the higher risk of mortality 1 month post event and their Gompertz proportional hazards
regression model (equations 6 and 7) to estimate the risk of mortality for surviving patients.166 A Gompertz
parametric form produces an exponential rise in death rates in older patients and is widely used to model
human survival.174
Proportional hazard ratios for age and type 1 diabetes and age and gender were used in the myocardial
infarction and stroke logistic regression model, respectively. A sex-specific Gompertz proportional hazards
model was used to represent patients with history of a CVD event and estimate the probability of survival
post event.
Patients were at risk of progressing to the end-stage renal disease (ESRD) state in the model only if they
had micro- or macroalbuminuria. We estimated a Gompertz proportional hazards model (equations 8
and 9) to determine the incidence of patients progressing to ESRD from published age- and sex-specific63
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64cumulative incidence graphs,167 using Dagra to estimate the data. These techniques were also applied to
the reported Kaplan–Meier survival curves for cardiovascular events and all-cause death for type 1 patients
with ESRD to determine rates of progress to a CVD event or death, respectively (equations 10 and 11).168Model testing and validation
All estimated proportional hazards models were tested for accuracy by comparing the estimated survival
curves with the published survival curves, ensuring that the model provided the best fit. We carried out a
validation exercise comparing simulation estimates of life expectancy among type 1 diabetes patients with
reported all-cause mortality rates among a general non-diabetic population from an analysis of the UK
General Practice Research Database (GPRD).175
To carry out this validation exercise, life expectancy estimates were derived using a hypothetical group of
10,000 patients, who were simulated for 85 years, with a mean age at entry into the type 1 simulation
model of 15 years.
Estimated mean life expectancy separated by sex and treatment group is shown in Figure 18. Men have a
mean life expectancy of 66.0 (95% CI 60.7 to 71.3) years in the intensive treatment group and 55.4
(95% CI 47.8 to 63.0) years in the conventional treatment group. Life expectancy for women was
estimated at 63.6 (95% CI 56.4 to 70.7) years for the conventional treatment arm and 72.2 (95% CI 68.7
to 75.6) years for the intensive treatment arm.
These results were compared to those of the UK type 1 diabetes GPRD study: life expectancies lay within
one standard deviation of those obtained by the external study.175 Women have a higher life expectancy
across all treatment groups, which is reflected in the life expectancy of the general population.176 Women
with type 1 diabetes have a higher risk of mortality, and this is reflected in the literature.175,177–181
To examine the validity of these model estimates, life expectancy was calculated using life table methods
by adjusting the UK life table to take into account the higher relative risk of mortality among people with
type 1 diabetes. The relative risks for this analysis were taken from a study that selected 7713 type 1
diabetes patients and compared them to 38,518 non-diabetic patients.175 The reported overall hazard
ratios of 3.3 for men and 4.5 for women were applied to UK life tables for 2007–9176 by multiplying the
age-specific mortality rates of the general population by the appropriate hazard ratios at 5-yearly intervals.
This gave figures for life expectancy at birth of 63.8 years for males and 65.6 years for females. Compared
with the mean life expectancy of 77.7 years in the general population of the United Kingdom,176 our
simulation model, and the external study,175 suggests a loss of approximately 14 years of life attributable
to type 1 diabetes.0 10 20 30 40
Life expectancy at birth (years)
50 60 70 80
66.0
55.4
63.8
72.2
63.6
65.6
Intensive treatment
Conventional treatment
Soedamah-Muthu et al. 2006175
Intensive treatment
Conventional treatment
Soedamah-Muthu et al. 2006175
Females
Males
FIGURE 18 Type 1 simulation outcomes for life expectancy separated by sex. Data extracted from
Soedamah-Muthu 2006.175
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Uncertainty
There is uncertainty around the estimates of health outcomes and costs derived from any simulation
model. Two forms of uncertainty are addressed within this modelling exercise: uncertainty in the individual
patient predictions generated by the system of model equations and uncertainty in the estimated
parameters of those equations. We addressed the former – the random variation between simulations – by
carrying out large numbers of Monte Carlo replications until the estimates of the outcome of interest were
stable. To model CIs around estimates we sampled from normal distributions using bootstrapping methods
with different sets of regression coefficients around key parameters, based on the standard errors of
coefficients reported in the literature. These analyses allow us to report CIs for the mean difference in
QALYs and costs.
To examine the degree to which different elements of the model contribute to uncertainty, 1000 draws
from normal distributions for the major parameters of the model were taken and used to estimate
95% CIs around life expectancy. In each draw, the mean value was used in the model and the variance
calculated using reported measures of standard error. The same model simulations were repeatedly run
with an increasing number of equations subject to parametric uncertainty.
Figure 19 shows the increased uncertainty in the life expectancy estimates in the form of 95% CIs as
uncertainty for each parameter is included incrementally. This comprises, reading from left to right:
l point estimates
l CIs when just the CVD incidence parameters were assigned distributions
l CIs when CVD and ESRD incidence parameters were adjusted
l all parameters were assigned distributions around their point estimates.
This was calculated for the life expectancy for the whole population, which included both conventional
and intensive treatment arms. Figure 18 shows that the CVD incidence parameters contributed the most
uncertainty in the current version of the model.Limitations
There are a number of limitations that require acknowledgement in our model. Multiple CVD events are
not included in the model, as the source equation from the DCCT reports only the first occurrence of a
CVD event. Second, although the DCCT/EDIC study has a comparatively long follow-up of around
17 years, this is a relatively short period when compared with a patient’s overall lifetime. Hence, there is
considerable uncertainty surrounding the lifetime extrapolation relating to the data. This is reflected in thePoint
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FIGURE 19 Uncertainty in the life expectancy estimates (95% CIs) when parameters were assigned distributions
incrementally (see text for a detailed explanation).
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66reported uncertainty surrounding the life expectancy estimates when allowing for parameter uncertainty.
When accounting for uncertainty in our model, we assumed independence between: (1) variables in the
same risk equation; and (2) different risk equations. If the covariance between parameters is significant, it
could impact on the level of uncertainty.
Our model also does not take into account recently published studies of risk in type 1 diabetes patients,
such as two recently published equations for CVD risk from Sweden182 and the United States.183
Furthermore, the transition probabilities for ESRD patients progressing to CVD and death have been
estimated using non-type-1 diabetes populations168 because of the lack of published studies in
the literature.A simulation model for type 2 diabetesThe simulation model for type 2 diabetes was based on the UKPDS outcomes model, which has been
widely used for economic evaluations of a wide variety of different interventions. The standard model
required adaption, as it does not include parameters relating to markers of renal progression such as
albuminuria and eGFR.Model structure
The UKPDS outcomes model is a computer simulation model for forecasting quality-adjusted life
expectancy and other outcomes for people with type 2 diabetes. It was developed using patient-level data
from the UKPDS and was primarily intended as a tool to assist in the evaluation of new interventions to
manage patients with type 2 diabetes.68
The outcomes model involves probabilistic discrete-time computer simulation and is based on an
integrated system of parametric proportional hazards risk equations. These were estimated over a median
period of 11 years from diagnosis of diabetes using individual patient data.68 The model includes both
macrovascular (e.g. myocardial infarction, other ischaemic heart disease, congestive heart failure, stroke)
and selected microvascular (e.g. blindness) complications. It can be used to assess the impact of the
disease on morbidity and mortality, and can also be used to estimate health-care costs associated with the
disease. The existing risk factors and complications covered by the model are summarised in Figure 20.
These equations are used to estimate the probability of occurrence of different complications given risk
factors such as a patient’s age, sex, duration of diabetes, systolic blood pressure, HbA1c, lipid levels
and smoking status. The relative risk for each of these factors by type of complication is also reported
in Figure 21.
Simulation algorithm
Figure 21 comprises an algorithm that illustrates the sequence of modelling events for the existing model.
In each cycle, the probability of experiencing each of the diabetes-related complications and death is
calculated using the estimated risk equations. At the beginning of each cycle, the order of the equations is
randomised to account for competing risks (i.e. if a patient dies in any cycle of the model, he or she
cannot experience an event defined by equations lower in the order). The probability is compared with a
random number ranging from zero to one from a uniform distribution to determine whether an event
occurs. If the model predicts that a death has occurred, the years lived and quality-adjusted years lived are
calculated. If the patient is predicted to have survived that cycle, the risk factor equations are used to
update the current risk factor values (e.g. systolic blood pressure) and these are carried forward to the next
cycle of the model along with the updated event history.
Although the model can estimate the risk over time of each complication and death in this study, it will
primarily be used to estimate life expectancy and QALYs.NIHR Journals Library www.journalslibrary.nihr.ac.uk
Diabetes mortality
(In subsequent years)
Ischaemic heart
disease (IHD)
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HbA1c
SBP
Ln (TOTAL:HDL)
1.03
0.62
1.13
1.10
4.47
(Equation 1, 231 events)
(Equation 6, 104 events)
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1.07
(Equation 3, n = 97)
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myocardial infarction (MI)
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HbA1c
SBP
Ln(TOTAL : HDL)
IHD
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1.06
0.44
0.27
1.41
1.13
1.11
3.29
2.49
4.75
(Equation 2, n = 495)
Stroke
Age
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SMOK
ATRFIB
HbA1c
SBP
TOTAL : HDL
CHF
1.09
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1.43
4.17
1.12
1.32
1.12
5.71
(Equation 4, n = 157)
Amputation (AMP)
PVD
HbA1c
SBP
Blind
11.42
1.55
1.25
6.12
(Equation 5, 40 events )
Renal failure (Renal)
SBP
Blind
1.50
8.02
(Equation 7, 24 events)
Other death
(In force at all times)
Age × Female
Age × (1–Female)
SMOK
1.08
1.11
1.36
(Equation 10, 250 deaths)
Event fatality (ORs)
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HbA1c
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Stroke
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Ln (Age_Event)
TOTAL : HDL
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Stroke event
Stroke post
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113.40
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51.38
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16.56
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1.00
2.81
4.88
16.00
1.12
14.01
2.85
1.00
1.00
1.00
Diabetes related mortality 
(Equation 8, 342 deaths)
(Equation 9, 100 deaths)
FIGURE 20 Summary of model equations for the type 2 diabetes simulation model (based on the UKPDS outcomes
model)68 showing event-related dependencies and hazard-to-odds ratio for each risk factor.
 
Start: define the following patient characteristics:
Age at diagnosis, ethnicity, sex, BMI, HbA1c, Total : HDL (lipids), blood pressure, smoking status,
atrial fibrillation at diagnosis, peripheral vascular disease (PVD) at diagnosis
History of diabetes-related events:
    ischaemic heart disease (IHD), congestive heart failure (CHF), blindness, amputation, 
    renal failure, myocardial infarction (MI) and stroke
Randomly order and run event equations:
Ischaemic heart disease (IHD)
Myocardial infarction (MI)
Congestive heart failure (CHF)
Stroke
Amputation
Blindness
Renal failure
Diabetes-related mortality
  (conditional on CHF, amputation, 
  and renal failure, MI or stroke 
  having occurred)
Other mortality
Equation 1
Equation 2
Equation 3
Equation 4
Equation 5
Equation 6
Equation 7
Equation 8
Equation 9
Equation 10
Update patient risk factors using risk
factor equations: 
HbA1c
Blood pressure
Total : HDL
Smoking
Update history of diabetes-related
events
Equation 11
Equation 12
Equation 13
Equation 14
Calculate life
years and QALYs
Commence model cycle
Dead?
Yes No
FIGURE 21 Algorithm used for the UKPDS model. Source: UKPDS 68.68
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68Reduced rates of complications may reduce health-care costs, producing savings that may offset some of
the costs of improving treatment. The sources of costs and utility values are discussed in Chapter 6. To
capture these benefits, the simulation model was also used to estimate lifetime health-care costs of
diabetes-related complications. Non-diabetic morbidities are not specifically included in the simulation
model, although non-diabetic mortality is included.
The methods described above to deal with uncertainty in the type 1 simulation model were also used to
address the uncertainty in the type 2 model. The aim, as before, was to facilitate reporting of the CIs for
the mean difference in QALYs and costs.How the model has been adapted for this project
The population parameters of the UKPDS outcomes model were adjusted to more accurately reflect the
type 2 diabetes population in the UK, including ethnic distribution. The data used to carry out this
adjustment were extracted from the UKPDS,184 including data that compared intensive glucose therapy to
conventional dietary therapy among 4209 newly diagnosed type 2 patients. Patient characteristics used
were mean age, proportion of males, body mass index, HbA1c, blood pressure and cholesterol, and
ethnic distribution.
The simulation model reported in Chapter 445 was integrated into the UKPDS outcomes model for the
purposes of this project. This involved integrating programming codes in Stata version 11 that classify
patients according to whether they have either hypertension or kidney disease. Increased risk of kidney
disease or risk of CVD and mortality was incorporated into the UKPDS outcomes model.169,185 Patients
detected as having kidney disease were assumed to be treated with ACEi and A2RB (see Chapter 2 for
further discussion) and benefit from the mortality reductions was quantified for these treatments.
The utilities derived from a meta-analysis for diabetes patients with no complications, myocardial
infarction, stroke and end-stage kidney disease were integrated into the model,170 whereas for all other
health utilities (ischaemic heart disease, congestive heart failure, amputation and blindness) the original
values as reported in the original UKPDS outcomes model were used.68 Costs for the analysis of renal
screening were also integrated into the model, and these will be reported in Chapter 6.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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function for type 1 and type 2 diabetes
This section presents the methods and results of a series of cost-effectiveness analyses that evaluatealternative screening programmes for renal function in people with diabetes. The models described in
Chapter 5 were used to estimate both costs and effects. The simulation models outlined in Chapters 3 and
4 for the progression and screening of ACR levels in type 1 and type 2 diabetes patients were incorporated
into the models presented in Chapter 5. The results for screening people with type 1 and type 2 diabetes
are presented first, followed by interpretation and discussion of the results to facilitate decisions regarding
the implementation of renal function monitoring programmes by the NHS.Methods
Economic evaluation
Incremental cost-effectiveness analyses were carried out for each of the various screening strategies.
The incremental net cost and net cost-effectiveness were calculated in relation to the comparator, and
expressed as a ratio for each strategy. As the economic evaluation perspective was that of the health-care
purchaser, only direct health service costs were included. Both costs and effects were discounted at 3.5%
per year for the first 30 years and 3% subsequently, in line with current guidelines.186
All outcomes are expressed as QALYs, as this measure captures both increases in life expectancy and
improved quality of life resulting from prevention of complications, providing a composite outcomes
measure of fatal and non-fatal events that permits comparisons among a wide range of interventions.
In the main analyses, we vary the screening interval between 1 and 10 years, initially using 5-year and then
1-year increments. Where possible, results are reported as mean values and standard deviations, or mean
differences with CIs, and as ‘cost-to-clinical-effectiveness’ ratios. The effect of uncertainty surrounding
costs and the utility values used in the study were examined using sensitivity analyses.Model simulations
Using the models outlined in Chapter 5, simulations were undertaken at a patient level. The simulations
include (as treatment effects) estimates of the proportion of true-positive/true-negative/false-positive/
false-negative tests and the consequences of these outcomes in terms of additional benefit and cost of
treatment. These models were used to examine the impact of various monitoring policies on the incidence
of important health states (e.g. CVD). The results presented are the average of 1000 simulations, which
stabilise the expectation of different individual Monte Carlo simulations.Resource data and costs (type 1 and the United Kingdom Prospective
Diabetes Study outcomes model)
The economic evaluation was carried out from the perspective of the health-care provider and, therefore,
the following costs were included in the analysis: cost of monitoring; cost of further investigations; cost of
treating diagnosed kidney disease in people with diabetes; and the cost of subsequent complications.
All costs included were obtained from published UK sources (individually referenced below) and the values
and sources of cost data are described in the following sections. Costs are expressed in 2011 pounds
sterling and data from previous years have been adjusted to 2011 value using the Hospital and
Community Services pay and price index.186
Table 21 summarises the main sources of information on therapy unit costs, implementation unit costs and
immediate (and subsequent) costs of CVD complications. As described in previous chapters, a maximum of69
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TABLE 21 Summary of all costs used in the type 1 simulation model
Item Unit cost (£) Source
Therapy costs
ACEi 27.74 (per year) Prescription Cost Analysis England (2010)189
Angiotensin receptor blockers 191.12 (per year)
Other drugs
Implementation unit costs
GP (clinic visit) 15.41 (per visit) Unit Costs of Health and Social Care (2010),188
Chronic Kidney Disease Costing Report (2008)187
Practice nurse (clinic visit) 13.50 (per visit)
ACR test 2.16 (per test)
Immediate (subsequent years) costs of selected complications
Hospital costs Clarke et al. (2002),190 adjusted for inflation using the
Hospital and Community Services pay and price index
Fatal MI 1832 (1497–2221)
Fatal stroke 5382 (3079–8461)
Non-fatal MI 6475 (5696–7513)
Non-fatal stroke 3766 (2544–5209)
No complications 243 (230–257) Clarke et al. (2002),190 adjusted for inflation using the
Hospital and Community Services pay and price index
ESRD costs
Dialysis 29,800 Chronic Kidney Disease Costing Report (2008)187
and Klebe et al. (2007)191
First year costs 11,479.11
MI, myocardial infarction.
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70three urinary ACR tests are taken during each year of monitoring. To determine whether a patient with
normoalbuminuria has progressed to microalbuminuria or macroalbuminuria, two positive tests are
required before patients are confirmed to have progression of kidney disease requiring intensification of
treatment. The cost of the ACR test is estimated at £2.16 according to the Chronic Kidney Disease Costing
Report, published by the National Institute for Health and Care Excellence in 2008.187 ACR tests are
administered by the practice nurse, and we approximate each test to take 10 minutes of the nurse’s time.
According to the Unit Costs for Health and Social Care 2010,188 a 10-minute clinic visit costs £13.50. Once
a patient is confirmed to have progressed from normoalbuminuria to microalbuminuria, a GP is consulted
to discuss what action to take and the administering of an ACEi, which we estimate to take around
5 minutes of a GP’s time (£15.41).188
If patients are confirmed to require treatment intensification through use of the ACR test, they are
recommended to start an ACEi, or A2RB if they cannot tolerate ACEi. Pursuant to Prescription Cost
Analysis England 2010,189 ACEi and A2RB cost £27.74 and £191.12 per year, respectively.
Furthermore, UKPDS 65 provides estimates of inpatient and outpatient costs for complications related to
type 2 diabetes in the UK for fatal/non-fatal myocardial infarction, fatal/non-fatal stroke, no complications
and a history of cardiovascular events.190 These were included in the model to estimate potential cost
offsets from lower rates of CVD.
End-stage kidney disease costs were divided into two parts. The National Costing Report estimated a mean
annual cost of £29,800 per patient for haemodialysis, which is the main mode of renal replacementNIHR Journals Library www.journalslibrary.nihr.ac.uk
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diagnosis to be £11,479,191 which takes into account the cost of initial investigations, total referral cost
and follow-up. For patients who move to end-stage kidney disease, the model includes a cost of around
£40,000 in the first year (i.e. combining both diagnosis and dialysis costs), and £29,800 for every
subsequent year they survive in that state.Utility values
The economic evaluation for screening people with either type 1 or type 2 diabetes uses QALYs to adjust
length of life for quality of life. A QALY value of 1 is equivalent to being in full health and 0 is equivalent
to death. The values used are based on a recent meta-analysis.170 Patients without complications were
assumed to have a QALY of 0.81, reflecting that people with diabetes are on average in less than full
health. In the type 1 simulation model, which uses a composite cardiovascular event, we assumed
two-thirds had a myocardial infarction (reducing their utility to 0.75) and one-third of patients had a stroke
(reducing their utility to 0.59) over their remaining lifetime. ESRD patients are assumed to have a utility of
0.48. We also incorporated these utility values into the UKPDS outcomes model, and used the original
utility values for all other diabetes complications (Table 22).
Model baseline parameters
For the type 1 diabetes evaluation, a cohort of 10,000 patients was progressed through the type 1
simulation model (see Chapter 5). Screening for albuminuria commenced when patients were aged
≥ 12 years, in keeping with UK guidelines. The frequency of the screening was varied from annual to
10-yearly using the model described in Chapter 3.
A similar evaluation was undertaken for screening in patients with type 2 diabetes using the adapted
version of the UKPDS outcomes model described in Chapter 5. For these simulations, the mean age of
patients was assumed to be 62 years and the baseline characteristics were based on the patients in the
post-study monitoring phase of UKPDS. Following UK guidelines, screening occurred annually beginning
from time of diagnosis for type 2 diabetes patients. Again, the incremental cost-effectiveness ratios (ICERs)
are calculated for different screening intervals from annual to 10-yearly using the model described in
Chapter 4.Analysis
Results are reported as mean values and standard deviations, or mean differences with CIs, and as
cost-to-clinical-effectiveness ratios. To provide a visual representation of the results, the costs and health
outcomes were mapped onto the cost-effectiveness plane and reported as acceptability curves.193 The
effect of uncertainty surrounding some aspects of cost and the utility values used in the study were
examined using sensitivity analyses.TABLE 22 A summary of diabetes complications and their respective health utility values and publication sources
Diabetes complication Health utility value Source
No complications 0.81 Lung et al. 2011170
Myocardial infarction 0.75 Lung et al. 2011170
Stroke 0.59 Lung et al. 2011170
ESRD 0.48 Lung et al. 2011170
Ischaemic heart disease 0.80 UKPDS 6868
Congestive heart failure 0.70 UKPDS 6868
Blindness 0.53 UKPDS 6868
Amputation 0.56 UKPDS 6868
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72A series of sensitivity analyses were carried out to examine whether the results in the main analysis were
robust to a series of assumptions:
l the effect of costs: higher ACR test cost
l the effect of changing progression values of ACR in the simulation models outlined in Chapters 3 and
4 to fixed values at the upper and lower end of the reported 95% CIs
l the impact of assumptions about glycaemic control: estimating ICERs if all patients were simulated
over a lifetime in two scenarios using each of the conventional and intensive treatment groups of
the DCCT.Results
Screening people with type 1 diabetes: results of the type 1 model
The characteristics of the patients in the type 1 cohort are summarised in Table 23. For the base-case
scenario over a lifetime, around 40% of patients are estimated to have a cardiovascular event, and 25%
progress to end-stage kidney disease. Life expectancy is estimated at 63.1 years, which is similar to the
figure obtained in Soedamah-Muthu and colleagues’ study on type 1 diabetes patients in the UK. Females
have a higher risk of mortality, and this is reflected in the literature.175,177–181
The base-case scenario examined was annual screening of newly diagnosed type 1 diabetes patients
≥ 12 years old; the model determined total cost and QALYs gained over the duration of the simulation for
the base case and for screening at greater intervals. Results of the simulation using the type 1 model are
shown in Table 24. The columns of the table represent an incremental comparison of reducing the
screening interval from 5 years progressively to 1 year. The costs associated with screening increase in
proportion to its frequency, with the cost of annual screening being around five times greater than
5-yearly screening. The benefit in terms of incremental QALYs gained increases at a slower rate and hence
the ICER increases from £3612 (£6586) to £9601 (£34,112), but all of these ratios are well within NICE’s
QALY threshold of £30,000 per QALY.TABLE 23 Baseline characteristics (± standard deviation)
of type 1 diabetes patients in the DCCT.
Source: Nathan et al. 200545
Variable Data
Mean age (years) 27 ± 7
Males 49%
Body mass index (kg/m2) 23.3 ± 2.7
Blood pressure (mmHg)
Systolic 113 ± 12
Diastolic 72 ± 9
Cholesterol (mg/dl)
Total 177 ± 33
Low-density lipoprotein 110 ± 29
High-density lipoprotein 51 ± 12
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 24 Mean (standard deviation) difference in cost, QALYs and incremental cost per QALY for comparisons
between different screening intervals for people with type 1 diabetes
Estimated outcomes
Screening interval
2-year vs. 1-year
screening
3-year vs. 2-year
screening
4-year vs. 3-year
screening
5-year vs. 4-year
screening
Average increase in
difference in cost (£)
2431 (3567) 1904 (3452) 576 (1626) 289 (330)
Average increase in
difference in QALYs
0.26 (0.33) 0.39 (0.342) 0.15 (0.327) 0.08 (0.67)
Increase in cost per
increase in QALY
9601 (34,112) 4941 (17,818) 2522 (27,249) 3612 (6586)
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14The probabilistic uncertainties surrounding these estimates are shown in Figure 22, which illustrates a
cost-effectiveness plane comparing biennial with annual screening intervals, and Figure 23 shows the
corresponding cost-effectiveness acceptability curve. Figure 23 shows the probability that annual screening
is cost-effective based on different thresholds for a QALY. The probability the intervention is cost-saving
is around 25%, and it has around an 80% chance of being below the cost-effectiveness threshold
of £30,000.Incremental effect
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FIGURE 22 Cost-effectiveness plane when comparing biennial screening intervals with annual screening intervals for
patients with type 1 diabetes.
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patients with type 1 diabetes.
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74Screening people with type 2 diabetes: results of the type 2 model
Using this model, 1000 patients were simulated for 30 years; the mean age of patients newly diagnosed
with type 2 diabetes was 62 years. Baseline characteristics are reported in Table 25. According to UK
guidelines, screening occurred annually beginning from time of diagnosis for type 2 diabetes patients.
Results of the cost-effectiveness analysis are shown in Table 26. The differences in costs and QALYs
between biennial and annual screening were reported as £209 (standard deviation £309) and 0.42
(standard deviation 0.12), resulting in an overall ratio of £606 (standard deviation £1782), which makes
the intervention highly cost-effective. When the screening interval is increased beyond 5 years, there is a
minimal difference between QALYs, suggesting that increasing the screening interval further has little
impact on QALYs and that, potentially, a ‘sojourn period’ is reached.
Similarly, the differences in costs reflect the decreasing costs of ACR tests, but the increasing number
of patients being treated for hypertension and kidney disease. Figures 24 and 25 represent the
uncertainty surrounding the cost-effectiveness of renal screening in patients with type 2 diabetes.
The cost-effectiveness plane is illustrated in Figure 24, showing a positive incremental benefit andTABLE 25 Reported baseline characteristics (± standard
deviation) for type 2 diabetes patients in the UKPDS
outcomes model. Source: Holman et al. 2008184
Variable Data
Mean age (years) 62 ± 8
Males 58.5%
Body mass index (kg/m2) 29.4 ± 5.5
Blood pressure (mmHg)
Systolic 137 ± 19
Diastolic 77 ± 10
HbA1c 8%
Cholesterol (mg/dl)
Total 198 ± 39
Low-density lipoprotein 127 ± 34
High-density lipoprotein 42 ± 12
TABLE 26 Mean difference (standard deviation) in cost, QALYs and incremental cost per QALY for comparisons
between different screening intervals for people with type 2 diabetes
Estimated
outcomes
Screening interval
2-year vs. 1-year
screening
3-year vs. 2-year
screening
4-year vs. 3-year
screening
5-year vs. 4-year
screening
Average difference
in cost (£)
209 (309) 112 (131) 70 (129) 71 (130)
Average difference
in QALYs
0.42 (0.12) 0.11 (0.26) 0.24 (0.10) 0.09 (0.11)
Incremental cost per
QALY
606 (1782) 493 (834) 331 (275) 763 (9031)
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patients with type 2 diabetes.
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14incremental cost for all observations. This suggests that, although annual screening provides added
benefits in terms of QALYs, it comes at a higher cost. Figure 25 shows a very high probability (97%) of
annual screening being below the cost-effectiveness threshold of £30,000 per QALY. Based on these
results, annual screening appears to be a cost-effective option.
Sensitivity analysis results
The sensitivity analysis results for both type 1 and type 2 models are shown in Tables 27–29. We compared
biennial screening intervals to annual screening intervals in all our analyses to help determine what factors
drive our model. The results of these analyses are reported below.
Increasing cost of albumin-to-creatinine ratio test
For the type 1 model, the difference in cost between annual and biennial screening intervals was
calculated to be £3639, with no change in the difference in QALYs of 0.26, resulting in an increased ICER
of £13,997 per QALY when compared with our initial analysis. Similarly, in the UKPDS model, differences
in costs increased to £811, resulting in an increased ICER of £1932 per QALY.Albumin-to-creatinine ratio progression
Changing the values for progression of ACR in the simulation models outlined in Chapters 3 and 4 had a
large impact on the results for both diabetes models. Changing the ACR progression variables to their
lower 95% CI value saw a small proportion of patients progress to requiring treatment and thus ESRD,75
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TABLE 27 Sensitivity analyses conducted and differences in cost, QALYs and incremental cost per QALY for
comparing yearly screening intervals with biennial screening intervals for people with type 1 diabetes
Variable Changes
Difference
in cost (£)
Difference
in QALYs ICERs (£)
ACR test costs Increased to £15 each 3639 0.26 13,997
ACR progression Lower 95% CI value 816 0.02 40,801
Upper 95% CI value 1077 0.04 26,945
CVD (equations 1 and 2) Conventional treatment only 3193 0.22 14,517
Intensive treatment only 1547 0.31 5079
Utility Lower 95% CI value 2431 0.25 9839
Upper 95% CI value 2431 0.26 9193
TABLE 28 Sensitivity analyses conducted and differences in cost, QALYs and incremental cost per QALY for
comparing yearly screening intervals with biennial screening intervals for people with type 2 diabetes
Variable Changes
Difference
in cost (£)
Difference
in QALYs ICERs (£)
ACR test costs Increased to £15 each 811 0.42 1932
ACR progression Lower 95% CI value 793 0.02 51,324
Upper 95% CI value 1059 0.04 25,447
Utility Lower 95% CI value 209 0.36 580
Upper 95% CI value 209 0.55 380
TABLE 29 Undiscounted costs for annual and biennial screening intervals for both type 1 and type 2 diabetes
patients for the screening costs and treatment and hospitalisation costs as well as the mean difference between
these costs and a comparison between total undiscounted and discounted costs (3.5% discount rate)
Costs
Type 1 diabetes Type 2 diabetes
Screening interval Screening interval
Annual Biennial
Mean
difference Annual Biennial
Mean
difference
Screening costs (£) 5121 2937 2184 1275 808 467
Treatment and hospitalisation costs (£) 12,978 7787 5191 4225 4050 175
Total costs, undiscounted (£) 18,099 10,724 7375 5499 4858 641
Total costs, 3.5% discount rate (£) 9314 6883 2431 2867 2658 209
COST-EFFECTIVENESS OF MONITORING RENAL FUNCTION FOR TYPE 1 AND TYPE 2 DIABETES
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DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14resulting in a reduction in the difference in costs and QALYs. The ICER calculated of £40,801 lies outside
NICE’s recommendation, suggesting that annual screening is not cost-effective. The UKPDS model shows a
similar result of £51,324 per QALY, rendering this particular scenario cost-ineffective.
When adjusting the variables to the upper 95% CI limit, annual screening was very effective in identifying
patients because of their quick progression to requiring treatment, and thus ESRD. Hence, the ICERs for
both models were lower when using the higher CI limit than when using the lower CI limit: £26,945 and
£25,447 per QALY for type 1 diabetes and type 2 diabetes patients, respectively.
Figures 26 and 27 show the results of modelling progression of the ACR over time from diagnosis. The
modelling integrates the equations that estimate the true progression of renal function in the simulation
models for type 1 and type 2 diabetes patients. The simulation uses estimates of the upper and lower
95% CI limits of coefficients for the observed mean rate of ACR progression to present two alternative
scenarios for progression. The figures show that, for the upper 95% CI values, progression occurs very
quickly and, therefore, annual screening would identify more patients with microalbuminuria than biennial
screening. However, it might be too late to treat some of these patients before they develop end-stage
kidney disease.
In comparison, modelling with mean ACR progression estimates based on the lower limit of the 95% CI
shows that the progression of kidney disease is very slow, and thus neither annual nor biennial screening
intervals would reliably identify the small number of patients progressing to microalbuminuria. Therefore, it
is likely to be less cost-effective than the upper 95% CI limit scenario, and possibly cost-ineffective.0
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FIGURE 26 Sensitivity analysis for rate of ACR progression based on running simulations for the 95% CI of the
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FIGURE 27 Sensitivity analysis for rate of ACR progression based on running simulations for the 95% CI of the
average rate of progression for type 2 diabetes.
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78Adjusting cardiovascular equations (type 1 model only)
If all patients in the economic evaluation were assumed to have conventional treatment as stipulated by
the DCCT, the ICER is calculated at £9711.71 per QALY.45 However, if all patients were assumed to have
intensive treatment, the ICER would be smaller, at £5079 per QALY. The latter scenario would see an
increase in QALYs, and a decrease in cardiovascular events and thus costs.Utility values
Adjusting utility values to the upper and lower 95% CI values for all diabetes events was shown to have
little impact on the cost-effectiveness of screening, as the type 1 diabetes model and the UKPDS model
found both scenarios to be very cost-effective.Comparison of discounted and undiscounted costs
Table 29 reports the costs separately in two major categories: screening costs (i.e. tests and follow-up) and
treatment and hospitalisations costs. Doubling the frequency of screening substantially increases the costs
(e.g. from £2937 to £5121 in the case of type 1 diabetes). Screening and treatment costs are much higher
for the type 1 diabetes patients because of the extended nature of the screening (i.e., for patients with
type 1 diabetes, screening and treatment continue over their lifetime of around 50 years compared with
roughly 15 years for the average person with type 2 diabetes).Discussion and interpretation of the results
Main conclusion
Annual screening appears to be a cost-effective option for both type 1 and type 2 diabetes compared with
biennial screening and other health-care interventions. For type 1 diabetes, screening produces benefit at a
cost, but this cost is well below accepted thresholds used for other types of health care. For type 2
diabetes screening, the cost-effectiveness ratio is highly favourable. The data on which our analysis was
based did not provide information about more frequent screening intervals than 1 year; however, the
results did indicate that the benefit might be greater if the underlying rate of progression of ACR is higher
than the average in the population.Comparisons with previous literature
We have found renal screening for people with type 1 and type 2 diabetes to be cost-effective in a UK
context with cost-effectiveness ratios that would compare favourably with many other funded health
interventions. With regard to the benefits, it would appear that screening produces comparable or greater
outcomes to that observed in a general population screening. For example, it has been previously
estimated that biennial mammography for women aged 50 produces less than 1 additional month of
survival and Pap smears less than 3 months.194 Here, particularly with type 2 diabetes, the gains in QALYs
range from a few months to over half a year.
The findings of this study are also consistent with two studies of the cost-effectiveness of blood pressure
treatment in type 2 diabetes. A study based on an analysis alongside the UKPDS indicated that tight blood
pressure control policies (including use of ACE inhibitors) produces several months’ increase in QALYs at a
cost of only £300 per QALY.195 Similarly, an analysis of the ADVANCE study showed treatment with a fixed
combination of blood pressure therapies (again, including ACE inhibitors) produced significant increases in
life expectancy and was cost-effective.196
The higher cost-effectiveness ratio in screening type 1 diabetes patients is a result of a number of factors
impacting on relative outcomes and costs of screening among these groups. First, when benefits are not
discounted, the gains in QALYs of screening are similar in type 1 diabetes and type 2 diabetes, but the
long duration between the commencement of screening and when the majority of patient experience
cardiovascular events significantly reduces discounted QALYs. Another reason for the differences across
these patients is the effect of treatment on ACR. In the case of type 2 diabetes, we have assumed anNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14average 52% reduction in ACR (see Chapter 2), whereas in type 1 diabetes the effect is 32% (see also
Chapter 2). The greater incremental effect in type 2 diabetes is a result of screening older patients who are
at a higher risk during the entire screening period and the treatment being more effective in slowing
progression to renal failure.
The average difference in lifetime screening costs is also much higher for type 1 patients, as, currently, the
guidelines for screening recommend annual screening from diagnosis with either type of diabetes.
Assuming that the age at diagnosis in type 1 diabetes is around 15 years, whereas in type 2 diabetes it is
62 years, patients with type 1 diabetes will have many more tests over their lifetime.
Further, these screening costs will be occurred at a constant rate, whereas any cost offsets associated
with CVD or kidney disease are likely to occur after the age of 40 years. In contrast, type 2 diabetes
patients are generally already at risk of complications at diagnosis and, therefore, the cost offsets will
occur much sooner.Clinical and research implications
While these simulations provide useful insights relating, in particular, to the additional benefits of universal
treatment over screening, it is difficult to draw firm policy conclusions regarding the merits of their
adoption in practice because of the limited number of studies reporting continued long-term ACE inhibitor
use. For example, although the ADVANCE study randomly allocated all patients with ACE inhibitors in
combination with another blood pressure medication, it involved screening patients’ toleration for this
treatment through an active run-in.61 Around 14% of patients withdrew during the 6-week active run-in
period and the study had a mean follow-up duration of only 4.3 years. Therefore, it is necessary to collect
more evidence surrounding the benefits and compliance associated with much longer periods of use
before universal treatment can be considered as a practical policy option. This should be examined in
future work.
A screening interval of 1 year appears optimal based on evidence of progression to renal failure of typical
diabetic patients in the UK. The sensitivity analysis suggests that rates of progression would have to be
substantially higher or lower than the average to have an important effect on our results. For example,
within some ethnic groups (e.g. the south Asian population; see Table 5) rates of progression towards
diabetic kidney disease may be substantially higher.44,197 Further empirical work could help to establish
whether more frequent monitoring of ACR might be justified, or whether alternative technologies might
be required to identify those at risk. Similarly, if individuals at low risk of progression could be prospectively
identified, then for future implementation of protocols for personalised care it might be possible to
consider screening at less frequent intervals.Strengths and limitations
Our type 1 diabetes model is subject to limitations, such as the exclusion of other major diabetes-related
complications (peripheral vascular disease, blindness and neuropathy), because of the timeframe and
available secondary data sources. Nevertheless, our model appears to make predictions for type 1 diabetes
patients’ life expectancy that match another large type 1 diabetes mortality study in the UK.175
The type 1 model includes important sources of major costs, including renal replacement therapy for
patients who have either true-positive or false-negative test results but progress to end-stage kidney
disease. Decrement of quality of life through occurrence of an ACE-related cough is not included, as the
model assumes that these individuals are treated with A2RB. We have also, based on the results in
Chapter 2, not added a disutility for treating patients with a false-positive test. We did not carry out a
sensitivity analysis to explore the impact of the reduction in costs of A2RB with a move to generic
prescribing, as this is a relatively small part of the overall costs and, in any case, would further increase
the cost-effectiveness of annual screening. The impact of non-adherence to therapy is not included in
this model.79
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80The type 1 diabetes model is a synthesis of multiple data sources from a variety of different countries.
Although the majority of sources are based on type 1 diabetes populations, some include type 2 diabetes
patients and non-diabetes-related patients as well, which is a limitation when trying to inform NHS clinical
practice for a UK-based screening programme. However, owing to the lack of published data specifically
regarding type 1 diabetes populations, this was unavoidable. Further validation does, however, need to be
conducted to reduce the uncertainty surrounding our estimates.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Chapter 7 Discussion and conclusionsSummary of findingsThe results of the studies reported in this monograph provide support for the current policies of annual
screening for the occurrence of albuminuria in people with diabetes, and subsequent treatment with ACEi
or A2RB if identified. These treatments are effective in reducing progression of renal albumin excretion for
those type 1 or type 2 diabetes patients identified as having albuminuria, and there is additional evidence
of a benefit even for patients with type 2 diabetes and no albuminuria. The current screening tests
available for detecting albuminuria, and the confirmatory testing strategy in use, lead to a substantial
overdiagnosis of people at risk. However, the consequences, in terms of both the balance of harms and
benefits and the costs, do not have a substantial impact. Therefore, less frequent testing intervals would
save relatively small amounts of money at the expense of failing to identify small numbers of individuals at
risk. For individuals with type 2 diabetes, screening to detect the presence of kidney disease (impaired
eGFR) in the absence of albuminuria is also important, but the numbers affected are small.
This work provides an evidence base to underpin current policy for microalbuminuria screening in an area
that has, until now, used consensus practice as a guide to action. To some extent the findings are
surprising in that, of those identified as being at risk, more individuals are misclassified than actually at
risk. However, although the costs and cost-effectiveness of this testing strategy are sensitive to the costs of
testing, a more expensive test with similar performance to the current test, used at annual intervals, would
still be cost-effective compared to use at 2-yearly intervals.
The sensitivity analyses suggest that, at current levels of annual screening costs, even if groups progressing
more slowly towards renal failure were identified, the cost-effectiveness would remain within acceptable
parameters.Strengths and limitations
Our analyses are based on statistical modelling rather than trials directly comparing different monitoring
strategies. The inefficiency and potential invalidity of randomised trials for diagnostic strategies have been
discussed elsewhere198 and apply equally to screening and monitoring strategies, making modelling studies
a frequent necessity. To overcome the issues associated with modelling, we have used external validation
(such as Figures 10 and 14) and sensitivity analyses (such as Tables 26 and 27). Compared with the original
protocol, these sensitivity analyses have been limited by the nature of the available data sets, but we have
established robustness of the models over time and to key sources of uncertainty as far as possible
(discussed in more detail below).
For our analyses in type 1 diabetes, we benefited from an observational cohort study, the ORPS,
with up to 20 years of follow-up; however, this included only children under 16 years at diagnosis
of diabetes, and hence to ages no higher than 35 years during follow-up. Our analyses for type 2 diabetes
benefited from a middle-aged, adult population, with a variety of durations of diabetes at recruitment,
but the CARDS data extended to relatively few years of follow-up, and was collected in a clinical trial
setting rather than routine care. In both cases, we addressed these limitations by comparing projections
from our models with observations from other large studies with a wide range of ages and durations of
type 1 and type 2 diabetes. Figures 10 and 14 show our models performing well against these external
data; there is generally greater variation among different studies than there is discrepancy between
our models and the observed data. The interpretation of these figures is complicated by the use of
different protocols for classifying microalbuminuria in different studies, which is likely to exaggerate the
discrepancies between studies and the model predictions. In Chapter 5, further external validation is
carried out when these models are extended to use long time horizons, to consider multiple morbidities81
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DISCUSSION AND CONCLUSIONS
82and mortality risks, and to allow for interactions between different complications of diabetes, as
recommended by the ADA Consensus Panel on computer modelling.199 As further information from trials
becomes available about the extent to which these assumptions are valid, the results of this analysis will
need to be revisited.
We have closely followed the ADA guidelines for diabetes modelling whenever relevant.199 In particular,
we have described our model with transparency; we have carried out external validations of the models in
Chapters 3 and 4 and based our cost-effectiveness modelling of type 2 diabetes on a model with previous
external validation; we have used multiple simulation runs to reduce Monte Carlo uncertainty and to
quantify statistical variability; we have taken into consideration the long time horizons, multiple organ
systems and multiple therapies relevant to lifetime modelling of diabetes and their impact on quality and
length of life; and we have stated the cost perspective of our analyses.
We have not addressed the health economics of eGFR measurement in this report. The low prevalence of
impaired eGFR in our type 1 data set limits to the degree to which such analysis is possible, but, more
importantly, it also shows that eGFR measurement has only a secondary role to urine albumin
measurement in screening for impaired renal function in type 1 diabetes. Although we base this on a
relatively young cohort with type 1 diabetes, it appears to be confirmed by follow-up of the DCCT/EDIC
cohort, in which declining eGFR is seen only in those with macroalbuminuria.150 In type 2 diabetes, we
also find that declining eGFR is a feature of patients who already have microalbuminuria or worse
(see Table 16).
We could not extend our modelling to look at testing intervals of < 1 year. Both our data sets collected
data at annual intervals, and studies that collect markers of diabetic kidney disease more frequently are
likely to have shorter follow-up. Owing to the low signal-to-noise ratio and the difficulty in distinguishing
change from underlying variation in the measure of both eGFR and ACR with a short interval between
measurements (see Chapters 3 and 4), we deemed that evaluating intervals shorter than 1 year would not
be justified. Future work might be focused on identifying individuals at greater risk of progression and
draw data from such groups to re-estimate parameters for rates of progression and interindividual
variation.Interpretation
The cost-effectiveness results reported in Chapter 6 can be viewed as quantifying overall impressions from
the systematic review and analyses of cohort data. The simulation modelling (see Chapters 3 and 4) found
that false-positive diagnoses of microalbuminuria are frequent and false-negative classification of
normoalbuminuria comparatively rare. The former would become less frequent, and the latter more
frequent, if biennial or triennial screening were adopted in place of annual screening. The cost-effectiveness
models of Chapter 5 consider how these two types of error – resulting, respectively, in overtreatment or
in missed or delayed opportunities to treat – might translate into financial costs for providers and health
costs for patients. In type 1 diabetes, the benefit of ACEi and A2RB treatment is strongly evident only
in patients who have microalbuminuria (see Chapter 2). Our cost-effectiveness model for type 1 diabetes
reports estimates and surrounding uncertainty for annual screening that are well within accepted thresholds
of cost-effectiveness, and comparable to similar procedures.
We have not, because data remain unclear, included any estimates of treatment at even earlier stages of
renal impairment, for example with hyperfiltration or with levels of albumin excretion in the upper tertiles
of normoalbuminuria. However, in type 2 diabetes, treatment with ACEi and A2RB appears to have renal
benefit even in patients who do not yet have microalbuminuria and, therefore, the overtreatment resulting
from false-positive diagnoses in annual screening results in benefits as well as costs. Screening for
microalbuminuria in type 2 diabetes appears, therefore, highly cost-effective.
Similarly, the findings from the statistical modelling in Chapters 3 and 4 are consistent with the overall
findings of the research. For example, the short-term variability of ACR and eGFR measurements is highNIHR Journals Library www.journalslibrary.nihr.ac.uk
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microalbuminuria or decreased eGFR are a result of measurement error rather than true change (see
Tables 10, 15 and 17). This is consistent with the previous findings, for other chronic conditions, that
annual screening leads to high rates of false-positive diagnoses.134,135 Further, because of the extreme
variability of ACR measurements (despite log transformation; illustrated by the 95th centiles in
Figures 8 and 13), even the practice of confirming microalbuminuria across multiple tests does not fully
prevent high rates of false-positive diagnoses. Our models predict that the prevalence of microalbuminuria
does not increase indefinitely with age until almost the whole population has diabetic kidney disease, but
‘levels off’ with about 50% affected (see Figures 10 and 15).Future research
This research has identified a number of issues into which further research is needed. These include areas
in which we have been unable to identify research that addresses our research questions, new issues
arising from our findings and issues relating to the translation of our findings into clinical practice.
The simulation models used in this work have been developed to enable further data to be added as they
become available. The type 2 model, drawing on data from UKPDS, is already in the process of revision by
the UKPDS group to take account of the data from long-term follow-up of the cohort. When the UKPDS
model becomes available, it will allow our findings to be reviewed and, if necessary, revised.
The type 1 diabetes simulation model is constructed from a number of sources, and as further data
become available from larger type 1 studies it can also be expanded, with new equations incorporated
into a revised model. It therefore offers a new tool for a wide range of cost–benefit studies which
have previously been carried out with models that draw heavily on data from studies of patients with
type 2 diabetes.
The uncertainty around the estimates for cost-effectiveness are largely driven by the rate at which new
microalbuminuria occurs. There are a number of potential ways in which these findings might be taken
forward. Our estimates of cost-effectiveness may be improved by establishing cohorts of individuals at
increased risk of developing microalbuminuria and diabetic kidney disease. For example, with increasing
capacity to personalise protocols for individual screening, those identified at increased or low risk for
progression could be screened more, or less, frequently. Another approach might be to establish whether
proactive treatment of those identified at risk might lead to longer-term benefits. However, recent
evidence suggests that rates of progression of diabetic kidney disease are falling.200 In establishing cohorts,
estimates of sample size may need to be adjusted to take account of these trends.
An alternative approach to screening for microalbuminuria may be to look for other markers that can be
used to identify risk of diabetic kidney disease or to monitor the impact of treatment intended to reduce
risk. Among the candidates for new markers is cystatin C, following studies that have shown accurate
identification of individuals with diabetes who are undergoing decline in renal function.201 Cystatin C has
been suggested as a more proximal marker of renal damage than microalbuminuria.202 Initial studies have
suggested that cystatin C may identify deterioration in renal function more accurately than eGFR in
patients with type 1 diabetes,203 but cost-effectiveness studies are needed to establish whether the
improved detection is of sufficient clinical importance to change treatment and, in particular, whether it
adds to management, based on occurrence of microalbuminuria. Other strategies that might facilitate an
assessment of risk include the measurement of uric acid, tumour necrosis factor receptors, certain
advanced glycation end products and chemokines. However, further research to establish the utility of
these measures and potentially further trials would be required to change clinical practice; the horizon for
such developments is some way into the future.
Attempts have been made to characterise groups at increased risk of developing microalbuminuria. For
example, data from a large cohort study have been used to develop a prediction rule for progression to
microalbuminuria in type 1 diabetes.33 However, it is not clear from our data whether more frequent83
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84measurement of albuminuria would be helpful. Further research is required to establish whether some of
those who have false-positive screening test results are unlikely to develop true microalbuminuria, or
whether the increased variability that leads to false-positive test results is a precursor of established
microalbuminuria and, therefore, treatment may be justified. This strategy is currently being tested in a
randomised trial.18
Another strategy that might be explored for managing cardiovascular risk in association with screening for
microalbuminuria is to investigate whether the occurrence of microalbuminuria, or increasing risk of it
developing, might justify other treatments in addition to ACEi/A2RB. Chapter 1 lists a number of
possibilities. One further possibility is whether aspirin might have an effect. Aspirin was previously
recommended for individuals with diabetes, as the condition was viewed as a cardiovascular risk
equivalent. More recent research has thrown doubt on this assumption, and a large-scale trial is currently
under way to identify benefit from aspirin in diabetes.204 Subgroup analysis of this trial based on the
occurrence of microalbuminuria, where data are available, might provide information to inform
assumptions around the benefits of screening included in our models. It is possible, for example, that, for
many individuals with diabetes, aspirin treatment may not be beneficial, but, among those at high risk and
identified with microalbuminuria, there might be a benefit from adding insulin to treatment regimens.
Qualitative work with subsequent surveys, and, if appropriate, trials, may also be helpful in establishing
whether patient knowledge of renal albumin status provides an additional motivational factor sufficient to
increase adherence to medication, without causing an adverse impact on well-being.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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This monograph was commissioned by the NIHR Health Technology Programme to provide an evidencebase for decisions about the optimal interval for testing for onset of diabetic kidney disease. During the
course of the work a number of minor amendments or modifications to this proposal were proposed and
agreed by the steering group.
Minor amendments and modifications included:
1. Of the literature reviews proposed in the original grant application, one, on the properties of test
characteristics, was superseded by the availability of patient-level data through a cohort study for which
we obtained separate funding: we undertook the work looking at qualitative methods of detecting
microalbuminuria in a parallel project in which two standard stick tests for albumin were compared
with laboratory albumin-creatinine testing. The protocol for the full systematic review and other study
components follow.
2. Our eventual selection of datasets with which to model progression of microalbuminuria and estimated
glomerular filtration rate was, in the event, dictated by the very limited number of studies in which the
relevant data had been collected at frequent enough intervals and could be made available for analysis.
The two data sets included were drawn from those initially proposed, but we could not obtain further
data sets for validation. The data sets were not sufficiently large for us to be able to examine predictors
of progression in the individual data sets. We therefore relied on estimates derived from the literature
to inform the sensitivity analyses carried out on our models of progression.
3. We used the methods for modelling progression of monitoring parameters specified in the original
grant proposal, except that the ‘variogram’ estimation method has been superseded by a random
effects modelling method; we therefore used the more recent method45
4. In our original application, the role of monitoring estimated glomerular filtration rate was given
emphasis alongside the role of monitoring the urine albumin-to-creatinine ratio. As our work
progressed it became clear that this was of less importance in clinical practice from the perspective of
initial detection of impaired renal function (see Chapters 3 and 4 for details).
5. In response to the comments of the Commissioning Board we agreed that we would try to model
patient relevant outcomes. We were able to do this through development of a type 1 simulation model
with newly available data, and adapt the UKPDS Health Economic Model using the additional data
obtained in this study.
We therefore undertook the following work:
1. Prepared a narrative review of the epidemiology of diabetic renal disease, treatment and monitoring
as an introductory chapter
2. Systematic reviews
– Impact of ACEi on outcomes
– Dose and outcomes in type 2 diabetes (published separately)
3. Limited systematic reviews
(a) Currently available models for examining impact of varying intervals for monitoring
(b) Outcomes (progression) from other studies of type 2 diabetes and rates of progression
of albuminuria
(c) Factors affecting progression of albuminuria
(d) Factors affecting impact of treatments for microalbuminuria103
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1044. Modelling of progression of measures of renal function.
– Type 1 from ORPS – ACR
– Type 2 from CARDS – ACR and eGFR
5. Health economic outcomes simulation models
– Type 1 model constructed from newly available data
– Type 1 model used to evaluate intervals for monitoring
– Existing type 2 model adapted and used to evaluate intervals for monitoringThis monograph presents this work and discusses the implications of these findings for the workSystematic review protocol: Impact of antihypertensive
agents on outcomes of diabetic patients with and without
kidney disease
Aims and objectives
Aim
To evaluate the benefits and harms of ACE inhibitors and ARB in comparison with placebo, other
antihypertensive agents or no treatment in patients with diabetes with and without kidney disease.
The review will focus on impact on overall mortality, renal and cardiovascular outcomes.Objectives
To evaluate the effects of interventions according to:
l Impact of ACEi and ARB in comparison to placebo, other antihypertensive agents or no treatment on
mortality, cardiovascular events and progression of renal disease in type 1 and type 2 diabetes
l Interaction of interventions above with type of diabetes, age, gender, stage of renal disease, ethnicity,
type of treatment (ACEi, ARB and other antihypertensive agent) and stage of renal disease on
mortality, cardiovascular events and progression of renal diseaseMethods
Criteria for considering studies for this review
Types of studies will include randomised control trials (RCTs) of at least 6 months duration in which ACEi
or ARB will be compared with placebo, other antihypertensive treatment or no treatment. We will only
include studies in which there is specific data available for the outcomes by type of diabetes and by renal
status defined by presence or absence of albuminuria.
Types of participants will include type 1 or type 2 diabetes patients with or without kidney disease.
Types of interventions (trial designs) included will be (i) ACEi or ARB versus placebo; (ii) ACEi or ARB versus
no treatment; (iii) ACEi or ARB versus other antihypertensive agents; (iv) ACE vs. ARB; and (v) ACE vs.
ACE/ARB at different doses.
Trial exclusion criteria are trials where no results are separately presented for type 1 or type 2 diabetes;
trials where urinary albumin status is not specified or results are not separately presented by urinary
albumin status; and trials in which there is no randomised comparison of ACE/ARB with either a placebo,
no treatment or another antihypertensive agent.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Variables used to define subgroups for analysis and/or moderators of effectl Type of diabetes
l Gender
l Ethnicity
l eGFR > 90, 60 to 90, 30 to 60, 15 to 30, < 15
l Albumin excretion (macro-, > 300mg/24 h, micro-, 30–300mg/24 h, normo-, < 30mg/24 h)
l Is the trial designed to match blood pressure control between groups?Types of outcome measuresl Death (any cause)
l Death (cardiovascular)
l Non-fatal CVD (MI, stroke)
l End-stage renal disease (defined as dialysis or transplant)
l Doubling of creatinine
l Number of patients who develop microalbuminuria (i.e. progression from normo-to microalbuminuria)
l Progression from micro- to macroalbuminuria
l Regression from macro- to microalbuminuria
l Regression to normoalbuminuria
l Urinary albumin/creatinine ratio
(*Dichotomous or categorical variable)Search methods for identification of studies
Searches of the following electronic biomedical databases will be conducted to identify relevant trials:
l The Cochrane Library (Cochrane Central Register of Controlled Trials, Database of Systematic Reviews
and Database of Abstracts and Reviews of Effectiveness),
l MEDLINE (1950–2009)
l EMBASE (1980–2009)
Hand searches of cross -references from original articles, reviews and conference abstracts.
The overall search strategy will combine searches for type 1 and type 2 diabetes, antihypertensive agents
and kidney disease with randomised controlled trials.Data Collection and Analysis
The search strategy will be performed to obtain lists of titles and abstracts of studies that may be relevant
to the review. The title and abstracts will be screened independently by two reviewers to discard studies
that do not meet the inclusion criteria. Studies and reviews that might include relevant data or information
will be retained initially. Where necessary the full text of articles will be obtained to determine which
studies satisfied the inclusion criteria. Data extraction will be carried out independently using standard data
extraction forms. Studies reported in non-English language journals will be translated. Where more than
one publication of one trial exists, only the publication with the most complete data will be included. Any
further information required from the original author will be requested by written correspondence. If any
additional information is acquired in this manner it will be included in the review.Study quality
The quality of studies to be included will be assessed by allocation concealment, intention-to-treat analysis,
blinding of investigators, participants and outcome assessors and completeness of follow-up.105
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Sequence generation and allocation concealment:
l Adequate: Randomisation method described that would not allow investigator/participant to know or
influence intervention group before eligible participant entered in the study.
l Unclear: Randomisation stated but no information on method used is available.
l Inadequate: Method of randomisation used such as alternate medical record numbers or unsealed
envelopes: any information in the study that indicated that investigators or participants could influence
intervention group.
Blinding and allocation concealment (Cochrane handbook):
l Blinding of investigators: Yes/no/not stated
l Blinding of participants: Yes/no/not stated
l Blinding of outcome assessor: Yes/no/not stated
l Blinding of data analysis: Yes/no/not stated
Risk of incomplete outcome data:
l Low risk: participants included in the analysis are exactly those who were randomised into the trial,
missing data is clearly reported to be an acceptable reason or if outcome data is missing in both
intervention groups, but reasons for these are both reported and balanced across groups.
l Unclear risk: the numbers randomised into each intervention group or the reasons for missing data are
not clearly reported.
l High risk: There is a difference in the proportion of incomplete outcome data across groups, or if
incomplete outcome data is balanced in numbers across groups, but the reasons for missing
outcomes differ.
Completeness of follow-up:
l Per cent of patients excluded or lost to follow-up.Statistical assessment
Data will be pooled for outcome, biochemical and safety data for the six categories of type 1 and type 2
diabetes, and normo, micro and macroalbuminuria. Comparisons will be (in order), ACE/ARB vs. placebo or
no treatment; ACE vs. other antihypertensive agent.
A separate comparison of ACE vs. ARB and ACE vs. ACE of a different type or dose will be carried out.
The effect of ACE, ARB or other antihypertensive agents will be summarised using risk ratios with 95% CIs
for mortality or morbidity data.
Continuous data will be pooled where possible using mean, standard deviation and sample size per group.
If unavailable then percentage change will be pooled with a random effects model, or if possible data will
be dichotomised.
Data comparing the same intervention will be pooled in a meta-analysis. Heterogeneity of treatment
effects between studies will be examined using the i-squared statistic.
Sub-group analysis (baseline albumin, ethnicity, baseline blood pressure if available.
If sufficient data is available we will use metaregression techniques to account for heterogeneity.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Data will be provided in the form of risk ratios for differing levels of renal function, and where possible,
other modifiers of treatment will be identified, to inform the estimates used in the decision modelling for
optimal albumin testing.Individual patient data modelling protocol
Research aims and objectives
Our aim is to develop a clinical and economic model of renal function decline, and then to estimate the
effectiveness and cost-effectiveness of different models for chronic kidney disease (CKD) monitoring in
type 1 and 2 diabetes.Research methods
Design
We will model eGFR and microalbumin measurements to (a) identify biological variability and measurement
error and determine coefficients of variation and (b) rates of change using individual patient data
cohorts of both type 1 and type 2 diabetes patients. This will allow us to model true- and
false-positive rates of testing at different intervals and in different patient groups, for reach specific
treatment-decision thresholds.Individual patient datasets
We will use individual patient data sets to build a model of rates progression of chronic kidney disease by
predictors in diabetes, provide data on the microalbumin screening test for CKD thresholds, and
monitoring data for the modelling of false- and true-positive rates of the eGFR at different thresholds. In
addition we intend to explore their potential for providing quantitative data about the change in albumin
excretion in response to treatment.TABLE X Individual patient datasets for which we have agreement in principle for access
Trial
Type of
diabetes
Age (y)
at cohort
inception
Proportion
on
ACE/AR2RB
at baseline†
Period of
follow up
(years)
Trial
intervention
Frequency of measurement
Repeated
albumin
measurements
Repeated
creatinine
measurements
ADVANCE Type 2
diabetes
66 48% 4.3 years Blood pressure
and glycaemic
control
Two-yearly
(urine alb/cr)
Yearly
FIELD Type 2
diabetes
62 40% 5 years Fenofibrate Two-yearly
(urine alb/cr)
Yearly
CARDS Type 2
diabetes
62 44% 4.5 years Atorvastatin Yearly
(urine alb/cr)
Yearly
ORPS Type 1
diabetes
9 < 1% 22 years Observational Yearly Yearly
EUCLID Type 1
diabetes
33 0% 2 years Lisinopril 6 monthly 6 monthly
† Control group for the randomised trials: ADVANCE, FIELD, CARDS, EUCLID.
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108Identified data sets
We have provisional agreement from the investigators for collaboration and sharing of anonymised data from
the following large, long-term population based studies: ADVANCE, FIELD, CARDS, ORPS and EUCLID. In
addition, we also have agreement for collaboration from the 1,000-patient Family Nephropathy study. These
include trials encompassing type 1 and type 2 diabetes with sufficient patient numbers, patients not taking
ACE or AR2B at cohort inception to allow sufficient patients for analysis. These studies have included detailed
base-line characterisation of patients, collected serial data about treatment and disease characteristics, and
have periodically measured renal function, including urinary albumin : creatinine ratios and serum creatinine.
The patient cohorts used for this analysis will be chosen to maximise the available data. If feasible we will
use a second cohort for both type 1 and type 2 diabetes to validate the findings from the first cohort. The
three type 2 diabetes trials have 4 to 5 year follow up of cohorts of between 3,000 to 11,000 patients.
The ORPS17 data set is an inception cohort of 22 years duration with measurements over a protracted
period, and will therefore provide high quality data relevant to the majority of the type 1 population.Comparison of published estimates and data from individual patent datasets
Predictors of progression and outcome identified from the review of the literature will, where possible, be
examined in the individual patient datasets. Predictive equations will be applied to the available data for
each individual within the dataset. We will omit variables from the predictive scores where unavailable, use
imputation where possible for missing data and adjust for the anticipated effects of treatments using
estimates from systematic reviews.Determining rates of progression and biological variability and
measurement error
Using individual patient data cohorts with both type 1 and type 2 diabetes patients we will model
long-term GFR and microalbumin measurement changes and errors. We will use this model to determine
the impact of different monitoring intervals on the false- and true-positive rates for renal changes, the
onset of microalbuminuria and clinically important change in eGFR. This modelling is based on estimating
three elements (i) within-person variability, (ii) the average rate of progression of renal impairment and
(iii) the variation in this average rate.
Based on this model we will estimate the utility of repeated measurements of urinary albumin to monitor
intensification of treatment and of using creatinine rather than eGFR to monitor renal function. The model
will include treatment effects as well as variability due to intercurrent infection and short term use of
medication. We will base our model on a single data-set for type 1 and type 2 diabetes, using the most
detailed, largest and longest data set.
We will check the assumptions of the model and in particular determine whether the rate of progression
of the monitored variables is linear or non-linear and transform the model if needed. Previous work
concluded that progression of albuminuria was non-linear. The average change in eGFR and
microalbumin : creatinine ratio can be estimated from the group averages at the available time-points. We
will examine the data to establish the optimal time-point for starting measurement, since the course of
measures from baseline may be initially affected by trial entry and initial therapy. Short-term variability will
be assessed by a ‘variogram’: a linear extrapolation backwards from the long-term measures to estimate
variance at time 0. In addition we will use the above data in a mixed-longitudinal model where we assume
that the rate of increase varies between individuals. Bland-Altman plots will be used to test for variability
between and within persons at differing levels of initial eGFR and microalbumin excretion levels. We will
also extend this analysis to a non-linear approach.
We will use the above data to model true- and false-positive rates of tests at different intervals and in
different patient groups for monitoring for microalbuminuria and for identifying progression of eGFR to
levels at which referral might be indicated. We will therefore identify true and false-positive rates of
attainment under specific treatment-decision thresholds.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Research methods
Design
We will use data about predictors of outcome, test characteristics, and baseline patient characteristics
together with diagnostic and treatment costs, to build and populate an individual sampling model to
identify cost per additional true-positive test for different frequencies of monitoring at different thresholds
in different groups of patients. The results of this study will inform clinical practice and lead to evidence
based recommendations for intervals for eGFR and microalbumin testing in patients with diabetes.Modelling of cost-and effectiveness
We will develop an individual sampling model including a ‘trend’ module, a ‘variability’ module and
a ‘costs’ module. The analysis algorithm will draw on these modules to estimate both true and
false-positive rates, and cost of any given screening strategy. The trend module for GFR, creatinine and
urine albumin will be based on the results of the work on rate of progression; and the variability module
on the results of the variability of each of the measures. We will populate the model with a baseline
data-set typical of the general diabetes population. The costs module will be developed from previous trial
results, literature and NHS sources. This modular approach will allow flexibility depending on the extent of
the data that we are able to draw from each of the individual patient data-sets.
The model will allow us to identify, for each of (a) urinary albumin : creatinine ratio and (b) eGFR and
(c) hybrid strategies, a shortlist of monitoring strategies. These strategies will include more effective
schemes with similar costs, lower cost schemes with similar effectiveness and strategies that improve on
both cost and cost-effectiveness. The key decision points will be (i) identification of diabetic nephropathy
through microalbuminuria screening with initiation of ACE therapy and intensification of blood pressure
targets, and (ii) progression of disease through stages of CKD. Impact of potential modifiers of progression
including blood pressure treatment and patient characteristics (including ethnicity) will be incorporated.
The model will handle competing risks (e.g. death rates at differing levels of nephropathy), and if
necessary we will also address competing risks in the trend models.
The model will use cost data derived from consultations with NHS providers. In addition we will use
standard PSSRU reference costs for health care interventions. We will use an NHS perspective for the
analysis. Total costs will be discounted at 3.5%.
Development of the individual simulation model will be supervised by PC and RS using similar processes to
those used in development of the UKPDS Outcomes Model and the UKPDS Risk Engine. Programming will
be carried out in the statistical modelling language R, using a modular design as described above. The
American Diabetes Association guidelines on computer modelling will be followed wherever relevant: in
particular, we will use internal validation to verify the accuracy of the program and cross-validation to
estimate its external validity. We will handle both Monte-Carlo uncertainty (induced by simulation and
handled by averaging over multiple runs) and statistical uncertainty (represented as CIs, calculated by
a parametric bootstrap method). Other areas of uncertainty will be explored with a sensitivity analysis.
Different testing and screening policies will have differing associated costs, both in terms of the testing,
but also in terms of associated interventions (e.g. commencement and intensification of therapy). There are
also potential harms, such as incidence of hypoglycaemia with intensified glycaemic control. Costs and
benefits will be formally assessed by modelling the cost-effectiveness of different screening and
testing strategies. The initial focus of the analysis will be to examine cost-effectiveness of alternative
screening policies using cost per true positive (incremental cost per additional true positive detected
compared to the existing monitoring programme). We will also consider number of false negatives per109
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Farmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 1
110false positive as a secondary measure of cost-effectiveness. We will also examine the feasibility of
extending this analysis to final outcome measure such as a Quality Adjusted Life Expectancy, which
would form a secondary analysis if there is sufficient evidence to extend the model to capture this
long-term outcome.
We will also explore the extent to which the uncertainties in the model might be informed by further
research, and the extent to which the likely costs of this research would reduce the uncertainty to a level
where additional benefit to patients and the NHS might be obtained.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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systematic reviews (Chapter 2)MEDLINE
MEDLINE search terms1. exp antihypertensive agents/
2. (antihypertensive$ adj (agent$ or drug)).tw.
3. chlorothiazide.tw.
4. chlorthalidone.tw.
5. hydralazine.tw.
6. hydrochlorothiazide.tw.
7. indapamide.tw.
8. minoxidil.tw.
9. exp angiotensin converting enzyme inhibitors/
10. captopril.tw.
11. enalapril.tw.
12. cilazapril.tw.
13. enalaprilat.tw.
14. fosinopril.tw.
15. lisinopril.tw.
16. perindopril.tw.
17. ramipril.tw.
18. saralasin.tw.
19. teprotide.tw.
20. exp losartan/
21. losartan.tw.
22. imidazole$.tw.
23. irbesartan.tw.
24. candesartan.tw.
25. eprosartan.tw.
26. valsartan.tw.
27. olmesartan.tw.
28. telmisartan.tw.
29. (ace adj2 inhibitor$).tw.
30. (angiotensin adj2 receptor antagonist$).tw.
31. exp calcium channel blockers/
32. amlodipine.tw.
33. diltiazem.tw.
34. felodipine.tw.
35. nicardipine.tw.
36. nifedipine.tw.
37. nimodipine.tw.
38. nisoldipine.tw.
39. nitrendipine.tw.
40. verapamil.tw.
41. exp adrenergic beta-antagonists/111
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Farmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 2
11242. alprenolol.tw.
43. atenolol.tw.
44. metoprolol.tw.
45. nadolol.tw.
46. oxprenolol.tw.
47. pindolol.tw.
48. propranolol.tw.
49. exp adrenergic alpha-antagonists/
50. labetalol.tw.
51. prazosin.tw.
52. beta block$.tw.
53. exp diuretics/
54. spironolactone.tw.
55. triamterene.tw.
56. bumetanide.tw.
57. chlorthalidone.tw.
58. furosemide.tw.
59. indapamide.tw.
60. chlorothiazide.tw.
61. hydrochlorothiazide.tw.
62. or/1-61
63. exp diabetes mellitus/
64. diabetic nephropathies/
65. diabetic nephropath$.tw.
66. diabetic glomerulo$.tw.
67. ((diabetic or diabetes) and (kidney disease$ or renal disease$)).tw.
68. or/63-67
69. 62 and 68
70. randomized controlled trial.pt.
71. controlled clinical trial.pt.
72. randomized.ab.
73. placebo.ab.
74. clinical trials as topic.sh.
75. randomly.ab.
76. trial.ti.
77. 74 or 75 or 72 or 71 or 70 or 73 or 76
78. exp animals/ not humans.sh.
79. 77 not 78
80. 69 and 79
81. limit 80 to yr="2005 -Current"EMBASE search terms1. exp antihypertensive agents
2. (antihypertensive$ adj (agent$ or drug$)).tw.
3. (anti-hypertensive$ adj (agent$ or drug$)).tw.
4. chlorothiazide.tw.
5. chlorthalidone.tw.
6. hydralazine.tw.
7. hydrochlorothiazide.tw.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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9. minoxidil.tw.
10. losartan.tw.
11. imidazole$.tw.
12. irbesartan.tw.
13. candesartan.tw.
14. eprosartan.tw.
15. valsartan.tw.
16. olmesartan.tw.
17. telmisartan.tw.
18. exp angiotensin converting enzyme inhibitors
19. (ace adj2 inhibitor$).tw.
20. (acei or ace-i).tw.
21. captopril.tw.
22. enalapril.tw.
23. fosinopril.tw.
24. lisinopril.tw.
25. perindopril.tw.
26. ramipril.tw.
27. saralasin.tw.
28. teprotide.tw.
29. exp Angiotensin 2 Receptor Antagonist
30. exp Angiotensin Receptor Antagonist
31. Angiotensin II Antagonist
32. angiotensin II receptor antagonist$.tw.
33. angiotensin 2 receptor antagonist$.tw.
34. angiotensin II receptor block$.tw.
35. angiotensin 2 receptor block$.tw.
36. AT 2 receptor block$.tw.
37. AT 2 receptor antagon$.tw.
38. angiotensin receptor antagonist$.tw.
39. exp Calcium Channel Blockers/
40. amlodipine.tw.
41. diltiazem.tw.
42. felodipine.tw.
43. nicardipine.tw.
44. nifedipine.tw.
45. nimodipine.tw.
46. nisoldipine.tw.
47. nitrendipine.tw.
48. verapamil.tw.
49. exp adrenergic beta-antagonists/
50. alprenolol.tw.
51. atenolol.tw.
52. metoprolol.tw.
53. nadolol.tw.
54. oxprenolol.tw.
55. pindolol.tw.
56. propranolol.tw.
57. exp adrenergic alpha-antagonists/
58. labetalol.tw.113
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11459. prazosin.tw.
60. beta block$.tw.
61. exp diuretics/
62. spironolactone.tw.
63. triamterene.tw.
64. bumetanide.tw.
65. furosemide.tw.
66. indapamide.tw.
67. or/1-66
68. exp Diabetes Mellitus/
69. diabetes mellitus.tw.
70. (IDDM or NIDDM).tw.
71. Diabetic Nephropathies/
72. diabetic nephrop$.tw.
73. diabetic glomerulo$.tw.
74. ((diabetic or diabetes) and (kidney disease$ or renal disease$ or nephro$ or nephrit$ or glomerulo$)).tw.
75. or/68-74
76. and/67,75
77. random$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
78. factorial$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
79. crossover$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
80. cross over$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
81. cross-over$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
82. placebo$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
83. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
84. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
85. assign$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
86. allocat$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
87. volunteer$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
88. 84 or 85 or 83 or 80 or 78 or 79 or 81 or 87 or 77 or 86 or 82
89. 88 and 76NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14The Cochrane Library search terms#1 (ANTIHYPERTENSIVE AGENTS explode all trees (MeSH))
#2 chlorothiazide
#3 chlorthalidone
#4 hydralazine
#5 hydrochlorothiazide
#6 indapamide
#7 minoxidil
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 captopril
#10 enalpril
#11 cilazapril
#12 enalaprilat
#13 fosinopril
#14 lisinopril
#15 perindopril
#16 ramipril
#17 saralasin
#18 teprotide
#19 (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)
#20 LOSARTAN explode all trees (MeSH)
#21 losartan
#22 imidazole
#23 irbesartan
#24 candesartan
#25 eprosartan
#26 valsartan115
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116#27 olmesartan
#28 telmisartan
#29 (ace near inhibitor*)
#30 (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29)
#31 CALCIUM CHANNEL BLOCKERS explode all trees (MeSH)
#32 amlodipine
#33 diltiazem
#34 felodipine
#35 nicardipine
#36 nifedipine
#37 nimodipine
#38 nisoldipine
#39 nitrendipine
#40 verapamil
#41 (#31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40)
#42 ADRENERGIC AGONISTS explode all trees (MeSH)
#43 alprenolol
#44 atenolol
#45 metoprolol
#46 nadolol
#47 oxprenolol
#48 pindolol
#49 propranolol
#50 labetalol
#51 prazosin
#52 (#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51)
#53 DIURETICS explode all trees (MeSH)NIHR Journals Library www.journalslibrary.nihr.ac.uk
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#55 triamterene
#56 bumetanide
#57 chlorthalidone
#58 furosemide
#59 indapamide
#60 chlorothiazide
#61 hydrochlorothiazide
#62 (#53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61)
#63 RECEPTORS ANGIOTENSIN single term (MeSH)
#64 ANGIOTENSINS explode tree 1 (MeSH)
#65 (angiotensin near inhibit*)
#66 (angiotensin near antagonist*)
#67 (angiotensin near blocker*)
#68 antihypertensive*
#69 (#64 OR #65 OR #66 OR #67 OR #68)
#70 (#8 OR #19 OR #30 OR #41 OR #52 OR #62 OR #69)
#71 DIABETES MELLITUS explode tree 1 (MeSH)
#72 (diabetes next mellitus)
#73 (iddm or niddm)
#74 DIABETIC NEPHROPATHIES single term (MeSH)
#75 (diabetic next nephrop*)
#76 (diabetic next glomerul*)
#77 (diabetic and (kidney next disease*))
#78 (diabetic and (renal next disease*))
#79 (diabetes and (renal next disease*))
#80 (diabetes and (kidney next disease*))117
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118#81 (diabetes and nephro*)
#82 (diabetes and nephri*)
#83 (diabetes and glomerulo*)
#84 (diabetic and glomerulo*)
#85 (diabetic and nephrit*)
#86 (diabetic and nephro*)
#87 (#71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR
#83 OR #84 OR #85 OR #86)
#88 (#70 AND #87), from 2005 to 2009NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Appendix 3 Data extraction form (Chapter 2
systematic review)Study data extraction formStudy Author/journal/year
Number in trial
Intervention drug
Comparator drug
Trial details Country of trial
Length of trial
Intervention dose
Number in intervention
Comparator dose
Number in comparator
Existing hypertension
Blood pressure-lowering allowed
Participant
characteristics
Type of diabetes
Normoalbuminuria/microalbuminuria
Age
Trial quality Randomisation
Blinding
Informed consent
Intention to treat
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120Study resultsUrinary albumin
AER/ACR
Units
Intervention group Baseline
End point
Change
Comparator group Baseline
End point
Change
Progression/regression
Normo to micro Intervention
Comparator
Micro to macro Intervention
Comparator
Micro to normo Intervention
Comparator
Adverse events Intervention group
Comparator group
Mortality Intervention group
Comparator group
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systematic review)Study
(first author, year)
Type of
diabetes Urinary albumin Reasons for excluding
Scognamiglio 1997205 1 Normoalbuminuria Not all normoalbuminuric at baseline
Bakris 199493 1 NS Normoalbuminuria and microalbuminuria
not analysed separately
Parving 1989206 ‘IDDM’ Macroalbuminuria Interim report of trial reported in Parving
2001105
Capek 1994207 2 Microalbuminuria Results reported are not consistent
throughout the paper
Tütüncü 2001208 2 Microalbuminuria ACEi vs. AR2B
Stornello 1989,
1992209,210
2 Macroalbuminuria All patients received both treatments
Crepaldi 199581 2 Normo- and
microalbuminuria
Could not extract consistent data
Velussi 1996211 2 Normo- and
microalbuminuria
Not clearly a RCT
Rizzoni 2005212 2 Normo- and
microalbuminuria
Normo- and microalbuminuric patients
could not be separately analysed
Ko 2005213 2 Normo- or microalbuminuria Normo- and microalbuminuric patients
could not be separately analysed
Cordonnier 199979 2 Micro- and
macroalbuminuria
Outcome urinary protein not urinary albumin
Lacourcière 2000214 2 20–350 µg/minute ACEi vs. AR2B
DETAIL 2004215 2 Mixed Normo- and microalbuminuric patients
could not be separately analysed
ABCD study216 2 NS Normo- and microalbuminuric patients
not identified
Baba 200186 2 NS Normo- and microalbuminuric patients
not identified
Joglekar 1998217 2 NS Normo- and microalbuminuric patients
not identified
Lin 1995218 2 NS Normo- and microalbuminuric patients
not identified
FACET 1998219 Mixed Normo- and
microalbuminuria
Mixed type 1 and type 2
HOPE 2000220 Mixed Normo- and
microalbuminuria
Mixed type 1 and type 2
Bakris 1992221 Mixed Macroalbuminuria Mixed type 1 and type 2
Marre 1987222 Mixed Microalbuminuria Mixed type 1 and type 2
Nankervis 1998223 Mixed Microalbuminuria Mixed type 1 and type 2
O’Donnell 1993224 Mixed Microalbuminuria Mixed type 1 and type 2
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Study
(first author, year)
Type of
diabetes Urinary albumin Reasons for excluding
Phillips 1993225 NS Microalbuminuria Mixed type 1 and type 2
Sato226 NS Micro- and
macroalbuminuria
Mixed type 1 and type 2
AIPRI 1996227 – Normo- and
microalbuminuria
Not all diabetes
ABCD, appropriate blood pressure control in non-insulin-dependent diabetes mellitus; AIPRI, Angiotensin-converting-
enzyme Inhibition in Progressive Renal Insufficiency study; DETAIL, diabetics exposed to telmisartan and enalapril study;
FACET, Fosinopril versus Amlodipine Cardiovascular Events randomized Trial; IDDM, insulin-dependent diabetes mellitus;
NS, not specified; RCT, randomised controlled trial.
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economic modelsDo current models allow the impact of treatment based on
renal status to be evaluated?The following table lists is a detailed list of health economic models for diabetes including a brief comment
about the extent to which the models include parameters relating to the presence of and severity of
nephropathy in modelling costs or outcomes.Model Reference
Extent to which
nephropathy addressed
Type of
diabetes
Type 1 diabetes models
DCCT 1996 Diabetes Control and Complications Trial
Research Group. Lifetime benefits and costs of
intensive therapy as practiced in the Diabetes
Control and Complications Trial. The Diabetes
Control and Complications Trial Research Group.
JAMA 1996;276:1409–15
Includes Markov submodel for
nephropathy
Type 1
Palmer et al.
2000
Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A,
Singh G, et al. The cost-effectiveness
of different management strategies for type I
diabetes: a Swiss perspective. Diabetologia
2000;43:13–26
Includes modelling as a
progression through disease
states to ESRD mortality
Type 1
Type 2 diabetes models
Eastman et al.
1997
Eastman RC, Javitt JC, Herman WH, Dasbach EJ,
Zbrozek AS, Dong F, et al. Model of complications
of NIDDM: I. model construction and
assumptions. Diabetes Care 1997;20:725–34.
URL: http://care.diabetesjournals.org/content/20/
5/725.short
Includes four submodels for
nephropathy
Type 2
Global diabetes
model
Brown JB, Russell A, Chan W, Pedula K, Aickin
M. The global diabetes model: user friendly
version 3.0. Diabetes Res Clin Pract 2000;50:
S15–46
Makes use of the Eastman
et al. 1997 model
Type 2
Cardiff diabetes
model156
No publication found – reported in: http://care.
diabetesjournals.org/content/30/6/1638.full.pdf
Includes data on renal events
from DCCT45 and UKPDS 6422
Type 2
Sheffield diabetes
model156
No publication found – reported in: http://care.
diabetesjournals.org/content/30/6/1638.full.pdf
Includes a submodel for
nephropathy. Nephropathy
model based on Eastman
et al. 1997 model of diabetes
progression and the DCCT
research group228
Type 2
UKPDS outcomes
model
Clarke PM, Gray AM, Briggs A, Farmer A, Fenn P,
Stevens R, et al. A model to estimate the lifetime
health outcomes of patients with type 2 diabetes:
the United Kingdom Prospective Diabetes Study
(UKPDS) outcomes model. Diabetologia
2004;47:1747–59. URL: www.springerlink.com/
content/29qrwyvccp0yjeje/fulltext.pdf
Model contains a single
Weibull equation to predict
renal failure
Type 2
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UKPDS risk
engine
Stevens RJ, Kothari V, Adler AI, Stratton IM,
Holman RR. The UKPDS risk engine: a model for
the risk of coronary heart disease in type II
diabetes (UKPDS 56). Clin Science 2001;101:
671–9. URL: http://www.clinsci.org/cs/101/
0671/1010671.pdf
No renal component Type 2
CDC/RTI type 2
diabetes
progression
model
Hoerger TJ, Harris R, Hicks KA, Donahue K,
Sorensen S, Engelgau M. Screening for type 2
diabetes mellitus: a cost-effectiveness analysis.
Ann Intern Med 2004;140:689–99. URL: www.
annals.org/content/140/9/689.full.pdf
Includes simulation for
nephropathy and ESRD
Type 2
Caro et al. 2000 Caro JJ, Klittich WS, Raggio G, Kavanagh PL,
O’Brien JA, Shomphe LA, et al. Economic
assessment of troglitazone as an adjunct to
sulfonylurea therapy in the treatment of type 2
diabetes. Clin Ther 2000;22:116–27
Includes five states of
nephropathy
Type 2
Palmer et al.
2000
Palmer A, Sendi P, Spinas G. Applying some UK
Prospective Diabetes Study results to Switzerland:
the cost-effectiveness of intensive glycaemic
control with metformin versus conventional
control in overweight patients with type-2
diabetes. Schweiz Med Wochenschr
2000;130:1034
Includes renal failure and
death from renal disease
Type 2
Bagust et al.
2001
Bagust A, Hopkinson P, Maier W, Currie C.
An economic model of the long-term health
care burden of type II diabetes. Diabetologia
2001;44:2140–55
Includes three independent
modules governing
nephropathy
Type 2
US Centre for
Disease Control
2002
Hoerger T, Bethke A, Richter A, Sorensen S,
Engelgau M, Thompson T, et al. Cost-
effectiveness of intensive glycemic control,
intensified hypertension control, and serum
cholesterol level reduction for type 2 diabetes.
JAMA 2002;287:2542–51
Renal outcomes modelled
as progression through to
death by ESRD
Type 2
Zhou et al. 2005 Zhou H, Isaman DJ, Messinger S, Brown MB,
Klein R, Brandle M, et al. A computer simulation
model of diabetes progression, quality of life, and
cost. Diabetes Care 2005;28:2856–63
Includes separate Markov
submodel corresponding to
three states of nephropathy
Type 2
Tilden et al. 2007 Tilden DP, Mariz S, O’Bryan-Tear G, Bottomley J,
Diamantopoulos A. A lifetime modelled economic
evaluation comparing pioglitazone and
rosiglitazone for the treatment of type 2 diabetes
mellitus in the UK. Pharmacoeconomics
2007;25:39–54
Includes renal failure Type 2
Types 1 and 2 diabetes models
IMIB model Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock
H, Wenzel H. Outline of a diabetes disease
management model: principles and applications.
Diabetes Res Clin Pract 2000;50:S47–56. URL:
www.sciencedirect.com/science/article/pii/
S0168822700002163
Includes renal submodel of
eight states
Type 1 and
type 2
EAGLE model Mueller E, Maxion-Bergemann S, Gultyaev D,
Walzer S, Freemantle N, Mathieu C, et al.
Development and validation of the economic
assessment of glycemic control and long-term
effects of diabetes (EAGLE) model. Diabetes
Technol Ther 2006;8:219–36. URL: www.
liebertonline.com/doi/pdfplus/10.1089/
dia.2006.8.219
Can simulate kidney system
(microalbuminuria,
macroalbuminuria, ESRD)
Type 1 and
type 2
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Model Reference
Extent to which
nephropathy addressed
Type of
diabetes
Core diabetes
model
Palmer AJ, Roze S, Valentine WJ, Minshall ME,
Foos V, Lurati FM, et al. The CORE diabetes
model: projecting long-term clinical outcomes,
costs and cost-effectiveness of interventions in
diabetes mellitus (types 1 and 2) to support
clinical and reimbursement decision-making.
Curr Med Res Op 2004;20(Suppl. 1):S5–26
Includes simulations for
nephropathy
Type 1 and
type 2
Archimedes
model
Eddy DM, Schlessinger L. Archimedes: a
trial-validated model of diabetes. Diabetes
Care 2003;26:3093–101. URL: http://care.
diabetesjournals.org/content/26/11/3093.full.pdf
Not clear – briefly discusses
nephropathy and causes
Type 1 and
type 2
Grima et al. 2007 Grima DT, Thompson MF, Sauriol L. Modelling
cost effectiveness of insulin glargine for the
treatment of type 1 and 2 diabetes in Canada.
Pharmacoeconomics 2007;25:253–66
Includes ESRD as a state Type 1 and
type 2
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DOI: 10.3310/hta18140 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 14Appendix 6 Health state valuations in diabetesAbstract of a research paper, the research for which was
carried out in parallel with the research programme
establishing health state values that was subsequently
incorporated into the health outcome simulation models
(Chapters 5 and 6)
A meta-analysis of health state valuations for people with diabetes:
explaining the variation across methods and implications for
economic evaluation
Lung TW, Hayes AJ, Hayen A, Farmer A, Clarke PM. Qual Life Res 2011;20:1669–78.Purpose
To review published studies on the effect of diabetes and its complications on utility scores to establish
whether there is systematic variation across studies and to examine the implications for the estimation
of QALYs.Methods
A systematic review was performed using studies reporting QALY measures elicited from people with
diabetes including those with a history of complications. Meta-analysis was used to obtain the average
utility, and metaregression was employed to examine the impact of study characteristics and elicitation
methods on these values. The effect of different utility scores on QALYs was examined using diabetes
simulation models.Results
In the meta-analysis based on 45 studies reporting 66 values, the average utility score was 0.76 (95% CI
0.75–0.77). A metaregression showed significant variation due to age, method of elicitation and the
proportion of males. The average utility score for individual complications ranged from 0.48 (95% CI 0.25,
0.71) for chronic renal disease to 0.75 (95% CI 0.73, 0.78) for myocardial infarction, and these differences
produced meaningful changes in simulated QALYs. There was significant heterogeneity between studies.ConclusionsWe provide summary utility scores for diabetes and its major complications that could help inform
economic evaluation and policy analysis.127
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